



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, 16/18, A61K 38/17, G01N 33/68</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/31263</b>
			(43) International Publication Date: <b>2 June 2000 (02.06.00)</b>
(21) International Application Number: <b>PCT/US99/28013</b> (22) International Filing Date: <b>23 November 1999 (23.11.99)</b> (30) Priority Data: 60/109,592      23 November 1998 (23.11.98)      US 60/118,610      4 February 1999 (04.02.99)      US 60/127,990      6 April 1999 (06.04.99)      US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US      60/109,592 (CIP) Filed on      23 November 1998 (23.11.98) US      60/118,610 (CIP) Filed on      4 February 1999 (04.02.99) US      60/127,990 (CIP) Filed on      6 April 1999 (06.04.99) (71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View,</b>		CA 94040 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). (74) Agents: <b>BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</b> (81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b> Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: <b>GTPASE ASSOCIATED PROTEINS</b>			
(57) Abstract  The invention provides human GTPase associated proteins (GTPAP) and polynucleotides which identify and encode GTPAP. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GTPAP.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CJ	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## GTPASE ASSOCIATED PROTEINS

### TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of GTPase associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, and immune system disorders.

5

### BACKGROUND OF THE INVENTION

Guanine nucleotide binding proteins (GTP-binding proteins) participate in a wide range of regulatory functions in all eukaryotic cells, including metabolism, cellular growth, differentiation, signal transduction, cytoskeletal organization, and intracellular vesicle transport and secretion. In higher organisms they are involved in signaling that regulates such processes as the immune response (Aussel, C. et al (1988) J. Immunol. 140:215-220), apoptosis, differentiation, and cell proliferation including oncogenesis (Dhanasekaran, N. et al. (1998) Oncogene 17:1383-1394). Exchange of bound GDP for GTP followed by hydrolysis of GTP to GDP provides the energy that enables GTP-binding proteins to alter their conformation and interact with other cellular components. The superfamily of GTP-binding proteins consists of several families and may be grouped as translational factors, heterotrimeric GTP-binding proteins involved in transmembrane signaling processes (also called G-proteins), and low molecular weight GTP-binding proteins including the proto-oncogene Ras proteins and products of rab, rap, rho, rac, smg21, smg25, YPT, SEC4, and ARF genes, and tubulins (Kaziro, Y. et al. (1991) Ann. Rev. Biochem. 60:349-400). In all cases, the GTPase activity is regulated through interactions with other proteins.

GTP-binding proteins involved in protein biosynthesis include initiation factor 2 (IF-2), elongation factor 2 (EF-Tu), and elongation factor G (EF-G), observed in prokaryotes; and initiation factor 2 (eIF-2), elongation factor 1 $\alpha$  (EF-1 $\alpha$ ) and elongation factor 2 (EF-2) observed in eukaryotes (Kaziro, supra). IF-2 promotes the GTP-dependent binding of the tRNA to the small subunit of the ribosome, the step that initiates protein translation. Similarly, elongation factors promote the binding of tRNA and GTP and the displacement of GDP after hydrolysis as protein biosynthesis proceeds.

Heterotrimeric GTP-binding proteins are composed of 3 subunits ( $\alpha$ ,  $\beta$  and  $\gamma$ ) which, in their inactive conformation, associate as a trimer at the inner face of the plasma membrane.  $G_{\alpha}$  binds GDP or GTP and contains the GTPase activity. The  $\beta\gamma$  complex enhances binding of  $G_{\alpha}$  to a receptor.  $G_{\gamma}$  is necessary for the folding and activity of  $G_{\beta}$ . (Neer, E.J. et al. (1994) Nature 371:297-300.) Multiple homologs of each subunit have been identified in mammalian tissues, and different combinations of subunits have specific functions and tissue specificities. (Spiegel, A.M. (1997) J.

Inher. Metab. Dis. 20:113-121.) G protein activity is triggered by seven-transmembrane cell surface receptors (G-protein coupled receptors) which respond to lipid analogs, amino acids and their derivatives, peptides, cytokines, and specialized stimuli such as light, taste, and odor. Activation of the receptor by its stimulus causes the replacement of the G protein-bound GDP with GTP. G $\alpha$ -GTP dissociates from the receptor/ $\beta\gamma$  complex and each of these separated components can interact with and regulate downstream effectors. The signaling stops when G $\alpha$  hydrolyzes its bound GTP to GDP and reassociates with the  $\beta\gamma$  complex (Neer, supra).

The alpha subunits of heterotrimeric G proteins can be divided into four distinct classes. The  $\alpha$ -s class is sensitive to ADP-ribosylation by pertussis toxin which uncouples the receptor:G-protein interaction. This uncoupling blocks signal transduction to receptors that decrease cAMP levels which normally regulate ion channels and activate phospholipases. The inhibitory  $\alpha$ -I class is also susceptible to modification by pertussis toxin which prevents  $\alpha$ -I from lowering cAMP levels. Two novel classes of  $\alpha$  subunits refractory to pertussis toxin modification are  $\alpha$ -q, which activates phospholipase C, and  $\alpha$ -12, which has sequence homology with the *Drosophila* gene concertina and may contribute to the regulation of embryonic development (Simon, M.I. (1991) Science 252:802-808).

The mammalian G $\beta$  and G $\gamma$  subunits, each about 340 amino acids long, share more than 80% homology. The G $\beta$  subunit (also called transducin) contains seven repeating units, each about 43 amino acids long. The activity of both subunits may be regulated by other proteins such as calmodulin and phosducin or the neural protein GAP 43 (D. Clapham and E. Neer, 1993, Nature 365:403-406). The  $\beta$  and  $\gamma$  subunits are tightly associated. The  $\beta$  subunit sequences are highly conserved between species, implying that they perform a fundamentally important role in the organization and function of G-protein linked systems (Van der Voorn L. (1992) Febs. Lett. 307 (2):131-134). They contain seven tandem repeats of the WD-repeat sequence motif, a motif found in many proteins with regulatory functions. WD-repeat proteins contain from four to eight copies of a loosely conserved repeat of approximately 40 amino acids which participates in protein-protein interactions. Mutations and variant expression of  $\beta$  transducin proteins are linked with various disorders. Mutations in LIS1, a subunit of the human platelet activating factor acetylhydrolase, cause Miller-Dieker lissencephaly. RACK1 binds activated protein kinase C, and RbAp48 binds retinoblastoma protein. CstF is required for polyadenylation of mammalian pre-mRNA in vitro and associates with subunits of cleavage-stimulating factor. Defects in the regulation of  $\beta$ -catenin contribute to the neoplastic transformation of human cells. The WD40 repeats of the human F-box protein  $\beta$ TrCP mediate binding to  $\beta$ -catenin, thus regulating the targeted degradation of  $\beta$ -catenin by

ubiquitin ligase (Neer, *supra*; Hart, M. et al (1999) *Curr. Biol.* 9:207-210). The  $\gamma$  subunit primary structures are more variable than those of the  $\beta$  subunits. They are often post-translationally modified by isoprenylation and carboxyl-methylation of a cysteine residue four amino acids from the C-terminus; this appears to be necessary for the interaction of the  $\beta\gamma$  subunit with the membrane and  
5 with other GTP-binding proteins. The  $\beta\gamma$  subunit has been shown to modulate the activity of isoforms of adenylyl cyclase, phospholipase C, and some ion channels. It is involved in receptor phosphorylation via specific kinases, and has been implicated in the p21ras-dependent activation of the MAP kinase cascade and the recognition of specific receptors by GTP-binding proteins. (Clapham and Neer, *supra*).

10 G-proteins interact with a variety of effectors including adenylyl cyclase (Clapham and Neer, *supra*). The signaling pathway mediated by cAMP is mitogenic in hormone-dependent endocrine tissues such as adrenal cortex, thyroid, ovary, pituitary, and testes. Cancers in these tissues have been related to a mutationally activated form of a  $G\alpha_s$ , known as the gsp (Gs protein) oncogene (Dhanasekaran, *supra*). Another effector is phosducin, a retinal phosphoprotein, which forms a  
15 specific complex with retinal  $G\beta$  and  $G\gamma$  ( $G\beta\gamma$ ) and modulates the ability of  $G\beta\gamma$  to interact with retinal  $G\alpha$  (Clapham and Neer, *supra*).

Irregularities in the GTP-binding protein signaling cascade may result in abnormal activation of leukocytes and lymphocytes, leading to the tissue damage and destruction seen in many inflammatory and autoimmune diseases such as rheumatoid arthritis, biliary cirrhosis, hemolytic  
20 anemia, lupus erythematosus, and thyroiditis. Abnormal cell proliferation, including cyclic AMP stimulation of brain, thyroid, adrenal, and gonadal tissue proliferation is regulated by G proteins. Mutations in  $G\alpha$  subunits have been found in growth-hormone-secreting pituitary somatotroph tumors, hyperfunctioning thyroid adenomas, and ovarian and adrenal neoplasms (Meij, J.T.A. (1996) *Mol. Cell. Biochem.* 157:31-38; Aussel, *supra*).

25 LMW GTP-binding proteins are GTPases which regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. They consist of single polypeptides which, like the alpha subunit of the heterotrimeric GTP-binding proteins, are able to bind to and hydrolyze GTP, thus cycling between an inactive and an active state. LMW GTP-binding proteins respond to extracellular signals from receptors and activating proteins by transducing mitogenic signals involved  
30 in various cell functions. The binding and hydrolysis of GTP regulates the response of LMW GTP-binding proteins and acts as an energy source during this process (Bokoch, G. M. and Der, C. J. (1993) *FASEB J.* 7:750-759).

At least sixty members of the LMW GTP-binding protein superfamily have been identified

and are currently grouped into the ras, rho, arf, sar1, ran, and rab subfamilies. Activated ras genes were initially found in human cancers, and subsequent studies confirmed that ras function is critical in determining whether cells continue to grow or become differentiated. Ras1 and Ras2 proteins stimulate adenylate cyclase (Kaziro, *supra*), affecting a broad array of cellular processes. Stimulation of cell surface receptors activates Ras which, in turn, activates cytoplasmic kinases. These kinases translocate to the nucleus and activate key transcription factors that control gene expression and protein synthesis (Barbacid, M. (1987) *Ann. Rev Biochem.* 56:779-827, Treisman, R. (1994) *Curr. Opin. Genet. Dev.* 4:96-98). Other members of the LMW GTP-binding protein superfamily have roles in signal transduction that vary with the function of the activated genes and the locations of the GTP-binding proteins that initiate the activity. Rho GTP-binding proteins control signal transduction pathways that link growth factor receptors to actin polymerization, which is necessary for normal cellular growth and division. The rab, arf, and sar1 families of proteins control the translocation of vesicles to and from membranes for protein processing, localization, and secretion. Vesicle- and target- specific identifiers (v-SNAREs and t-SNAREs) bind to each other and dock the vesicle to the acceptor membrane. The budding process is regulated by the closely related ADP ribosylation factors (ARFs) and SAR proteins, while rab proteins allow assembly of SNARE complexes and may play a role in removal of defective complexes (J. Rothman and F. Wieland (1996) *Science* 272:227-234). Ran GTP-binding proteins are located in the nucleus of cells and have a key role in nuclear protein import, the control of DNA synthesis, and cell-cycle progression (Hall, A. (1990) *Science* 249:635-640; Barbacid, M. (1987) *Ann. Rev Biochem.* 56:779-827; Ktistakis, N. (1998) *BioEssays* 20:495-504; and Sasaki, T. and Takai, Y. (1998) *Biochem. Biophys. Res. Commun.* 245:641-645).

The cycling of LMW GTP-binding proteins between the GTP-bound active form and the GDP-bound inactive form is regulated by additional proteins. Guanosine nucleotide exchange factors (GEFs) increase the rate of nucleotide dissociation by several orders of magnitude, thus facilitating release of GDP and loading with GTP. The best characterized is the mammalian homologue of the *Drosophila* Son-of-Sevenless protein. Certain Ras-family proteins are also regulated by guanine nucleotide dissociation inhibitors (GDIs), which inhibit GDP dissociation. The intrinsic rate of GTP hydrolysis of the LMW GTP-binding proteins is typically very slow, but it can be stimulated by several orders of magnitude by GTPase-activating proteins (GAPs) (Geyer, M. and Wittinghofer, A. (1997) *Curr. Opin. Struct. Biol.* 7:786-792). Both GEF and GAP activity may be controlled in response to extracellular stimuli and modulated by accessory proteins such as RaBP1 and POB1. Mutant Ras-family proteins, which bind but can not hydrolyze GTP, are permanently activated, and cause cell proliferation or cancer, as do GEFs that inappropriately activate LMW GTP-binding proteins, such as the human oncogene NET1, a Rho-GEF (Drivas, G. T. et al. (1990) *Mol. Cell. Biol.* -

10:1793-1798; Alberts, A. S. and Treisman, R. (1998) EMBO J. 14:4075-4085).

A novel group of GTP-binding proteins is the GTP1/OBG family, which are found in species ranging from bacteria to yeast to humans. These proteins contain characteristic GTP-binding motifs and are similar to one another but do not show sequence homology to other GTP-binding proteins.

- 5 The exact functions of these proteins are as yet uncertain, but they have been shown to be important for regulation of cell differentiation and development (Okamoto, S. and Ochi, K. (1998). Mol. Microbiol 30:107-119; Sazaka, T. et al. (1992) Biochem. Biophys. Res. Commun. 189:363-370).

- The discovery of new GTPase associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis,  
10 prevention, and treatment of cell proliferative, autoimmune/inflammatory, and immune system disorders.

### SUMMARY OF THE INVENTION

- The invention features substantially purified polypeptides, GTPase associated proteins,  
15 referred to collectively as "GTPAP" and individually as "GTPAP-1," "GTPAP-2," "GTPAP-3,"  
"GTPAP-4," "GTPAP-5," "GTPAP-6," "GTPAP-7," "GTPAP-8," "GTPAP-9," "GTPAP-10,"  
"GTPAP-11," "GTPAP-12," "GTPAP-13," "GTPAP-14," "GTPAP-15," "GTPAP-16," "GTPAP-17,"  
"GTPAP-18," "GTPAP-19," "GTPAP-20," "GTPAP-21," "GTPAP-22," "GTPAP-23," "GTPAP-24,"  
"GTPAP-25," "GTPAP-26," "GTPAP-27," "GTPAP-28," and "GTPAP-29." In one aspect, the  
20 invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also includes a polypeptide comprising an amino acid sequence that differs by one or more conservative amino acid substitutions from an amino acid sequence selected from the group consisting of SEQ ID NO:1-29.

- The invention further provides a substantially purified variant having at least 90% amino acid  
25 identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide  
30 encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof. The

invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

5 The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of: (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

10 The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof. The invention also provides an isolated and  
15 purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group  
20 consisting of SEQ ID NO:1-29. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing a polynucleotide of the invention under conditions suitable for the expression of the polypeptide; and (b) recovering the  
25 polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from  
30 the group consisting of SEQ ID NO:1-29 and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially



purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

### BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding GTPAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of GTPAP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding GTPAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze GTPAP, along with applicable descriptions, references, and threshold parameters.

### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same

meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing  
5 the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

## DEFINITIONS

“GTPAP” refers to the amino acid sequences of substantially purified GTPAP obtained from  
10 any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term “agonist” refers to a molecule which intensifies or mimics the biological activity of GTPAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GTPAP either by directly interacting with  
15 GTPAP or by acting on components of the biological pathway in which GTPAP participates.

An “allelic variant” is an alternative form of the gene encoding GTPAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to  
20 allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding GTPAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GTPAP or a  
25 polypeptide with at least one functional characteristic of GTPAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GTPAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GTPAP. The encoded protein may also be “altered,” and may contain deletions, insertions, or  
30 substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GTPAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GTPAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged -

amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

5           The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein  
10 molecule.

          "Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

          The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity  
15 of GTPAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GTPAP either by directly interacting with GTPAP or by acting on components of the biological pathway in which GTPAP participates.

          The term "antibody" refers to intact immunoglobulin molecules as well as to fragments  
20 thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GTPAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.  
25 Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

          The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to  
30 immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

          The term "antisense" refers to any composition containing a nucleic acid sequence which is

complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic GTPAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GTPAP or fragments of GTPAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the

protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
5	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
10	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
15	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
20	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

25 Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the  
30 absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function  
35 of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of GTPAP or the polynucleotide encoding GTPAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up  
40 to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment

used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:30-58 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:30-58, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:30-58 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:30-58 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:30-58 and the region of SEQ ID NO:30-58 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-29 is encoded by a fragment of SEQ ID NO:30-58. A fragment of SEQ ID NO:1-29 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-29. For example, a fragment of SEQ ID NO:1-29 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-29. The precise length of a fragment of SEQ ID NO:1-29 and the region of SEQ ID NO:1-29 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the

substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps  
5 in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e  
10 sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue  
15 weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from  
20 several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2  
25 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

30     *Matrix: BLOSUM62*  
      *Reward for match: 1*  
      *Penalty for mismatch: -2*  
      *Open Gap: 5 and Extension Gap: 2 penalties*  
      *Gap x drop-off: 50*

*Expect: 10*

*Word Size: 11*

*Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example,  
5 as defined by a particular SEQ ID number, or may be measured over a shorter length, for example,  
over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at  
least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous  
nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported  
by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a  
10 length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode  
similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes  
in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid  
sequences that all encode substantially the same protein.

15 The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to  
the percentage of residue matches between at least two polypeptide sequences aligned using a  
standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some  
alignment methods take into account conservative amino acid substitutions. Such conservative  
substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the  
20 site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default  
parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e  
sequence alignment program (described and referenced above). For pairwise alignments of  
polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap  
25 penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default  
residue weight table. As with polynucleotide alignments, the percent identity is reported by  
CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise  
comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9  
30 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

*Gap x drop-off: 50*

*Expect: 10*



Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

10       “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

15       “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

25       Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY;

specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration  
5 may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to  
10 those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A  
15 hybridization complex may be formed in solution (e.g., C<sub>0</sub>t or R<sub>0</sub>t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide  
20 sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

25 The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of GTPAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other  
30 biological, functional, or immunological properties of GTPAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Probe" refers to nucleic acid sequences encoding GTPAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5. 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to

5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

20 A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding GTPAP, or fragments thereof, or GTPAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, -

RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may

have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

## THE INVENTION

The invention is based on the discovery of new human GTPase associated proteins (GTPAP), the polynucleotides encoding GTPAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, and immune system disorders.

Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding GTPAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each GTPAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each GTPAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical

methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding GTPAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:30-58 and to distinguish between SEQ ID NO:30-58 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express GTPAP as a fraction of total tissues expressing GTPAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing GTPAP as a fraction of total tissues expressing GTPAP. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the specific expression of SEQ ID NO:43 in only one library, a human testis tissue library; the specific expression of SEQ ID NO:49 in only 4 libraries, one of which is associated with cell proliferation and 3 of which are associated with inflammation; and the specific expression of SEQ ID NO:40 in only 5 libraries, 3 of which are associated with cell proliferation and one of which is associated with inflammation.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding GTPAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses GTPAP variants. A preferred GTPAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GTPAP amino acid sequence, and which contains at least one functional or structural characteristic of GTPAP.

The invention also encompasses polynucleotides which encode GTPAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:30-58, which encodes GTPAP.

The invention also encompasses a variant of a polynucleotide sequence encoding GTPAP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 90%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GTPAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:30-58 which has at least about 70%, or alternatively at least about 90%, or even at least about

95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:30-58. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GTPAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GTPAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GTPAP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GTPAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GTPAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GTPAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GTPAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GTPAP and GTPAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GTPAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:30-58 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment



of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding GTPAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been

size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

- 5           Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate  
10   software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

- In another embodiment of the invention, polynucleotide sequences or fragments thereof  
15   which encode GTPAP may be cloned in recombinant DNA molecules that direct expression of GTPAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GTPAP.

- The nucleotide sequences of the present invention can be engineered using methods generally  
20   known in the art in order to alter GTPAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction  
25   sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

- In another embodiment, sequences encoding GTPAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, GTPAP itself or a fragment thereof may be synthesized using chemical methods. For  
30   example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of GTPAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active GTPAP, the nucleotide sequences encoding GTPAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GTPAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GTPAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GTPAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GTPAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GTPAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or

tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GTPAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GTPAP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GTPAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of GTPAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of GTPAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GTPAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of GTPAP. Transcription of sequences encoding GTPAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GTPAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader

sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GTPAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of GTPAP in cell lines is preferred. For example, sequences encoding GTPAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *ap<sup>r</sup>* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.

(See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GTPAP is inserted within a marker gene sequence, transformed cells containing  
5 sequences encoding GTPAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GTPAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GTPAP and that express  
10 GTPAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GTPAP using either  
15 specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GTPAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See,  
20 e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and  
25 may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GTPAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GTPAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available,  
30 and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for

ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GTPAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein  
5 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GTPAP may be designed to contain signal sequences which direct secretion of GTPAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the  
10 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for  
15 post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GTPAP may be ligated to a heterologous sequence resulting in translation of a  
20 fusion protein in any of the aforementioned host systems. For example, a chimeric GTPAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GTPAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),  
25 maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies  
30 that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GTPAP encoding sequence and the heterologous protein sequence, so that GTPAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10).

A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GTPAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

Fragments of GTPAP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of GTPAP may be synthesized separately and then combined to produce the full length molecule.

### **THERAPEUTICS**

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GTPAP and GTPase associated proteins. In addition, the expression of GTPAP is closely associated with proliferating tissues associated with cancer and fetal development, inflamed tissues, and tissues involved in the immune response. Therefore, GTPAP appears to play a role in cell proliferative, autoimmune/inflammatory, and immune system disorders. In the treatment of disorders associated with increased GTPAP expression or activity, it is desirable to decrease the expression or activity of GTPAP. In the treatment of disorders associated with decreased GTPAP expression or activity, it is desirable to increase the expression or activity of GTPAP.

Therefore, in one embodiment, GTPAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis,



autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis,

5 glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner

10 syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and an immune system disorder, such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobinemia of Bruton, common variable immunodeficiency (CVI), DiGeorge's syndrome (thymic hypoplasia), thymic dysplasia, isolated IgA deficiency, severe combined immunodeficiency disease (SCID),

15 immunodeficiency with thrombocytopenia and eczema (Wiskott-Aldrich syndrome), Chediak-Higashi syndrome, chronic granulomatous diseases, hereditary angioneurotic edema, and immunodeficiency associated with Cushing's disease, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease.

In another embodiment, a vector capable of expressing GTPAP or a fragment or derivative

20 thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified GTPAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP including, but not

25 limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GTPAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GTPAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of GTPAP may be administered to a subject to treat or

30 prevent a disorder associated with increased expression or activity of GTPAP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, and immune system disorders described above. In one aspect, an antibody which specifically binds GTPAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for

bringing a pharmaceutical agent to cells or tissues which express GTPAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GTPAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GTPAP including, but not limited to, those described above.

5 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the  
10 various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GTPAP may be produced using methods which are generally known in the art. In particular, purified GTPAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GTPAP. Antibodies to GTPAP may  
15 also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans,  
20 and others may be immunized by injection with GTPAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in  
25 humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GTPAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the  
30 entire amino acid sequence of a small, naturally occurring molecule. Short stretches of GTPAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GTPAP may be prepared using any technique which provides for

the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and  
5 Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda,  
10 S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GTPAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

15 Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299.)

Antibody fragments which contain specific binding sites for GTPAP may also be generated.  
20 For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) *Science* 246:1275-1281.)

25 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GTPAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies  
30 reactive to two non-interfering GTPAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GTPAP. Affinity is expressed as an

association constant,  $K_a$ , which is defined as the molar concentration of GTPAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GTPAP epitopes, represents the average affinity, or avidity, of the antibodies for GTPAP. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular GTPAP epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the GTPAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GTPAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GTPAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GTPAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding GTPAP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding GTPAP. Thus, complementary molecules or fragments may be used to modulate GTPAP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GTPAP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides

encoding GTPAP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding GTPAP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding GTPAP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in  
5 the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing  
10 complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding GTPAP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for  
15 the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

20 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GTPAP.

25 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of  
30 candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques

for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GTPAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA  
5 constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase  
10 linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.  
15 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical  
25 or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of GTPAP, antibodies to GTPAP, and mimetics, agonists, antagonists, or inhibitors of GTPAP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical  
30 carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial,

intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's

solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of GTPAP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GTPAP or fragments thereof, antibodies of GTPAP, and agonists, antagonists or inhibitors of GTPAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be



determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the  $LD_{50}/ED_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

10       The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

20       Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

## DIAGNOSTICS

25       In another embodiment, antibodies which specifically bind GTPAP may be used for the diagnosis of disorders characterized by expression of GTPAP, or in assays to monitor patients being treated with GTPAP or agonists, antagonists, or inhibitors of GTPAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GTPAP include methods which utilize the antibody and a label to detect GTPAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GTPAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GTPAP expression. Normal or standard values for GTPAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to  
5 GTPAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GTPAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

10 In another embodiment of the invention, the polynucleotides encoding GTPAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GTPAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess  
15 expression of GTPAP, and to monitor regulation of GTPAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GTPAP or closely related molecules may be used to identify nucleic acid sequences which encode GTPAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a  
20 conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GTPAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GTPAP encoding sequences. The hybridization probes of the subject  
25 invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:30-58 or from genomic sequences including promoters, enhancers, and introns of the GTPAP gene.

Means for producing specific hybridization probes for DNAs encoding GTPAP include the cloning of polynucleotide sequences encoding GTPAP or GTPAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may  
30 be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GTPAP may be used for the diagnosis of disorders associated with expression of GTPAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and an immune system disorder, such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobulinemia of Bruton, common variable immunodeficiency (CVI), DiGeorge's syndrome (thymic hypoplasia), thymic dysplasia, isolated IgA deficiency, severe combined immunodeficiency disease (SCID), immunodeficiency with thrombocytopenia and eczema (Wiskott-Aldrich syndrome), Chediak-Higashi syndrome, chronic granulomatous diseases, hereditary angioneurotic edema, and immunodeficiency associated with Cushing's disease, leukemias such as multiple myeloma, and lymphomas such as Hodgkin's disease. The polynucleotide sequences encoding GTPAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin. and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GTPAP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GTPAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GTPAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GTPAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GTPAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GTPAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding GTPAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a

polynucleotide encoding GTPAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding GTPAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

5       Methods which may also be used to quantify the expression of GTPAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is  
10       presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

      In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify  
15       genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

      Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)  
20

      In another embodiment of the invention, nucleic acid sequences encoding GTPAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence.  
25       The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

30       Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the

location of the gene encoding GTPAP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

5        In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides  
10        valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention  
15        may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

      In another embodiment of the invention, GTPAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a  
20        solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GTPAP and the agent being tested may be measured.

      Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are  
25        synthesized on a solid substrate. The test compounds are reacted with GTPAP, or fragments thereof, and washed. Bound GTPAP is then detected by methods well known in the art. Purified GTPAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

30        In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GTPAP specifically compete with a test compound for binding GTPAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GTPAP.

In additional embodiments, the nucleotide sequences which encode GTPAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

5 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Without further elaboration, it is believed that one skilled in the art can, using the preceding  
10 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. Nos. 60/109,592, 60/118,610, and 60/127,990 are hereby expressly incorporated  
15 by reference.

## EXAMPLES

### I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some  
20 tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

25 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A<sup>+</sup>) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA  
30 purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the

recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-  
5 1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent E. coli  
10 cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a  
15 Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

20 Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence  
25 scanner (Labsystems Oy, Helsinki, Finland).

## III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific)  
30 or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled



polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in 5 Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable 10 descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the 15 greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned 20 sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, 25 and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length 30 amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene

families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:30-58. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding GTPAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

#### V. Extension of GTPAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:30-58 were produced by extension of

an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and  $\beta$ -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5  $\mu$ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham

Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

- 5           The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
- 10 recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

- In like manner, the nucleotide sequences of SEQ ID NO:30-58 are used to obtain 5'
- 15 regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

#### **VI. Labeling and Use of Individual Hybridization Probes**

- Hybridization probes derived from SEQ ID NO:30-58 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base
- 20 pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a
- 25 SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

- The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon
- 30 membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and

compared.

## VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

## VIII. Complementary Polynucleotides

Sequences complementary to the GTPAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GTPAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GTPAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GTPAP-encoding transcript.

## IX. Expression of GTPAP

Expression and purification of GTPAP is achieved using bacterial or virus-based expression

systems. For expression of GTPAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GTPAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GTPAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GTPAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GTPAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GTPAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GTPAP obtained by these methods can be used directly in the following activity assay.

#### X. Demonstration of GTPAP Activity

The role of GTPAP can be assayed in vitro by monitoring the mobilization of  $Ca^{++}$  as part of the signal transduction pathway. (See, e.g., Grynkievicz, G. et al. (1985) J. Biol. Chem. 260:3440; McColl, S. et al. (1993) J. Immunol. 150:4550-4555; and Aussel, C. et al. (1988) J. Immunol. 140:215.) The assay requires preloading neutrophils or T cells with a fluorescent dye such as FURA-2.

Upon binding  $\text{Ca}^{++}$ , FURA-2 exhibits an absorption shift that can be observed by scanning the excitation spectrum between 300 and 400 nm, while monitoring the emission at 510 nm. When the cells are exposed to one or more activating stimuli artificially (i.e., anti-CD3 antibody ligation of the T cell receptor) or physiologically (i.e., by allogeneic stimulation),  $\text{Ca}^{++}$  flux takes place.  $\text{Ca}^{++}$  flux results from the release of  $\text{Ca}^{++}$  from intracellular organelles or from  $\text{Ca}^{++}$  entry into the cell through activated  $\text{Ca}^{++}$  channels. This flux can be observed and quantified by assaying the cells in a fluorometer or fluorescence activated cell sorter. Measurements of  $\text{Ca}^{++}$  flux are compared between cells in their normal state and those preloaded with GTPAP. Increased mobilization attributable to increased GTPAP availability results in increased emission.

- 10 Alternatively, GTPAP activity is measured by quantifying the amount of a non-hydrolyzable GTP analogue, GTP $\gamma$ S, bound over a 10 minute incubation period. Varying amounts of GTPAP are incubated at 30°C in 50mM Tris buffer, pH 7.5, containing 1mM dithiothreitol, 1mM EDTA and 1 $\mu$ M [ $^{35}\text{S}$ ]GTP $\gamma$ S. Samples are passed through nitrocellulose filters and washed twice with a buffer consisting of 50mM Tris-HCl, pH 7.8, 1mM  $\text{NaN}_3$ , 10mM  $\text{MgCl}_2$ , 1mM EDTA, 0.5mM
- 15 dithiothreitol, 0.01mM PMSF, and 200mM NaCl. The filter-bound counts are measured by liquid scintillation to quantify the amount of bound [ $^{35}\text{S}$ ]GTP $\gamma$ S. GTPAP activity may also be measured as the amount of GTP hydrolysed over a 10 minute incubation period at 37°C. GTPAP is incubated in 50mM Tris-HCl buffer, pH 7.8, containing 1mM dithiothreitol, 2mM EDTA, 10 $\mu$ M [ $\alpha$ - $^{32}\text{P}$ ]GTP, and 1 $\mu$ M H-rab protein. GTPase activity is initiated by adding  $\text{MgCl}_2$  to a final concentration of 10 mM.
- 20 Samples are removed at various time points, mixed with an equal volume of ice-cold 0.5mM EDTA, and frozen. Aliquots are spotted onto polyethyleneimine-cellulose thin layer chromatography plates, which are developed in 1M LiCl, dried, and autoradiographed. The signal detected is proportional to GTPAP activity.

- Alternatively, GTPAP activity may be demonstrated as the ability to interact with its
- 25 associated G $\alpha$  or LMW GTPase in an in vitro binding assay. The candidate GTPases are expressed as fusion proteins with glutathione S-transferase (GST), and purified by affinity chromatography on glutathione-Sepharose. The GTPases are loaded with GDP by incubating 20 mM Tris buffer, pH 8.0, containing 100 mM NaCl, 2 mM EDTA, 5 mM  $\text{MgCl}_2$ , 0.2 mM DTT, 100  $\mu$ M AMP-PNP and 10  $\mu$ M GDP at 30°C for 20 minutes. GTPAP is expressed as a FLAG fusion proteins in a baculovirus system.
- 30 Extracts of these baculovirus cells containing GTPAP-FLAG fusion proteins are precleared with GST beads, then incubated with GST-GTPase fusion proteins. The complexes formed are precipitated by glutathione-Sepharose and separated by SDS-polyacrylamide gel electrophoresis. The separated proteins are blotted onto nitrocellulose membranes and probed with commercially available anti-

FLAG antibodies. GTPAP activity is proportional to the amount of GTPAP-FLAG fusion protein detected in the complex.

#### **XI. Functional Assays**

GTPAP function is assessed by expressing the sequences encoding GTPAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GTPAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GTPAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding GTPAP and other genes of interest can be analyzed by northern analysis or microarray techniques.



## **XII. Production of GTPAP Specific Antibodies**

GTPAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

5 Alternatively, the GTPAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

10 Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-  
15 GTPAP activity by, for example, binding the peptide or GTPAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

## **XIII. Purification of Naturally Occurring GTPAP Using Specific Antibodies**

Naturally occurring or recombinant GTPAP is substantially purified by immunoaffinity chromatography using antibodies specific for GTPAP. An immunoaffinity column is constructed by  
20 covalently coupling anti-GTPAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GTPAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GTPAP (e.g., high ionic strength  
25 buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GTPAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GTPAP is collected.

## **XIV. Identification of Molecules Which Interact with GTPAP**

GTPAP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter  
30 reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GTPAP, washed, and any wells with labeled GTPAP complex are assayed. Data obtained using different concentrations of GTPAP are used to calculate values for the number, affinity, and association of

GTPAP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be  
5 understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	30	708398	SYNORAT04	56987X31 (MMLR3DT01), 708398H1, 708398X11, 708398X15, 708398X16, 708398X17, and 708398X21 (SYNORAT04), 2170523F6 (ENDCNOT03), 3374750H1 (CONNTUT05)
2	31	1259937	MENITUT03	913652R6 (STOMNOT02), 1259937F6 and 1259937H1 (MENITUT03), 1476721F1 (CORPNOT02), 1729248F6 (BRSTTUT08), 2191963H1 (THYRTUT03), 3129757F6 (LUNGUT02), 3268746X15F1 (BRAINOT20), 3428891F6 (SKINNOT04)
3	32	1452285	PENITUT01	1452285F6 and 1452285H1 (PENITUT01), 2605011H1 (LUNGUT07), 3505135H1 (ADRENOT11)
4	33	1812894	PROSTUT12	1812894H1, 1812894X12 and 1809113T6 (PROSTUT12), 1904479F6 (OVARNOT07), 2232535X15F1 and 2232535X18F1 (PROSNOT16), 2267486X16C1 (UTRSNOT02), 2508562F6 (CONUTUT01)
5	34	3074884	BONEUNT01	225362F1 (PANCNOT01), 900707R1 (BRSTTUT03), 1339234F6 (COLNTUT03), 1759046R6 (PITUNOT03), 3074884H1 (BONEUNT01), SBDA02767F1
6	35	3452277	UTRSNON03	1684553F6 (PROSNOT15), 1951534H1 (PITUNOT01), 3452277H1 (UTRSNON03), 4092781T6 (BSCNSZT01), SBFA01413F1, SBFA03044F1, SBFA01805F1
7	36	4203832	BRAITUT29	723394F1 (SYNOOAT01), 8622290R1, and 8622290T1 (BRAITUT03), 1560918F1 (SPLNNOT04), 3509241H1 (CONCNOT01), 4203832H1 (BRAITUT29)
8	37	104368	BMARNOT02	104368H1 (BMARNOT02), SAEA03574F1, SAEA01063F1, SAEA00392F1, SAEA02287F1
9	38	1441680	THYRNOT03	1441680F6, 1441680H1, and 1441680T6 (THYRNOT03), 1904222F6 (OVARNOT07), 2477983F6 (SMCANOT01)
10	39	1494955	PROSNON01	965986R1 (BRSTNOT05), 1429037F1 and 1429037T1 (SINTBST01), 1453487F6 (PENITUT01), 1486114H1 (CORPNOT02), 1494955H1 (PROSNON01), 1995426R6 (BRSTTUT03), 2112074X18F1 and 2112348R6 (BRAITUT03)
11	40	1508161	LUNGNOT14	1508161F6 and 1508161H1 (LUNGNOT14), 3334303H1 (BRAIFET01), 4755656H1 (BRAHNOT01)
12	41	1811877	PROSTUT12	493795H1 (HNT2NOT01), 1573136H1 (LNODNOT03), 1811877F6 and 1811877H1 (PROSTUT12), 1825223F6 (LSUBNOT03), 2454143H1 (ENDANOT01), 2651022H1 (BLADTUT08), 3487062H1 (EPIGNOT01), 4536531H1 (OVARNOT12), 4795253H1 (LIVRTUT09), 4854087H1 (TESTNOT10), 4906149H2 (TYLNNOT08), 5196386H1 (LUNLTUT04)

Table 1 (cont.)

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
13	42	1848674	LUNGFET03	1574127F6, 3857867X306F1, and 3857867X313F1 (LNODNOT03), 1848674H1 (LUNGFET03), 1877170F6 (LEUKNOT03), 2695307H1 (UTRSNOT12), 4148654H1 (SINITUT04), 4984182H1 (HELATX05), 5288671H1 (LIVRTUS02)
14	43	2012970	TESTNOT03	2012970H1, 2012970R6, 2012970X11F (TESTNOT03)
15	44	2254315	OVARTUT01	022341F1 (ADENINB01), 198476R6 (KIDNNOT02), 2254315H1 (OVARTUT01), 2370170F6 (ADRENOT07), 2451278F6 (ENDANOT01)
16	45	2415545	HNT3AZT01	775722H1 (COLNNOT05), 870320R6 (LUNGAST01), 889023R1 (STOMTUT01), 895724R1 (BRSTNOT05), 1398541F1 (BRAITUT08), 1662585F6 (BRSTNOT09), 2415545H1 (HNT3AZT01), 2985066H1 (CARGDIT01), 3462702H1 (293TF2T01)
17	46	2707969	PONSAZT01	282552R1, 282552X23, and 282552X7 (CARDNOT01), 889783R1 (STOMTUT01), 1995451R6 (BRSTTUT03), 2707969H1 (PONSAZT01), SAAC00359R1.comp, SAAB00136R1, SAAC00330R1
18	47	2817769	BRSTNOT14	041660R1 (TBLYNOT01), 077378R1 (SYNORAB01), 740028R1 (PANCNOT04), 1593201F6 (BRAINOT14), 1924025R6 (BRSTTUT01), 2817769H1 (BRSTNOT14)
19	48	2917557	THYMFET03	473002F1 and 473002R1 (MMLR1DT01), 690999R6 (LUNGTUT02), 997483R1 (KIDNTUT01), 1430662F6 (SINTBST01), 1514017F1 (PANCUTUT01), 1740475R6 (HIPONON01), 2109547H1 (BRAITUT03), 2917557H1 (THYMFET03), 4309528H1 (BRAUNOT01), 4990135H1 (LIVRTUT11)
20	49	3421335	UCMCNOT04	777588R6 and 777588T6 (COLNNOT05), 3421335H1 (UCMCNOT04)
21	50	605761	BRSTTUT01	605761F1, 605761H1, and 605761R6 (BRSTTUT01), 1271131X15 (TESTTUT02), 1516985F1 (PANCUTUT01), 1524935H1 (UCMCL5T01), 2234846F6 (PANCUTUT02)
22	51	483862	HNT2RAT01	483862H1 and 483862R1 (HNT2RAT01), 1750781X305F1, 1750781X307D2 (LIVRTUT01)
23	52	1256777	MENITUT03	264041R6 (HNT2AGT01), 826449R1 (PROSNOT06), 1256777H1 (MENITUT03), 2276061R6 (PROSNON01), 4614049H1 (BRAHNOT01)
24	53	2198779	SPLNFET02	1557708F6 (BLADTUT04), 1922490R6 (BRSTTUT01), 2198779H1 (SPLNFET02), 2541193F7 (BONRTUT01), 3039254F6 (BRSTNOT16), 3057079H1 (LNODNOT08), 3105017H1 (COLNUCT03), 4239592H1 (SYNWDIT01), 5064513H1 (ARTFTDT01)

Table 1 (cont.)

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
25	54	22261116	SEWVNOT01	1662607F6 (BRSTNOT09), 1662607T6 (BRSTNOT09), 2226116F6 (SEWVNOT01), 2226116H1 (SEWVNOT01), 2930011F6 (TLYVNOT04), 3015747T6 (MUSCNOT07), 4087670H1 (LIVRNOT06)
26	55	2504472	CONUTUT01	420365F1 (BRSTNOT01), 762246R1 (BRAITUT02), 907754R2 (COLNNOT09), 1007508H1 (HEALDIT02), 1302342F6 (PLACNOT02), 1913887H1 (PROSTUT04), 2023822F6 (CONNNOT01), 2023822X11R1 (CONNNOT01), 2504472H1 (CONUTUT01), 2951618F6 (KIDNFET01)
27	56	3029920	HEARFET02	354846T6 (RATRNOT01), 418533R6 (BRSTNOT01), 935073R1 (CERVNOT01), 1340722F1 (COLNTUT03), 1416203T6 (BRAINOT12), 1524567F1 (UCMCL5T01), 1773043H1 (MENTUNON3), 2590310H2 (LUNGNOT22), 3029920H1 (HEARFET02), 4873053H1 (COLDNOT01), 5687696H1 (BRAIUNT01)
28	57	3332415	BRAIFET01	118166R1 (MUSCNOT01), 1257348H1 (MENITUT03), 1288237T6 (BRAINOT11), 1335936F6 (COLNNOT13), 1452268H1 (PENITUT01), 1996016R6 (BRSTTUT03), 2116665R6 (BRSTTUT02), 2206894F6 (SINTFET03), 2540063H1 (BONRTUT01), 2808268H1 (BLADTUT08), 3086221H1 (HEAONOT03), 3127508H1 (LUNGUTUT12), 3295812H1 (TLYJINT01), 3332415H1 (BRAIFET01), 3604705H1 (LUNGNOT30), 4821203H1 (PROSTUT17), 4970353H1 (KIDEUNC10), 5055775H1 (COLATMT01)
29	58	4031536	BRAINOT23	029167X3 (SPLNFET01), 350137R1 (LVENNOT01), 408825X1 (EOSIHET02), 689446X23 (LUNGUTUT02), 1963062R6 (BRSTNOT04), 2288043R6 (BRAINON01), 4031536H1 (BRAINOT23)

Table 2

Polyptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
1	1002	T30 S224 T405 S499 T533 S558 S701 T737 T845 S864 S6 T152 T268 T412 T442 T464 T514 T528 T693 S814 S815 S823 T880 Y117 Y842	N446	G524-T531: ATP/GTP- binding site motif	GTP-binding protein [Mus musculus] g53169	BLAST MOTIFS
2	338	S21 S77 T86 S200 T246 T299 S77 S306 Y131	N244		CAMP- regulated Guanine nucleotide exchange factor [Rattus norvegicus] g4079657	BLAST
3	211	S159 S199	N33, N74	G16-T23: ATP/GTP- binding site motif	GTP-binding protein [Rattus norvegicus] g206543	BLAST MOTIFS PFAM BLOCKS PRINTS
4	516	T14 S42 T237 S270 S347 S360 T371 T395 T433 S500 T3 S13 S96 T316 S430			Fos-related antigen [Rattus norvegicus] g1016712 Rabaptin-4 [H. sapiens] g3832516	BLAST MOTIFS
5	445	T44 T114 T219 T297 S314 S341 S356 T412 T24 S72 T91 T328 T388 T394		G230-T237: ATP/GTP- binding site motif	GTP-binding protein [H. sapiens] g2765411	BLAST MOTIFS

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
6	445	S174 S202 S289 S29 S305 S323 T434 T11 T147 T197 T198 S270 S273 S371 S397 Y125	N73		Regulator of G-protein signaling-9 [H. sapiens] g3284012	BLAST
7	281	S182 S210 S254 S13 T56 S110 S182 S32 T46 S66 S177	N130 N181	G31-T38:ATP/GTP- binding site motif	Putative ras- like protein [H. sapiens] g4092830	MOTIFS PRINTS BLAST PFAM
8	301	S92 T2 T3 Y15 S18 S19 S20 S25 S97 T120 S165 S296 T94 S116 T120 S284		E47-G66, S116-E178, Y188-G272: Phosducin signature	Phosducin- like protein [Rattus rattus] g1323727	MOTIFS BLAST PRINTS
9	485	T6 Y57 S82 T91 S112 S187 T231 T257 S309 T6 T81 S132 S157 S210 S241 T462	N460	L49-S82: Beta G protein	Similar to WD domain Beta transducin- like protein [C. elegans] g5596646	MOTIFS BLAST PRINTS
10	447	S420 S94 T107 S118 T167 T179 T308 S390 S39 S58 T78 T113 S129 T160 T167 Y174 T199 S216 S291 T302 T323 T359 T384 S423 T438	N76 N92 N231 N289 N378 N421	M294-T308: Beta transducin	WS beta- transducin repeat protein [Homo sapiens] g4704417	MOTIFS BLAST
11	199	S90 T55 T140 S190		K6-E130: Ras Guanine exchange factor	Putative guanine nucleotide releasing factor [Drosophila affinis] g2981229	MOTIFS BLAST PFAM

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
12	694	S57 S67 S99 T150 T346 S416 S467 S500 T522 T684 S99 T156 S209 S285 T331 T360 T388 T430 T477 T650 T688		L10-I24, M96-L110: Beta transducin	Transducin- like protein [H. sapiens] g414536	MOTIFS BLAST
13	654	T10 S15 T49 S97 S102 S104 S112 S113 S377 S432 S638 T46 S54 S84 S97 T177 S217 T307 S401 S450 S504 T515 S546 T547 S561 Y618	N353 N362 N502	L197-F211: Beta transducin	Similar to the beta transducin family [C. elegans] g2315521	MOTIFS BLAST
14	180	S14		G23-S30: ATP-GTP binding site	Rab7C (small GTP binding protein) [Lotus japonicus] g1370186	MOTIFS BLAST
15	374	T100 T249 S260 T308 T328 S338 S351 S30 T73 T157 S237 T308	N114 N189 N222	G26-T33: ATP-GTP binding site	ATP(GTP)- binding protein [H. sapiens] g3646130	MOTIFS BLAST
16	649	S67 T344 S366 S63 S68 S75 S122 S177 S265 T282 T332 S373 S380 S563 T569 S634 S20 T94 S128 S314 T382 T385 T458 T559		F307-S544: Probable rabGAP domain	Similar to probable rabGAP [C. elegans] g3925265	MOTIFS BLAST PFAM
17	698	T244 S262 S17 T41 T42 T196 S206 S317 S479 S522 S556 T586 T680 T31 S95 T99 T140 T173 S257 T322 S374 T450 S568 T619	N171 N194 N685		Small GTP- binding protein associated protein [Mus musculus] g725274	MOTIFS BLAST



Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
18	396	T325 S115 T133 S232 S275 T336 S22 T221 S232 T320	N60 N230 N286	G29-S36: ATP-GTP binding site	Putative GTP- binding protein [C. elegans] g3880615	MOTIFS BLAST
19	634	T197 S3 S5 S9 T14 S132 T197 T285 T553 T40 T56 S160 T189 S261 S582 Y20 Y396 Y419		G52-T59: ATP-GTP binding site	Putative GTP- binding protein [H. sapiens] g3169010	MOTIFS BLAST
20	196	T60 S73 S90 S99 S73 S193		G19-T26: ATP-GTP binding site	Kidney injury associated protein HW052 Acc No W86322 ADP- ribosylation factor-like protein 3 [Rattus norvegicus] g560006	MOTIFS BLAST
21	446	T10 T24 T93 S122 T243 S263 S270 T305 S317 S325 T357 S372 T379 S100 S170 S223 T227 S285 T348	N79	L323-L337: Beta transducin	Putative WD40 repeat protein [A. thaliana] g4191784	MOTIFS BLAST
22	265	T184 T76 T137 S139 T161 T174 T183 S213	N159	L141, L148, L155 L: zipper gene regulatory motif	TipD; similar to beta transducin family [D. discoideum] g2407788	MOTIFS BLAST

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
23	185	T55 S111 S127 S148 S171 S14 S94 Y103		G10-T17: ATP/GTP binding site (P- loop) A4-S72: Ras domain		MOTIFS PFAM PRINTS
24	554	S388 T488 S30 S75 T111 S149 S220 S237 T255 S305 S325 T339 T359 S363 S509 S172 T195 S211 T378 T438 T470 Y203	N5	N297-D336, P345- D383, G481-Q519: Beta-transducin WD40 repeats	WD-repeat protein [Arabidopsis thaliana] g3924603	BLAST MOTIFS PFAM PRINTS
25	434	S164 S341 T347 S36 S68 S92 T286 S364	N22 N383	G259-S266:ATP/GTP binding site (P- loop): G113-R433: GTP1/OBG domain	Predicted GTP binding protein [C. elegans] g3878629	BLAST MOTIFS PFAM BLOCKS PRINTS
26	826	S122 T243 T247 T427 S454 S519 T528 S623 S701 S715 S809 T58 S143 S266 T411 S505 S577 S603 T661 S735 T753 S791 T815	N23 N264 N576 N600 N789	R48-E91, L97-S143, F197 K237, V273- W319, W378-A416, W604 K642, A659- G697: Beta- transducin WD40 repeats	Predicted WD repeat protein [S. cerevesiae] P42935	BLAST MOTIFS PFAM PRINTS
27	618	T414 S59 T105 S126 T139 T143 S196 T203 S311 S325 T370 T390 S477 T483 S541 T583 T94 S148 T247 Y160 Y383 Y456	N118 N154 N346	G11-T18, G425-S432: ATP/GTP binding site (P-loop) R6-K187: Ras domain	GTP-binding protein APD08 [H.sapiens] Accession W75771	BLAST MOTIFS PFAM PRINTS

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods and Databases
28	596	S17 S21 S50 S152 S153 T533 S539 T594 S36 S38 S80 T163 T169 S183 S211 T240 S306 T329 T417 S457 S508 T545 S45 T64 S88 T124 S139 S299 S451 S459 S528 S568 Y180 Y364		A178-L355: Rho- family guanine nucleotide exchange factor (RhoGEF) domain	Guanine nucleotide regulatory protein (NET1 homologue) [Mus musculus] g3834631	BLAST MOTIFS PFAM BLOCKS
29	589	T108 S20 T90 S127 S176 S278 S467 T521 S522 T189 S254 T284 T292 T321 T324 T345 T364 T423 S444 T484 T527	N572	L252-S289, G293- N329, G333-D369, G373-D409, E413- D449, G453-D489, G493-D532: Beta- transducin WD40 repeats R160-K206: F-box domain	SEL-10 [C.elegans] g2677836	BLAST MOTIFS PFAM PRINTS

Table 3

Nucleotide Seq ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
30	628-711	Reproductive (0.256) Nervous (0.154) Gastrointestinal (0.154)	Cell Proliferation (0.692) Inflammation (0.372)	PSPORT1
31	1094-1129	Reproductive (0.268) Cardiovascular (0.146) Nervous (0.146)	Cell Proliferation (0.731) Inflammation (0.219) Neurological (0.049)	pINCY
32	652-703	Cardiovascular (0.375) Reproductive (0.375) Dermatologic (0.125) Endocrine (0.125)	Cell Proliferation (0.875) Trauma (0.125)	pINCY
33	1224-1292	Reproductive (0.412) Gastrointestinal (0.147) Hematopoietic/Immune (0.147)	Cell Proliferation (0.647) Inflammation (0.264)	pINCY
34	16-65	Nervous (0.211) Reproductive (0.197) Gastrointestinal (0.169)	Cell Proliferation (0.507) Inflammation (0.352)	pINCY
35	947-1043	Reproductive (0.444) Nervous (0.333) Gastrointestinal (0.111) Urologic (0.111)	Cell Proliferation (0.667) Inflammation (0.111) Neurological (0.111)	pINCY
36	840-1001	Nervous (0.340) Reproductive (0.208) Gastrointestinal (0.151)	Cell Proliferation (0.641) Inflammation (0.302) Neurological (0.038)	pINCY

Table 3 (cont.)

Nucleotide Seq ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
37	507-551	Hematopoietic/Immune (0.269) Nervous (0.269) Reproductive (0.154)	Inflammation (0.423) Cell Proliferation (0.269)	PBLUESCRIPT
38	218-262	Cardiovascular (0.357) Nervous (0.214) Gastrointestinal (0.143)	Cell Proliferation (0.572) Inflammation (0.214)	pINCY
39	164-208	Nervous (0.280) Reproductive (0.260) Developmental (0.120)	Cell Proliferation (0.740) Inflammation (0.180)	PSPORT1
40	369-411	Cardiovascular (0.250) Developmental (0.250) Gastrointestinal (0.250)	Cell Proliferation (0.500) Inflammation (0.250)	pINCY
41	272-316	Reproductive (0.392) Gastrointestinal (0.118) Hematopoietic/Immune (0.118)	Cell Proliferation (0.626) Inflammation (0.137)	pINCY
42	664-708	Nervous (0.211) Reproductive (0.211) Cardiovascular (0.158)	Cell Proliferation (0.614) Inflammation (0.281)	pINCY
43	226-270	Reproductive (1.000)	Inflammation (1.000)	PBLUESCRIPT
44	11-55	Reproductive (0.254) Gastrointestinal (0.206) Cardiovascular (0.159)	Cell Proliferation (0.698) Inflammation (0.206)	PSPORT1

Table 3 (cont.)

Nucleotide Seq ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
45	637-681	Reproductive (0.281) Nervous (0.188) Gastrointestinal (0.156)	Cell Proliferation (0.781) Inflammation (0.234)	pINCY
46	1016-1060	Nervous (0.330) Reproductive (0.183) Hematopoietic/Immune (0.122)	Cell Proliferation (0.582) Inflammation (0.235)	pINCY
47	737-781	Nervous (0.218) Reproductive (0.188) Gastrointestinal (0.158)	Cell Proliferation (0.655) Inflammation (0.211)	pINCY
48	469-513	Reproductive (0.222) Hematopoietic/Immune (0.160) Nervous (0.160)	Cell Proliferation (0.543) Inflammation (0.272)	pINCY
49	226-270	Gastrointestinal (0.333) Hematopoietic/Immune (0.333) Reproductive (0.333)	Inflammation (1.000)	pINCY
50	456-500	Reproductive (0.289) Gastrointestinal (0.133) Hematopoietic/Immune (0.133)	Cell Proliferation (0.778) Inflammation (0.156)	PSPORT1
51	252-296	Nervous (0.500) Gastrointestinal (0.200) Cardiovascular (0.100)	Cell Proliferation (1.000) Inflammation (0.200)	PBLUESCRIPT
52	60-104	Nervous (0.326) Reproductive (0.326) Cardiovascular (0.152)	Cell proliferation (0.565) Inflammation (0.369)	pINCY

Table 3 (cont.)

Nucleotide Seq ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
53	488-532	Reproductive (0.232) Nervous (0.195) Hematopoietic/Immune (0.146)	Cell proliferation (0.622) Inflammation (0.427)	pINCY
54	686-730	Reproductive (0.250) Gastrointestinal (0.150) Hematopoietic/Immune (0.150)	Cell proliferation (0.700) Inflammation (0.400)	pINCY
55	543-587 1299-1343	Reproductive (0.282) Nervous (0.155) Gastrointestinal (0.146)	Cell proliferation (0.592) Inflammation (0.359)	pINCY
56	345-389 792-836	Nervous (0.268) Reproductive (0.169) Cardiovascular (0.113) Hematopoietic/Immune (0.113)	Cell proliferation (0.606) Inflammation (0.296)	pINCY
57	163-207	Reproductive (0.270) Gastrointestinal (0.189) Nervous (0.156)	Cell proliferation (0.705) Inflammation (0.254)	pINCY
58	381-425 726-770	Nervous (0.317) Reproductive (0.250) Gastrointestinal (0.117)	Cell proliferation (0.450) Inflammation (0.283)	pINCY

Table 4

Nucleotide SEQ ID NO:	Library	Library Description
30	SYNORAT04	This library was constructed using RNA isolated from the wrist synovial membrane tissue of a 62-year-old female with rheumatoid arthritis.
31	MENITUT03	This library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer.
32	PENITUT01	This library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.
33	PROSTUT12	This library was constructed using RNA isolated from prostate tumor tissue removed from a 65-year-old male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA).
34	BONEUNT01	This library was constructed using RNA isolated from Saos-2, a primary osteogenic sarcoma cell line (ATCC HTB-85) derived from an 11-year-old Caucasian female.
35	UTRSNON03	This library was constructed from 6.4 million independent clones from a uterine library. RNA for these libraries was isolated from uterine myometrial tissue removed from a 41-year-old female during a vaginal hysterectomy with dilation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. The normalization and hybridization conditions were adapted from Soares et al. (Proc.Natl.Acad.Sci. USA (1994) 91:9928).
36	BRAITUT29	This library was constructed using RNA isolated from brain tumor tissue removed from the parietal lobe of a 43-year-old female during excision of a cerebral meningeal lesion. Pathology indicated high grade glioma. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia.
37	BMARNOT02	This library was constructed using RNA isolated from the bone marrow of 24 male and female Caucasian donors, 16 to 70 years old. (RNA came from Clontech.)



Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
38	THYRN0T03	This library was constructed using RNA isolated from thyroid tissue removed from the left thyroid of a 28-year-old Caucasian female during a complete thyroidectomy. Pathology indicated a small nodule of adenomatous hyperplasia present in the left thyroid. Pathology for the associated tumor tissue indicated dominant follicular adenoma, forming a well-encapsulated mass in the left thyroid.
39	PROSN0N01	This normalized library was constructed from 4.4 million independent clones from a prostate library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a self-inflicted gunshot wound. The normalization and hybridization conditions were adapted from Soares, M.B. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228-9232, using a longer (19 hour) reannealing hybridization period.
40	LUNGNOT14	This library was constructed using RNA isolated from lung tissue removed from the left lower lobe of a 47-year-old Caucasian male during a segmental lung resection. Pathology for the associated tumor tissue indicated a grade 4 adenocarcinoma, and the parenchyma showed calcified granuloma. Patient history included benign hypertension and chronic obstructive pulmonary disease. Family history included type II diabetes and acute myocardial infarction.
41	PROSTUT12	This library was constructed using RNA isolated from prostate tumor tissue removed from a 65-year-old Caucasian male during a radical prostatectomy. Pathology indicated an adenocarcinoma (Gleason grade 2+2). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA).
42	LUNGFET03	This library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus who died at 20 weeks' gestation.
43	TESTNOT03	This library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
44	OVARTUT01	This library was constructed using RNA isolated from ovarian tumor tissue removed from a 43-year-old Caucasian female during removal of the fallopian tubes and ovaries. Pathology indicated grade 2 mucinous cystadenocarcinoma involving the entire left ovary. Patient history included mitral valve disorder, pneumonia, and viral hepatitis. Family history included atherosclerotic coronary artery disease, pancreatic cancer, stress reaction, cerebrovascular disease, breast cancer, and uterine cancer.
45	HNT3AZT01	This library was constructed using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated for three days with 0.35 micromolar 5-aza-2'-deoxycytidine (AZ).

Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
46	PONSAZT01	This library was constructed using RNA isolated from diseased pons tissue from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease.
47	BRSTNOT14	This library was constructed using RNA isolated from breast tissue obtained from a 62-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated an invasive grade 3 (of 4), nuclear grade 3 (of 3) adenocarcinoma, ductal type. Patient history included a benign colon neoplasm, hyperlipidemia, cardiac dysrhythmia, and obesity. Family history included atherosclerotic coronary artery disease, myocardial infarction, colon cancer, ovarian cancer, lung cancer, and cerebrovascular disease.
48	THYMFET03	This library was constructed using RNA isolated from thymus tissue removed from a Caucasian male fetus.
49	UCMCNOT04	This library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of multiple individuals of mixed age and sex. The cells were treated with G-CSF.
50	BRSTTUT01	This library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. Family history included benign hypertension, atherosclerotic coronary artery disease, cerebrovascular disease, and depressive disorder.
51	HNT2RAT01	This library was constructed at Stratagene (STR937231), using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated with retinoic acid for 24 hours.
52	MENITUT03	This library was constructed using RNA isolated from brain meningioma tissue removed from a 35-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer.
53	SPLNFET02	This library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation.
54	SEMVNOT01	This library was constructed using RNA isolated from seminal vesicle tissue removed from a 58-year-old Caucasian male during radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 3+2) of the prostate. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included a malignant breast neoplasm.

Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
55	CONUTUT01	This library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo-oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites.
56	HEARFET02	This library was constructed using RNA isolated from heart tissue removed from a Caucasian male fetus, who was stillborn at 23 weeks' gestation with a hypoplastic left heart.
57	BRAIFET01	This library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who was stillborn at 23 weeks' gestation with a hypoplastic left heart.
58	BRAINOT23	This library was constructed using RNA isolated from right temporal lobe tissue removed from a 45-year-old Black male during a brain lobectomy. Pathology for the associated tumor tissue indicated dysembryoplastic neuroepithelial tumor of the right temporal lobe. The right temporal region dura was consistent with calcifying pseudotumor of the neuraxis. The patient presented with convulsive intractable epilepsy, partial epilepsy, and memory disturbance. Patient history included obesity, meningitis, backache, unspecified sleep apnea, acute stress reaction, acquired knee deformity, and chronic sinusitis. Family history included obesity, benign hypertension, cirrhosis of the liver, alcohol abuse, hyperlipidemia, cerebrovascular disease, and type II diabetes.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score>GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-29 and fragments thereof.

5

2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.

3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.

10

4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.

5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.

15

6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.

20

7. A method for detecting a polynucleotide, the method comprising the steps of:

(a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and

(b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.

25

8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.

9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:30-58 and fragments thereof.

30

10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.

11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.

12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.

5

13. A host cell comprising the expression vector of claim 12.

14. A method for producing a polypeptide, the method comprising the steps of:

- 10
- a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.

15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

15

16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.

20

18. A purified antagonist of the polypeptide of claim 1.

19. A method for treating or preventing a disorder associated with decreased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

25

20. A method for treating or preventing a disorder associated with increased expression or activity of GTPAP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

## SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.  
 HILLMAN, Jennifer L.  
 TANG, Y. Tom  
 BANDMAN, Olga  
 LAL, Preeti  
 YUE, Henry  
 LU, Dyung Aina M.  
 BAUGHN, Mariah R.  
 YANG, Junming  
 AZIMZAI, Yalda

<120> GTPASE ASSOCIATED PROTEINS

<130> PF-0629 PCT

<140> To Be Assigned  
 <141> Herewith

<150> 60/109,592; 60/118,610; 60/127,990  
 <151> 1998-11-23; 1999-02-04; 1999-04-06

<160> 58

<170> PERL Program

<210> 1  
 <211> 1002  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 708398CD1

<400> 1  
 Met Pro Ser Lys Phe Ser Cys Arg Gln Leu Arg Glu Ala Gly Gln  
 1 5 10 15  
 Cys Phe Glu Ser Phe Leu Val Val Arg Gly Leu Asp Met Glu Thr  
 20 25 30  
 Asp Arg Glu Arg Leu Arg Thr Ile Tyr Asn Arg Asp Phe Lys Ile  
 35 40 45  
 Ser Phe Gly Thr Pro Ala Pro Gly Phe Ser Ser Met Leu Tyr Gly  
 50 55 60  
 Met Lys Ile Ala Asn Leu Ala Tyr Val Thr Lys Thr Arg Val Arg  
 65 70 75  
 Phe Phe Arg Leu Asp Arg Trp Ala Asp Val Arg Phe Pro Glu Lys  
 80 85 90  
 Arg Arg Met Lys Leu Gly Ser Asp Ile Ser Lys His His Lys Ser  
 95 100 105  
 Leu Leu Ala Lys Ile Phe Tyr Asp Arg Ala Glu Tyr Leu His Gly  
 110 115 120  
 Lys His Gly Val Asp Val Glu Val Gln Gly Pro His Glu Ala Arg



	125		130		135
Asp Gly Gln Leu	Leu Ile Arg Leu Asp	Leu Asn Arg Lys Glu Val			
	140		145		150
Leu Thr Leu Arg	Leu Arg Asn Gly Gly	Thr Gln Ser Val Thr Leu			
	155		160		165
Thr His Leu Phe	Pro Leu Cys Arg Thr	Pro Gln Phe Ala Phe Tyr			
	170		175		180
Asn Glu Asp Gln	Glu Leu Pro Cys Pro	Leu Gly Pro Gly Glu Cys			
	185		190		195
Tyr Glu Leu His	Val His Cys Lys Thr	Ser Phe Val Gly Tyr Phe			
	200		205		210
Pro Ala Thr Val	Leu Trp Glu Leu Leu	Gly Pro Gly Glu Ser Gly			
	215		220		225
Ser Glu Gly Ala	Gly Thr Phe Tyr Ile	Ala Arg Phe Leu Ala Ala			
	230		235		240
Val Ala His Ser	Pro Leu Ala Ala Gln	Leu Lys Pro Met Thr Pro			
	245		250		255
Phe Lys Arg Thr	Arg Ile Thr Gly Asn	Pro Val Val Thr Asn Arg			
	260		265		270
Ile Glu Glu Gly	Glu Arg Pro Asp Arg	Ala Lys Gly Tyr Asp Leu			
	275		280		285
Glu Leu Ser Met	Ala Leu Gly Thr Tyr	Tyr Pro Pro Pro Arg Leu			
	290		295		300
Arg Gln Leu Leu	Pro Met Leu Leu Gln	Gly Thr Ser Ile Phe Thr			
	305		310		315
Ala Pro Lys Glu	Ile Ala Glu Ile Lys	Ala Gln Leu Glu Thr Ala			
	320		325		330
Leu Lys Trp Arg	Asn Tyr Glu Val Lys	Leu Arg Leu Leu Leu His			
	335		340		345
Leu Glu Glu Leu	Gln Met Glu His Asp	Ile Arg His Tyr Asp Leu			
	350		355		360
Glu Ser Val Pro	Met Thr Trp Asp Pro	Val Asp Gln Asn Pro Arg			
	365		370		375
Leu Leu Thr Leu	Glu Val Pro Gly Val	Thr Glu Ser Arg Pro Ser			
	380		385		390
Val Leu Arg Gly	Asp His Leu Phe Ala	Leu Leu Ser Ser Glu Thr			
	395		400		405
His Gln Glu Asp	Pro Ile Thr Tyr Lys	Gly Phe Val His Lys Val			
	410		415		420
Glu Leu Asp Arg	Val Lys Leu Ser Phe	Ser Met Ser Leu Leu Ser			
	425		430		435
Arg Phe Val Asp	Gly Leu Thr Phe Lys	Val Asn Phe Thr Phe Asn			
	440		445		450
Arg Gln Pro Leu	Arg Val Gln His Arg	Ala Leu Glu Leu Thr Gly			
	455		460		465
Arg Trp Leu Leu	Trp Pro Met Leu Phe	Pro Val Ala Pro Arg Asp			
	470		475		480
Val Pro Leu Leu	Pro Ser Asp Val Lys	Leu Lys Leu Tyr Asp Arg			
	485		490		495
Ser Leu Glu Ser	Asn Pro Glu Gln Leu	Gln Ala Met Arg His Ile			
	500		505		510
Val Thr Gly Thr	Thr Arg Pro Ala Pro	Tyr Ile Ile Phe Gly Pro			
	515		520		525
Pro Gly Thr Gly	Lys Thr Val Thr Leu	Val Glu Ala Ile Lys Gln			
	530		535		540

Val	Val	Lys	His	Leu	Pro	Lys	Ala	His	Ile	Leu	Ala	Cys	Ala	Pro	545	550	555
Ser	Asn	Ser	Gly	Ala	Asp	Leu	Leu	Cys	Gln	Arg	Leu	Arg	Val	His	560	565	570
Leu	Pro	Ser	Ser	Ile	Tyr	Arg	Leu	Leu	Ala	Pro	Ser	Arg	Asp	Ile	575	580	585
Arg	Met	Val	Pro	Glu	Asp	Ile	Lys	Pro	Cys	Cys	Asn	Trp	Asp	Ala	590	595	600
Lys	Lys	Gly	Glu	Tyr	Val	Phe	Pro	Ala	Lys	Lys	Lys	Leu	Gln	Glu	605	610	615
Tyr	Arg	Val	Leu	Ile	Thr	Thr	Leu	Ile	Thr	Ala	Gly	Arg	Leu	Val	620	625	630
Ser	Ala	Gln	Phe	Pro	Ile	Asp	His	Phe	Thr	His	Ile	Phe	Ile	Asp	635	640	645
Glu	Ala	Gly	His	Cys	Met	Glu	Pro	Glu	Ser	Leu	Val	Ala	Ile	Ala	650	655	660
Gly	Leu	Met	Glu	Val	Lys	Glu	Thr	Gly	Asp	Pro	Gly	Gly	Gln	Leu	665	670	675
Val	Leu	Ala	Gly	Asp	Pro	Arg	Gln	Leu	Gly	Pro	Val	Leu	Arg	Ser	680	685	690
Pro	Leu	Thr	Gln	Lys	His	Gly	Leu	Gly	Tyr	Ser	Leu	Leu	Glu	Arg	695	700	705
Leu	Leu	Ile	Tyr	Asn	Ser	Leu	Tyr	Lys	Lys	Gly	Pro	Asp	Gly	Tyr	710	715	720
Asp	Pro	Gln	Phe	Ile	Thr	Lys	Leu	Leu	Arg	Asn	Tyr	Arg	Ser	His	725	730	735
Pro	Thr	Ile	Leu	Asp	Ile	Pro	Asn	Gln	Leu	Tyr	Tyr	Glu	Gly	Glu	740	745	750
Leu	Gln	Ala	Cys	Ala	Asp	Val	Val	Asp	Arg	Glu	Arg	Phe	Cys	Arg	755	760	765
Trp	Ala	Gly	Leu	Pro	Arg	Gln	Gly	Phe	Pro	Ile	Ile	Phe	His	Gly	770	775	780
Val	Met	Gly	Lys	Asp	Glu	Arg	Glu	Gly	Asn	Ser	Pro	Ser	Phe	Phe	785	790	795
Asn	Pro	Glu	Glu	Ala	Ala	Thr	Val	Thr	Ser	Tyr	Leu	Lys	Leu	Leu	800	805	810
Leu	Ala	Pro	Ser	Ser	Lys	Lys	Gly	Lys	Ala	Arg	Leu	Ser	Pro	Arg	815	820	825
Ser	Val	Gly	Val	Ile	Ser	Pro	Tyr	Arg	Lys	Gln	Val	Glu	Lys	Ile	830	835	840
Arg	Tyr	Cys	Ile	Thr	Lys	Leu	Asp	Arg	Glu	Leu	Arg	Gly	Leu	Asp	845	850	855
Asp	Ile	Lys	Asp	Leu	Lys	Val	Gly	Ser	Val	Glu	Glu	Phe	Gln	Gly	860	865	870
Gln	Glu	Arg	Ser	Val	Ile	Leu	Ile	Ser	Thr	Val	Arg	Ser	Ser	Gln	875	880	885
Ser	Phe	Val	Gln	Leu	Asp	Leu	Asp	Phe	Asn	Leu	Gly	Phe	Leu	Lys	890	895	900
Asn	Pro	Lys	Arg	Phe	Asn	Val	Ala	Val	Thr	Arg	Ala	Lys	Ala	Leu	905	910	915
Leu	Ile	Ile	Val	Gly	Asn	Pro	Leu	Leu	Leu	Gly	His	Asp	Pro	Asp	920	925	930
Trp	Lys	Val	Phe	Leu	Glu	Phe	Cys	Lys	Glu	Asn	Gly	Gly	Tyr	Thr	935	940	945
Gly	Cys	Pro	Phe	Pro	Ala	Lys	Leu	Asp	Leu	Gln	Gln	Gly	Gln	Asn			

	950		955		960
Leu Leu Gln Gly	Leu Ser Lys Leu Ser	Pro Ser Thr Ser Gly	Pro		
	965		970		975
His Ser His Asp	Tyr Leu Pro Gln Glu Arg	Glu Gly Glu Gly	Gly		
	980		985		990
Leu Ser Leu Gln Val	Glu Pro Glu Trp Arg	Asn Glu			
	995		1000		

&lt;210&gt; 2

&lt;211&gt; 338

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1259937CD1

&lt;400&gt; 2

Met Ala Ala Leu Ala	Gln Glu Asp Gly	Trp Thr Lys Gly	Gln Val
1	5	10	15
Leu Val Lys Val Asn	Ser Ala Gly Asp	Ala Ile Gly Leu	Gln Pro
	20	25	30
Asp Ala Arg Gly Val	Ala Thr Ser Leu	Gly Leu Asn Glu	Arg Leu
	35	40	45
Phe Val Val Asn Pro	Gln Glu Val His	Glu Leu Ile Pro	His Pro
	50	55	60
Asp Gln Leu Gly Pro	Thr Val Gly Ser	Ala Glu Gly Leu	Asp Leu
	65	70	75
Val Ser Ala Lys Asp	Leu Ala Gly Gln	Leu Thr Asp His	Asp Trp
	80	85	90
Ser Leu Phe Asn Ser	Ile His Gln Val	Glu Leu Ile His	Tyr Val
	95	100	105
Leu Gly Pro Gln His	Leu Arg Asp Val	Thr Thr Ala Asn	Leu Glu
	110	115	120
Arg Phe Met Arg Arg	Phe Asn Glu Leu	Gln Tyr Trp Val	Ala Thr
	125	130	135
Glu Leu Cys Leu Cys	Pro Val Pro Gly	Pro Arg Ala Gln	Leu Leu
	140	145	150
Arg Lys Phe Ile Lys	Leu Ala Ala His	Leu Lys Glu Gln	Lys Asn
	155	160	165
Leu Asn Ser Phe Phe	Ala Val Met Phe	Gly Leu Ser Asn	Ser Ala
	170	175	180
Ile Ser Arg Leu Ala	His Thr Trp Glu	Arg Leu Pro His	Lys Val
	185	190	195
Arg Lys Leu Tyr Ser	Ala Leu Glu Arg	Leu Leu Asp Pro	Ser Trp
	200	205	210
Asn His Arg Val Tyr	Arg Leu Ala Leu	Ala Lys Leu Ser	Pro Pro
	215	220	225
Val Ile Pro Phe Met	Pro Leu Leu Leu	Lys Asp Met Thr	Phe Ile
	230	235	240
His Glu Gly Asn His	Thr Leu Val Glu	Asn Leu Ile Asn	Phe Glu
	245	250	255
Lys Met Arg Met Met	Ala Arg Ala Ala	Arg Met Leu His	His Cys
	260	265	270

Arg	Ser	His	Asn	Pro	Val	Pro	Leu	Ser	Pro	Leu	Arg	Ser	Arg	Val
				275					280					285
Ser	His	Leu	His	Glu	Asp	Ser	Gln	Val	Ala	Arg	Ile	Ser	Thr	Cys
				290					295					300
Ser	Glu	Gln	Ser	Leu	Ser	Thr	Arg	Ser	Pro	Ala	Ser	Thr	Trp	Ala
				305					310					315
Tyr	Val	Gln	Gln	Leu	Lys	Val	Ile	Asp	Asn	Gln	Arg	Glu	Leu	Ser
				320					325					330
Arg	Leu	Ser	Arg	Glu	Leu	Glu	Pro							
				335										

&lt;210&gt; 3

&lt;211&gt; 211

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1452285CD1

&lt;400&gt; 3

Met	Gln	Ala	Pro	His	Lys	Glu	His	Leu	Tyr	Lys	Leu	Leu	Val	Ile
1				5					10					15
Gly	Asp	Leu	Gly	Val	Gly	Lys	Thr	Ser	Ile	Ile	Lys	Arg	Tyr	Val
				20					25					30
His	Gln	Asn	Phe	Ser	Ser	His	Tyr	Arg	Ala	Thr	Ile	Gly	Val	Asp
				35					40					45
Phe	Ala	Leu	Lys	Val	Leu	His	Trp	Asp	Pro	Glu	Thr	Val	Val	Arg
				50					55					60
Leu	Gln	Leu	Trp	Asp	Ile	Ala	Gly	Gln	Glu	Arg	Phe	Gly	Asn	Met
				65					70					75
Thr	Arg	Val	Tyr	Tyr	Arg	Glu	Ala	Met	Gly	Ala	Phe	Ile	Val	Phe
				80					85					90
Asp	Val	Thr	Arg	Pro	Ala	Thr	Phe	Glu	Ala	Val	Ala	Lys	Trp	Lys
				95					100					105
Asn	Asp	Leu	Asp	Ser	Lys	Leu	Ser	Leu	Pro	Asn	Gly	Lys	Pro	Val
				110					115					120
Ser	Val	Val	Leu	Leu	Ala	Asn	Lys	Cys	Asp	Gln	Gly	Lys	Asp	Val
				125					130					135
Leu	Met	Asn	Asn	Gly	Leu	Lys	Met	Asp	Gln	Phe	Cys	Lys	Glu	His
				140					145					150
Gly	Phe	Val	Gly	Trp	Phe	Glu	Thr	Ser	Ala	Lys	Glu	Asn	Ile	Asn
				155					160					165
Ile	Asp	Glu	Ala	Ser	Arg	Cys	Leu	Val	Lys	His	Ile	Leu	Ala	Asn
				170					175					180
Glu	Cys	Asp	Leu	Met	Glu	Ser	Ile	Glu	Pro	Asp	Val	Val	Lys	Pro
				185					190					195
His	Leu	Thr	Ser	Thr	Lys	Val	Ala	Ser	Cys	Ser	Gly	Cys	Ala	Lys
				200					205					210
Ser														

&lt;210&gt; 4

&lt;211&gt; 516

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1812894CD1

&lt;400&gt; 4

Met	Glu	Thr	Met	Lys	Ala	Val	Ala	Glu	Val	Ser	Glu	Ser	Thr	Lys
1				5					10					15
Ala	Glu	Ala	Val	Ala	Ala	Val	Gln	Arg	Gln	Cys	Gln	Glu	Glu	Val
				20					25					30
Ala	Ser	Leu	Gln	Ala	Ile	Leu	Lys	Asp	Ser	Ile	Ser	Ser	Tyr	Glu
				35					40					45
Ala	Gln	Ile	Thr	Ala	Leu	Lys	Gln	Glu	Arg	Gln	Gln	Gln	Gln	Gln
				50					55					60
Asp	Cys	Glu	Glu	Lys	Glu	Arg	Glu	Leu	Gly	Arg	Leu	Lys	Gln	Leu
				65					70					75
Leu	Ser	Arg	Ala	Tyr	Pro	Leu	Asp	Ser	Leu	Glu	Lys	Gln	Met	Glu
				80					85					90
Lys	Ala	His	Glu	Asp	Ser	Glu	Lys	Leu	Arg	Glu	Ile	Val	Leu	Pro
				95					100					105
Met	Glu	Lys	Glu	Ile	Glu	Glu	Leu	Lys	Ala	Lys	Leu	Leu	Arg	Ala
				110					115					120
Glu	Glu	Leu	Ile	Gln	Glu	Ile	Gln	Arg	Arg	Pro	Arg	His	Ala	Pro
				125					130					135
Ser	Leu	His	Gly	Ser	Thr	Glu	Leu	Leu	Pro	Leu	Ser	Arg	Asp	Pro
				140					145					150
Ser	Pro	Pro	Leu	Glu	Pro	Leu	Glu	Glu	Leu	Ser	Gly	Asp	Gly	Gly
				155					160					165
Pro	Ala	Ala	Glu	Ala	Phe	Ala	His	Asn	Cys	Asp	Asp	Ser	Ala	Ser
				170					175					180
Ile	Ser	Ser	Phe	Ser	Leu	Gly	Gly	Gly	Val	Gly	Ser	Ser	Ser	Ser
				185					190					195
Leu	Pro	Gln	Ser	Arg	Gln	Gly	Leu	Ser	Pro	Glu	Gln	Glu	Glu	Thr
				200					205					210
Ala	Ser	Leu	Val	Ser	Thr	Gly	Thr	Leu	Val	Pro	Glu	Gly	Ile	Tyr
				215					220					225
Leu	Pro	Pro	Pro	Gly	Tyr	Gln	Leu	Val	Pro	Asp	Thr	Gln	Trp	Glu
				230					235					240
Gln	Leu	Gln	Thr	Glu	Gly	Arg	Gln	Leu	Gln	Lys	Asp	Leu	Glu	Ser
				245					250					255
Val	Ser	Arg	Glu	Arg	Asp	Glu	Leu	Gln	Glu	Gly	Leu	Arg	Arg	Ser
				260					265					270
Asn	Glu	Asp	Cys	Ala	Lys	Gln	Met	Gln	Val	Leu	Leu	Ala	Gln	Val
				275					280					285
Gln	Asn	Ser	Glu	Gln	Leu	Leu	Arg	Thr	Leu	Gln	Gly	Thr	Val	Ser
				290					295					300
Gln	Ala	Gln	Glu	Arg	Val	Gln	Leu	Gln	Met	Ala	Glu	Leu	Val	Thr
				305					310					315
Thr	His	Lys	Cys	Leu	His	His	Glu	Val	Lys	Arg	Leu	Asn	Glu	Glu
				320					325					330
Asn	Gln	Gly	Leu	Arg	Ala	Glu	Gln	Leu	Pro	Ser	Ser	Ala	Pro	Gln
				335					340					345
Gly	Ser	Gln	Gln	Glu	Gln	Gly	Glu	Glu	Glu	Ser	Leu	Pro	Ser	Ser

	350		355		360									
Val	Pro	Glu	Leu	Gln	Gln	Leu	Leu	Cys	Cys	Thr	Arg	Gln	Glu	Ala
	365		370		375									
Arg	Ala	Arg	Leu	Gln	Ala	Gln	Glu	His	Gly	Ala	Glu	Arg	Leu	Arg
	380		385		390									
Ile	Glu	Ile	Val	Thr	Leu	Arg	Glu	Ala	Leu	Glu	Glu	Glu	Thr	Val
	395		400		405									
Ala	Arg	Ala	Ser	Leu	Glu	Gly	Gln	Leu	Arg	Val	Gln	Arg	Glu	Glu
	410		415		420									
Thr	Glu	Val	Leu	Glu	Ala	Ser	Leu	Cys	Ser	Leu	Arg	Thr	Glu	Met
	425		430		435									
Glu	Arg	Val	Gln	Gln	Glu	Gln	Ser	Lys	Ala	Gln	Leu	Pro	Asp	Leu
	440		445		450									
Leu	Ser	Glu	Gln	Arg	Ala	Lys	Val	Leu	Arg	Leu	Gln	Ala	Glu	Leu
	455		460		465									
Glu	Thr	Ser	Glu	Gln	Val	Gln	Arg	Asp	Phe	Val	Arg	Leu	Ser	Gln
	470		475		480									
Ala	Leu	Gln	Val	Arg	Leu	Glu	Arg	Ile	Arg	Gln	Ala	Glu	Thr	Leu
	485		490		495									
Glu	Gln	Val	Arg	Ser	Ile	Met	Asp	Glu	Ala	Pro	Leu	Thr	Asp	Val
	500		505		510									
Arg	Asp	Ile	Lys	Asp	Thr									
	515													

&lt;210&gt; 5

&lt;211&gt; 445

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3074884CD1

&lt;400&gt; 5

Met	Pro	Glu	Asp	Ala	Asp	Glu	Asn	Ala	Glu	Glu	Glu	Leu	Leu	Arg
1				5					10					15
Gly	Glu	Pro	Leu	Leu	Pro	Ala	Gly	Thr	Gln	Arg	Val	Cys	Leu	Val
			20						25					30
His	Pro	Asp	Val	Lys	Trp	Gly	Pro	Gly	Lys	Ser	Gln	Met	Thr	Arg
			35						40					45
Ala	Glu	Trp	Gln	Val	Ala	Glu	Ala	Thr	Ala	Leu	Val	His	Thr	Leu
			50						55					60
Asp	Gly	Trp	Ser	Val	Val	Gln	Thr	Met	Val	Val	Ser	Thr	Lys	Thr
			65						70					75
Pro	Asp	Arg	Lys	Leu	Ile	Phe	Gly	Lys	Gly	Asn	Phe	Glu	His	Leu
			80						85					90
Thr	Glu	Lys	Ile	Arg	Gly	Ser	Pro	Asp	Val	Thr	Cys	Val	Phe	Leu
			95						100					105
Asn	Val	Glu	Arg	Met	Ala	Ala	Pro	Thr	Lys	Lys	Glu	Leu	Glu	Ala
			110						115					120
Ala	Trp	Gly	Val	Glu	Val	Phe	Asp	Arg	Phe	Thr	Val	Val	Leu	His
			125						130					135
Ile	Phe	Arg	Cys	Asn	Ala	Arg	Thr	Lys	Glu	Ala	Arg	Leu	Gln	Val
			140						145					150

Ala	Leu	Ala	Glu	Met	Pro	Leu	His	Arg	Ser	Asn	Leu	Lys	Arg	Asp	155	160	165
Val	Ala	His	Leu	Tyr	Arg	Gly	Val	Gly	Ser	Arg	Tyr	Ile	Met	Gly	170	175	180
Ser	Gly	Glu	Ser	Phe	Met	Gln	Leu	Gln	Gln	Arg	Leu	Leu	Arg	Glu	185	190	195
Lys	Glu	Ala	Lys	Ile	Arg	Lys	Ala	Leu	Asp	Arg	Leu	Arg	Lys	Lys	200	205	210
Arg	His	Leu	Leu	Arg	Arg	Gln	Arg	Thr	Arg	Arg	Glu	Phe	Pro	Val	215	220	225
Ile	Ser	Val	Val	Gly	Tyr	Thr	Asn	Cys	Gly	Lys	Thr	Thr	Leu	Ile	230	235	240
Lys	Ala	Leu	Thr	Gly	Asp	Ala	Ala	Ile	Gln	Pro	Arg	Asp	Gln	Leu	245	250	255
Phe	Ala	Thr	Leu	Asp	Val	Thr	Ala	His	Ala	Gly	Thr	Leu	Pro	Ser	260	265	270
Arg	Met	Thr	Val	Leu	Tyr	Val	Asp	Thr	Ile	Gly	Phe	Leu	Ser	Gln	275	280	285
Leu	Pro	His	Gly	Leu	Ile	Glu	Ser	Phe	Ser	Ala	Thr	Leu	Glu	Asp	290	295	300
Val	Ala	His	Ser	Asp	Leu	Ile	Leu	His	Val	Arg	Asp	Val	Ser	His	305	310	315
Pro	Glu	Ala	Glu	Leu	Gln	Lys	Cys	Ser	Val	Leu	Ser	Thr	Leu	Arg	320	325	330
Gly	Leu	Gln	Leu	Pro	Ala	Pro	Leu	Leu	Asp	Ser	Met	Val	Glu	Val	335	340	345
His	Asn	Lys	Val	Asp	Leu	Val	Pro	Gly	Tyr	Ser	Pro	Thr	Glu	Pro	350	355	360
Asn	Val	Val	Pro	Val	Ser	Ala	Leu	Arg	Gly	His	Gly	Leu	Gln	Glu	365	370	375
Leu	Lys	Ala	Glu	Leu	Asp	Ala	Ala	Val	Leu	Lys	Ala	Thr	Gly	Arg	380	385	390
Gln	Ile	Leu	Thr	Leu	Arg	Val	Arg	Leu	Ala	Gly	Ala	Gln	Leu	Ser	395	400	405
Trp	Leu	Tyr	Lys	Glu	Ala	Thr	Val	Gln	Glu	Val	Asp	Val	Ile	Pro	410	415	420
Glu	Asp	Gly	Ala	Ala	Asp	Val	Arg	Val	Ile	Ile	Ser	Asn	Ser	Ala	425	430	435
Tyr	Gly	Lys	Phe	Arg	Lys	Leu	Phe	Pro	Gly						440	445	

&lt;210&gt; 6

&lt;211&gt; 445

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3452277CD1

&lt;400&gt; 6

Met	Tyr	Tyr	Gln	Gln	Ala	Leu	Met	Arg	Ser	Thr	Val	Lys	Ser	Ser	1	5	10	15
Val	Ser	Leu	Gly	Gly	Ile	Val	Lys	Tyr	Ser	Glu	Gln	Phe	Ser	Ser				

20	25	30
Asn Asp Ala Ile Met Ser Gly Cys Leu Pro Ser Asn Pro Trp Ile		
35	40	45
Thr Asp Asp Thr Gln Phe Trp Asp Leu Asn Ala Lys Leu Val Glu		
50	55	60
Ile Pro Thr Lys Met Arg Val Glu Arg Trp Ala Phe Asn Phe Ser		
65	70	75
Glu Leu Ile Arg Asp Pro Lys Gly Arg Gln Ser Phe Gln Tyr Phe		
80	85	90
Leu Lys Lys Glu Phe Ser Gly Glu Asn Leu Gly Phe Trp Glu Ala		
95	100	105
Cys Glu Asp Leu Lys Tyr Gly Asp Gln Ser Lys Val Lys Glu Lys		
110	115	120
Ala Glu Glu Ile Tyr Lys Leu Phe Leu Ala Pro Gly Ala Arg Arg		
125	130	135
Trp Ile Asn Ile Asp Gly Lys Thr Met Asp Ile Thr Val Lys Gly		
140	145	150
Leu Lys His Pro His Arg Tyr Val Leu Asp Ala Ala Gln Thr His		
155	160	165
Ile Tyr Met Leu Met Lys Lys Asp Ser Tyr Ala Arg Tyr Leu Lys		
170	175	180
Ser Pro Ile Tyr Lys Asp Met Leu Ala Lys Ala Ile Glu Pro Gln		
185	190	195
Glu Thr Thr Lys Lys Ser Ser Thr Leu Pro Phe Met Arg Arg His		
200	205	210
Leu Arg Ser Ser Pro Ser Pro Val Ile Leu Arg Gln Leu Glu Glu		
215	220	225
Glu Ala Lys Ala Arg Glu Ala Ala Asn Thr Val Asp Ile Thr Gln		
230	235	240
Pro Gly Gln His Met Ala Pro Ser Pro His Leu Thr Val Tyr Thr		
245	250	255
Gly Thr Cys Met Pro Pro Ser Pro Ser Ser Pro Phe Ser Ser Ser		
260	265	270
Cys Arg Ser Pro Arg Lys Pro Phe Ala Ser Pro Ser Arg Phe Ile		
275	280	285
Arg Arg Pro Ser Thr Thr Ile Cys Pro Ser Pro Ile Arg Val Ala		
290	295	300
Leu Glu Ser Ser Ser Gly Leu Glu Gln Lys Gly Glu Cys Ser Gly		
305	310	315
Ser Met Ala Pro Arg Gly Pro Ser Val Thr Glu Ser Ser Glu Ala		
320	325	330
Ser Leu Asp Thr Ser Trp Pro Arg Ser Arg Pro Arg Ala Pro Pro		
335	340	345
Lys Ala Arg Met Ala Leu Ser Phe Ser Arg Phe Leu Arg Arg Gly		
350	355	360
Cys Leu Ala Ser Pro Val Phe Ala Arg Leu Ser Pro Lys Cys Pro		
365	370	375
Ala Val Ser His Gly Arg Val Gln Pro Leu Gly Asp Val Gly Gln		
380	385	390
Gln Leu Pro Arg Leu Lys Ser Lys Arg Val Ala Asn Phe Phe Gln		
395	400	405
Ile Lys Met Asp Val Pro Thr Gly Ser Gly Thr Cys Leu Met Asp		
410	415	420
Ser Glu Asp Ala Gly Thr Gly Glu Ser Gly Asp Arg Ala Thr Glu		
425	430	435



Lys Glu Val Ile Cys Pro Trp Glu Ser Leu  
440 445

<210> 7

<211> 281

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 4203832CD1

<400> 7

Met	Lys	Leu	Ala	Ala	Met	Ile	Lys	Lys	Met	Cys	Pro	Ser	Asp	Ser	
1				5					10					15	
Glu	Leu	Ser	Ile	Pro	Ala	Lys	Asn	Cys	Tyr	Arg	Met	Val	Ile	Leu	
				20					25					30	
Gly	Ser	Ser	Lys	Val	Gly	Lys	Thr	Ala	Ile	Val	Ser	Arg	Phe	Leu	
				35					40					45	
Thr	Gly	Arg	Phe	Glu	Asp	Ala	Tyr	Thr	Pro	Thr	Ile	Glu	Asp	Phe	
				50					55					60	
His	Arg	Lys	Phe	Tyr	Ser	Ile	Arg	Gly	Glu	Val	Tyr	Gln	Leu	Asp	
				65					70					75	
Ile	Leu	Asp	Thr	Ser	Gly	Asn	His	Pro	Phe	Pro	Ala	Met	Arg	Cys	
				80					85					90	
Leu	Ser	Ile	Leu	Thr	Gly	Asp	Val	Phe	Ile	Leu	Val	Phe	Ser	Leu	
				95					100					105	
Asp	Asn	Arg	Asp	Ser	Phe	Glu	Glu	Val	Gln	Arg	Leu	Arg	Gln	Gln	
				110					115					120	
Ile	Leu	Asp	Thr	Lys	Ser	Cys	Leu	Lys	Asn	Lys	Thr	Lys	Glu	Asn	
				125					130					135	
Val	Asp	Val	Pro	Leu	Val	Ile	Cys	Gly	Asn	Lys	Gly	Asp	Arg	Asp	
				140					145					150	
Phe	Tyr	Arg	Glu	Val	Asp	Gln	Arg	Glu	Ile	Glu	Gln	Leu	Val	Gly	
				155					160					165	
Asp	Asp	Pro	Gln	Arg	Cys	Ala	Tyr	Phe	Glu	Ile	Ser	Ala	Lys	Lys	
				170					175					180	
Asn	Ser	Ser	Leu	Asp	Gln	Met	Phe	Arg	Ala	Leu	Phe	Ala	Met	Ala	
				185					190					195	
Lys	Leu	Pro	Ser	Glu	Met	Ser	Pro	Asp	Leu	His	Arg	Lys	Val	Ser	
				200					205					210	
Val	Gln	Tyr	Cys	Asp	Val	Leu	His	Lys	Lys	Ala	Leu	Arg	Asn	Lys	
				215					220					225	
Lys	Leu	Leu	Arg	Ala	Gly	Ser	Gly	Gly	Gly	Gly	Gly	Asp	Pro	Gly	
				230					235					240	
Asp	Ala	Phe	Gly	Ile	Val	Ala	Pro	Phe	Ala	Arg	Arg	Pro	Ser	Val	
				245					250					255	
His	Ser	Asp	Leu	Met	Tyr	Ile	Arg	Glu	Lys	Ala	Ser	Ala	Gly	Ser	
				260					265					270	
Gln	Ala	Lys	Asp	Lys	Glu	Arg	Cys	Val	Ile	Ser					
				275					280						

<210> 8

<211> 301

<212> PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 104368CD1

&lt;400&gt; 8

```

Met Thr Thr Leu Asp Asp Lys Leu Leu Gly Glu Lys Leu Gln Tyr
 1          5          10          15
Tyr Tyr Ser Ser Ser Glu Asp Glu Asp Ser Asp His Glu Asp Lys
          20          25          30
Asp Arg Gly Arg Cys Ala Pro Ala Ser Ser Ser Val Pro Ala Glu
          35          40          45
Ala Glu Leu Ala Gly Glu Gly Ile Ser Val Asn Thr Gly Pro Lys
          50          55          60
Gly Val Ile Asn Asp Trp Arg Arg Phe Lys Gln Leu Glu Thr Glu
          65          70          75
Gln Arg Glu Glu Gln Cys Arg Glu Met Glu Arg Leu Ile Lys Lys
          80          85          90
Leu Ser Met Thr Cys Arg Ser His Leu Asp Glu Glu Glu Glu Gln
          95          100          105
Gln Lys Gln Lys Asp Leu Gln Glu Lys Ile Ser Gly Lys Met Thr
          110          115          120
Leu Lys Glu Phe Ala Ile Met Asn Glu Asp Gln Asp Asp Glu Glu
          125          130          135
Phe Leu Gln Gln Tyr Arg Lys Gln Arg Met Glu Glu Met Arg Gln
          140          145          150
Gln Leu His Lys Gly Pro Gln Phe Lys Gln Val Phe Glu Ile Ser
          155          160          165
Ser Gly Glu Gly Phe Leu Asp Met Ile Asp Lys Glu Gln Lys Ser
          170          175          180
Ile Val Ile Met Val His Ile Tyr Glu Asp Gly Ile Pro Gly Thr
          185          190          195
Glu Ala Met Asn Gly Cys Met Ile Cys Leu Ala Ala Glu Tyr Pro
          200          205          210
Ala Val Lys Phe Cys Lys Val Lys Ser Ser Val Ile Gly Ala Ser
          215          220          225
Ser Gln Phe Thr Arg Asn Ala Leu Pro Ala Leu Leu Ile Tyr Lys
          230          235          240
Gly Gly Glu Leu Ile Gly Asn Phe Val Arg Val Thr Asp Gln Leu
          245          250          255
Gly Asp Asp Phe Phe Ala Val Asp Leu Glu Ala Phe Leu Gln Glu
          260          265          270
Phe Gly Leu Leu Pro Glu Lys Glu Val Leu Val Leu Thr Ser Val
          275          280          285
Arg Asn Ser Ala Thr Cys His Ser Glu Asp Ser Asp Leu Glu Ile
          290          295          300
Asp

```

&lt;210&gt; 9

&lt;211&gt; 485

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1441680CD1

&lt;400&gt; 9

Met	Arg	Ala	Val	Leu	Thr	Trp	Arg	Asp	Lys	Ala	Glu	His	Cys	Ile	
1				5					10					15	
Asn	Asp	Ile	Ala	Phe	Lys	Pro	Asp	Gly	Thr	Gln	Leu	Ile	Leu	Ala	
				20					25					30	
Ala	Gly	Ser	Arg	Leu	Leu	Val	Tyr	Asp	Thr	Ser	Asp	Gly	Thr	Leu	
				35					40					45	
Leu	Gln	Pro	Leu	Lys	Gly	His	Lys	Asp	Thr	Val	Tyr	Cys	Val	Ala	
				50					55					60	
Tyr	Ala	Lys	Asp	Gly	Lys	Arg	Phe	Ala	Ser	Gly	Ser	Ala	Asp	Lys	
				65					70					75	
Ser	Val	Ile	Ile	Trp	Thr	Ser	Lys	Leu	Glu	Gly	Ile	Leu	Lys	Tyr	
				80					85					90	
Thr	His	Asn	Asp	Ala	Ile	Gln	Cys	Val	Ser	Tyr	Asn	Pro	Ile	Thr	
				95					100					105	
His	Gln	Leu	Ala	Ser	Cys	Ser	Ser	Ser	Asp	Phe	Gly	Leu	Trp	Ser	
				110					115					120	
Pro	Glu	Gln	Lys	Ser	Val	Ser	Lys	His	Lys	Ser	Ser	Ser	Lys	Ile	
				125					130					135	
Ile	Cys	Cys	Ser	Trp	Thr	Asn	Asp	Gly	Gln	Tyr	Leu	Ala	Leu	Gly	
				140					145					150	
Met	Phe	Asn	Gly	Ile	Ile	Ser	Ile	Arg	Asn	Lys	Asn	Gly	Glu	Glu	
				155					160					165	
Lys	Val	Lys	Ile	Glu	Arg	Pro	Gly	Gly	Ser	Leu	Ser	Pro	Ile	Trp	
				170					175					180	
Ser	Ile	Cys	Trp	Asn	Pro	Ser	Arg	Glu	Glu	Arg	Asn	Asp	Ile	Leu	
				185					190					195	
Ala	Val	Ala	Asp	Trp	Gly	Gln	Lys	Val	Ser	Phe	Tyr	Gln	Leu	Ser	
				200					205					210	
Gly	Lys	Gln	Ile	Gly	Lys	Asp	Arg	Ala	Leu	Asn	Phe	Asp	Pro	Cys	
				215					220					225	
Cys	Ile	Ser	Tyr	Phe	Thr	Lys	Gly	Glu	Tyr	Ile	Leu	Leu	Gly	Gly	
				230					235					240	
Ser	Asp	Lys	Gln	Val	Ser	Leu	Phe	Thr	Lys	Asp	Gly	Val	Arg	Leu	
				245					250					255	
Gly	Thr	Val	Gly	Glu	Gln	Asn	Ser	Trp	Val	Trp	Thr	Cys	Gln	Ala	
				260					265					270	
Lys	Pro	Asp	Ser	Asn	Tyr	Val	Val	Val	Gly	Cys	Gln	Asp	Gly	Thr	
				275					280					285	
Ile	Ser	Phe	Tyr	Gln	Leu	Ile	Phe	Ser	Thr	Val	His	Gly	Val	Tyr	
				290					295					300	
Lys	Asp	Arg	Tyr	Ala	Tyr	Arg	Asp	Ser	Met	Thr	Asp	Val	Ile	Val	
				305					310					315	
Gln	His	Leu	Ile	Thr	Glu	Gln	Lys	Val	Arg	Ile	Lys	Cys	Lys	Glu	
				320					325					330	
Leu	Val	Lys	Lys	Ile	Ala	Ile	Tyr	Arg	Asn	Arg	Leu	Ala	Ile	Gln	
				335					340					345	
Leu	Pro	Glu	Lys	Ile	Leu	Ile	Tyr	Glu	Leu	Tyr	Ser	Glu	Asp	Leu	
				350					355					360	

```

Ser Asp Met His Tyr Arg Val Lys Glu Lys Ile Ile Lys Lys Phe
      365                      370                      375
Glu Cys Asn Leu Leu Val Val Cys Ala Asn His Ile Ile Leu Cys
      380                      385                      390
Gln Glu Lys Arg Leu Gln Cys Leu Ser Phe Ser Gly Val Lys Glu
      395                      400                      405
Arg Glu Trp Gln Met Glu Ser Leu Ile Arg Tyr Ile Lys Val Ile
      410                      415                      420
Gly Gly Pro Pro Gly Arg Glu Gly Leu Leu Val Gly Leu Lys Lys
      425                      430                      435
Met Tyr Leu Leu Val Tyr Ser Phe Ile Leu Ile Val Lys Asp Tyr
      440                      445                      450
Phe Ser Leu Ser Thr Asp Val Leu Gly Asn Leu Thr Trp Lys His
      455                      460                      465
Val Cys Lys Lys His Tyr Trp Val Phe His Leu Phe Ser Trp Tyr
      470                      475                      480
Tyr Ile Phe Val Gln
      485

```

&lt;210&gt; 10

&lt;211&gt; 447

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1494955CD1

&lt;400&gt; 10

```

Met Glu Leu Ser Gln Met Ser Glu Leu Met Gly Leu Ser Val Leu
  1                      5                      10                      15
Leu Gly Leu Leu Ala Leu Met Ala Thr Ala Ala Val Ala Arg Gly
      20                      25                      30
Trp Leu Arg Ala Gly Glu Glu Arg Ser Gly Arg Pro Ala Cys Gln
      35                      40                      45
Lys Ala Asn Gly Phe Pro Pro Asp Lys Ser Ser Gly Ser Lys Lys
      50                      55                      60
Gln Lys Gln Tyr Gln Arg Ile Arg Lys Glu Lys Pro Gln Gln His
      65                      70                      75
Asn Phe Thr His Arg Leu Leu Ala Ala Ala Leu Lys Ser His Ser
      80                      85                      90
Gly Asn Ile Ser Cys Met Asp Phe Ser Ser Asn Gly Lys Tyr Leu
      95                      100                     105
Ala Thr Cys Ala Asp Asp Arg Thr Ile Arg Ile Trp Ser Thr Lys
      110                     115                     120
Asp Phe Leu Gln Arg Glu His Arg Ser Met Arg Ala Asn Val Glu
      125                     130                     135
Leu Asp His Ala Thr Leu Val Arg Phe Ser Pro Asp Cys Arg Ala
      140                     145                     150
Phe Ile Val Trp Leu Ala Asn Gly Asp Thr Leu Arg Val Phe Lys
      155                     160                     165
Met Thr Lys Arg Glu Asp Gly Gly Tyr Thr Phe Thr Ala Thr Pro
      170                     175                     180
Glu Asp Phe Pro Lys Lys His Lys Ala Pro Val Ile Asp Ile Gly

```

	185		190		195
Ile Ala Asn Thr Gly Lys Phe Ile Met Thr Ala Ser Ser Asp Thr					
	200		205		210
Thr Val Leu Ile Trp Ser Leu Lys Gly Gln Val Leu Ser Thr Ile					
	215		220		225
Asn Thr Asn Gln Met Asn Asn Thr His Ala Ala Val Ser Pro Cys					
	230		235		240
Gly Arg Phe Val Ala Ser Cys Gly Phe Thr Pro Asp Val Lys Val					
	245		250		255
Trp Glu Val Cys Phe Gly Lys Lys Gly Glu Phe Gln Glu Val Val					
	260		265		270
Arg Ala Phe Glu Leu Lys Gly His Ser Ala Ala Val His Ser Phe					
	275		280		285
Ala Phe Ser Asn Asp Ser Arg Arg Met Ala Ser Val Ser Lys Asp					
	290		295		300
Gly Thr Trp Lys Leu Trp Asp Thr Asp Val Glu Tyr Lys Lys Lys					
	305		310		315
Gln Asp Pro Tyr Leu Leu Lys Thr Gly Arg Phe Glu Glu Ala Ala					
	320		325		330
Gly Ala Ala Pro Cys Arg Leu Ala Leu Ser Pro Asn Ala Gln Val					
	335		340		345
Leu Ala Leu Ala Ser Gly Ser Ser Ile His Leu Tyr Asn Thr Arg					
	350		355		360
Arg Gly Glu Lys Glu Glu Cys Phe Glu Arg Val His Gly Glu Cys					
	365		370		375
Ile Ala Asn Leu Ser Phe Asp Ile Thr Gly Arg Phe Leu Ala Ser					
	380		385		390
Cys Gly Asp Arg Ala Val Arg Leu Phe His Asn Thr Pro Gly His					
	395		400		405
Arg Ala Met Val Glu Glu Met Gln Gly His Leu Lys Arg Ala Ser					
	410		415		420
Asn Glu Ser Thr Arg Gln Arg Leu Gln Gln Gln Leu Thr Gln Ala					
	425		430		435
Gln Glu Thr Leu Lys Ser Leu Gly Ala Leu Lys Lys					
	440		445		

&lt;210&gt; 11

&lt;211&gt; 199

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1508161CD1

&lt;400&gt; 11

Met Pro Val Lys Lys Lys His Arg Ala Arg Met Ile Glu Tyr Phe		
1	5	10
Ile Asp Val Ala Arg Glu Cys Phe Asn Ile Gly Asn Phe Asn Ser		
	20	25
Leu Met Ala Ile Ile Ser Gly Met Asn Met Ser Pro Val Ser Arg		
	35	40
Leu Lys Lys Thr Trp Ala Lys Val Lys Thr Ala Lys Phe Asp Ile		
	50	55
		60

```

Leu Glu His Gln Met Asp Pro Ser Ser Asn Phe Tyr Asn Tyr Arg
      65                      70                      75
Thr Ala Leu Arg Gly Ala Ala Gln Arg Ser Leu Thr Ala His Ser
      80                      85                      90
Ser Arg Glu Lys Ile Val Ile Pro Phe Phe Ser Leu Leu Ile Lys
      95                      100                     105
Asp Ile Tyr Phe Leu Asn Glu Gly Cys Ala Asn Arg Leu Pro Asn
      110                     115                     120
Gly His Val Asn Phe Glu Lys Phe Trp Glu Leu Ala Lys Gln Val
      125                     130                     135
Ser Glu Phe Met Thr Trp Lys Gln Val Glu Cys Pro Phe Glu Arg
      140                     145                     150
Asp Arg Lys Ile Leu Gln Tyr Leu Leu Thr Val Pro Val Phe Ser
      155                     160                     165
Glu Asp Ala Leu Tyr Leu Ala Ser Tyr Glu Ser Glu Gly Pro Glu
      170                     175                     180
Asn His Ile Glu Lys Asp Arg Trp Lys Ser Leu Arg Ser Ser Leu
      185                     190                     195
Leu Gly Arg Val

```

&lt;210&gt; 12

&lt;211&gt; 694

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1811877CD1

&lt;400&gt; 12

```

Met Ala Phe Asp Pro Thr Ser Thr Leu Leu Ala Thr Gly Gly Cys
  1          5          10          15
Asp Gly Ala Val Arg Val Trp Asp Ile Val Arg His Tyr Gly Thr
      20          25          30
His His Phe Arg Gly Ser Pro Gly Val Val His Leu Val Ala Phe
      35          40          45
His Pro Asp Pro Thr Arg Leu Leu Leu Phe Ser Ser Ala Thr Asp
      50          55          60
Ala Ala Ile Arg Val Trp Ser Leu Gln Asp Arg Ser Cys Leu Ala
      65          70          75
Val Leu Thr Ala His Tyr Ser Ala Val Thr Ser Leu Ala Phe Ser
      80          85          90
Ala Asp Gly His Thr Met Leu Ser Ser Gly Arg Asp Lys Ile Cys
      95          100         105
Ile Ile Trp Asp Leu Gln Ser Cys Gln Ala Thr Arg Thr Val Pro
      110         115         120
Val Phe Glu Ser Val Glu Ala Ala Val Leu Leu Pro Glu Glu Pro
      125         130         135
Val Ser Gln Leu Gly Val Lys Ser Pro Gly Leu Tyr Phe Leu Thr
      140         145         150
Ala Gly Asp Gln Gly Thr Leu Arg Val Trp Glu Ala Ala Ser Gly
      155         160         165
Gln Cys Val Tyr Thr Gln Ala Gln Pro Pro Gly Pro Gly Gln Glu
      170         175         180

```

Leu Thr His Cys Thr	Leu Ala His Thr	Ala Gly Val Val	Leu Thr
185		190	195
Ala Thr Ala Asp His	Asn Leu Leu Leu	Tyr Glu Ala Arg	Ser Leu
200		205	210
Arg Leu Gln Lys Gln	Phe Ala Gly Tyr	Ser Glu Glu Val	Leu Asp
215		220	225
Val Arg Phe Leu Gly	Pro Glu Asp Ser	His Val Val Val	Ala Ser
230		235	240
Asn Ser Pro Cys Leu	Lys Val Phe Glu	Leu Gln Thr Ser	Ala Cys
245		250	255
Gln Ile Leu His Gly	His Thr Asp Ile	Val Leu Ala Leu	Asp Val
260		265	270
Phe Arg Lys Gly Trp	Leu Phe Ala Ser	Cys Ala Lys Asp	Gln Ser
275		280	285
Val Arg Ile Trp Arg	Met Asn Lys Ala	Gly Gln Val Met	Cys Val
290		295	300
Ala Gln Gly Ser Gly	His Thr His Ser	Val Gly Thr Val	Cys Cys
305		310	315
Ser Arg Leu Lys Glu	Ser Phe Leu Val	Thr Gly Ser Gln	Asp Cys
320		325	330
Thr Val Lys Leu Trp	Pro Leu Pro Lys	Ala Leu Leu Ser	Lys Asn
335		340	345
Thr Ala Pro Asp Asn	Gly Pro Ile Leu	Leu Gln Ala Gln	Thr Thr
350		355	360
Gln Arg Cys His Asp	Lys Asp Ile Asn	Ser Val Ala Ile	Ala Pro
365		370	375
Asn Asp Lys Leu Leu	Ala Thr Gly Ser	Gln Asp Arg Thr	Ala Lys
380		385	390
Leu Trp Ala Leu Pro	Gln Cys Gln Leu	Leu Gly Val Phe	Ser Gly
395		400	405
His Arg Arg Gly Leu	Trp Cys Val Gln	Phe Ser Pro Met	Asp Gln
410		415	420
Val Leu Ala Thr Ala	Ser Ala Asp Gly	Thr Ile Lys Leu	Trp Ala
425		430	435
Leu Gln Asp Phe Ser	Cys Leu Lys Thr	Phe Glu Gly His	Asp Ala
440		445	450
Ser Val Leu Lys Val	Ala Phe Val Ser	Arg Gly Thr Gln	Leu Leu
455		460	465
Ser Ser Gly Ser Asp	Gly Leu Val Lys	Leu Trp Thr Ile	Lys Asn
470		475	480
Asn Glu Cys Val Arg	Thr Leu Asp Ala	His Glu Asp Lys	Val Trp
485		490	495
Gly Leu His Cys Ser	Arg Leu Asp Asp	His Ala Leu Thr	Gly Ala
500		505	510
Ser Asp Ser Arg Val	Ile Leu Trp Lys	Asp Val Thr Glu	Ala Glu
515		520	525
Gln Ala Glu Glu Gln	Ala Arg Gln Glu	Glu Gln Val Val	Arg Gln
530		535	540
Gln Glu Leu Asp Asn	Leu Leu His Glu	Lys Arg Tyr Leu	Arg Ala
545		550	555
Leu Gly Leu Ala Ile	Ser Leu Asp Arg	Pro His Thr Val	Leu Thr
560		565	570
Val Ile Gln Ala Ile	Arg Arg Asp Pro	Glu Ala Cys Glu	Lys Leu
575		580	585
Glu Ala Thr Met Leu	Arg Leu Arg Arg	Asp Gln Lys Glu	Ala Leu

	590		595		600
Leu Arg Phe Cys	Val Thr Trp Asn Thr	Asn Ser Arg His Cys His			
	605		610		615
Glu Ala Gln Ala	Val Leu Gly Val Leu	Leu Arg Arg Glu Ala Pro			
	620		625		630
Glu Glu Leu Leu	Ala Tyr Glu Gly Val	Arg Ala Ala Leu Glu Ala			
	635		640		645
Leu Leu Pro Tyr	Thr Glu Arg His Phe	Gln Arg Leu Ser Arg Thr			
	650		655		660
Leu Gln Ala Ala	Ala Phe Leu Asp Phe	Leu Trp His Asn Met Lys			
	665		670		675
Leu Pro Val Pro	Ala Ala Ala Pro Thr	Pro Trp Glu Thr His Lys			
	680		685		690
Gly Ala Leu Pro					

&lt;210&gt; 13

&lt;211&gt; 654

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1848674CD1

&lt;400&gt; 13

Met Glu Arg Ser	Gly Pro Ser Glu Val	Thr Gly Ser Asp Ala Ser
1	5	10 15
Gly Pro Asp Pro	Gln Leu Ala Val Thr	Met Gly Phe Thr Gly Phe
	20	25 30
Gly Lys Lys Ala	Arg Thr Phe Asp Leu	Glu Ala Met Phe Glu Gln
	35	40 45
Thr Arg Arg Thr	Ala Val Glu Arg Ser	Arg Lys Thr Leu Glu Ala
	50	55 60
Arg Glu Lys Glu	Glu Glu Met Asn Arg	Glu Lys Glu Leu Arg Arg
	65	70 75
Gln Asn Glu Asp	Ile Glu Pro Thr Ser	Ser Arg Ser Asn Val Val
	80	85 90
Arg Asp Cys Ser	Lys Ser Ser Ser Arg	Asp Thr Ser Ser Ser Glu
	95	100 105
Ser Glu Gln Ser	Ser Asp Ser Ser Asp	Asp Glu Leu Ile Gly Pro
	110	115 120
Pro Leu Pro Pro	Lys Met Val Gly Lys	Pro Val Asn Phe Met Glu
	125	130 135
Glu Asp Ile Leu	Gly Pro Leu Pro Pro	Pro Leu Asn Glu Glu Glu
	140	145 150
Glu Glu Ala Glu	Glu Glu Glu Glu Glu	Glu Glu Glu Glu Glu Asn
	155	160 165
Pro Val His Lys	Ile Pro Asp Ser His	Glu Ile Thr Leu Lys His
	170	175 180
Gly Thr Lys Thr	Val Ser Ala Leu Gly	Leu Asp Pro Ser Gly Ala
	185	190 195
Arg Leu Val Thr	Gly Gly Tyr Asp Tyr	Asp Val Lys Phe Trp Asp
	200	205 210
Phe Ala Gly Met	Asp Ala Ser Phe Lys	Ala Phe Arg Ser Leu Gln



Pro Cys Glu Cys	215	220	225
His Gln Ile Lys Ser		Leu Gln Tyr Ser Asn Thr	
	230	235	240
Gly Asp Met Ile		Ser Ser Gln Ala Lys Val	
	245	250	255
Ile Asp Arg Asp		Glu Cys Ile Lys Gly Asp	
	260	265	270
Gln Tyr Ile Val		Asp Met Ala Asn Thr Lys Gly His Thr Ala Met	
	275	280	285
Leu His Thr Gly		Ser Trp His Pro Lys Ile Lys Gly Glu Phe Met	
	290	295	300
Thr Cys Ser Asn		Asp Ala Thr Val Arg Thr Trp Glu Val Glu Asn	
	305	310	315
Pro Lys Lys Gln		Lys Ser Val Phe Lys Pro Arg Thr Met Gln Gly	
	320	325	330
Lys Lys Val Ile		Pro Thr Thr Cys Thr Tyr Ser Arg Asp Gly Asn	
	335	340	345
Leu Ile Ala Ala		Ala Cys Gln Asn Gly Ser Ile Gln Ile Trp Asp	
	350	355	360
Arg Asn Leu Thr		Val His Pro Lys Phe His Tyr Lys Gln Ala His	
	365	370	375
Asp Ser Gly Thr		Asp Thr Ser Cys Val Thr Phe Ser Tyr Asp Gly	
	380	385	390
Asn Val Leu Ala		Ser Arg Gly Gly Asp Asp Ser Leu Lys Leu Trp	
	395	400	405
Asp Ile Arg Gln		Phe Asn Lys Pro Leu Phe Ser Ala Ser Gly Leu	
	410	415	420
Pro Thr Met Phe		Pro Met Thr Asp Cys Cys Phe Ser Pro Asp Asp	
	425	430	435
Lys Leu Ile Val		Thr Gly Thr Ser Ile Gln Arg Gly Cys Gly Ser	
	440	445	450
Gly Lys Leu Val		Phe Phe Glu Arg Arg Thr Phe Gln Arg Val Tyr	
	455	460	465
Glu Ile Asp Ile		Thr Asp Ala Ser Val Val Arg Cys Leu Trp His	
	470	475	480
Pro Lys Leu Asn		Gln Ile Met Val Gly Thr Gly Asn Gly Leu Ala	
	485	490	495
Lys Val Tyr Tyr		Asp Pro Asn Lys Ser Gln Arg Gly Ala Lys Leu	
	500	505	510
Cys Val Val Lys		Thr Gln Arg Lys Ala Lys Gln Ala Glu Thr Leu	
	515	520	525
Thr Gln Asp Tyr		Ile Ile Thr Pro His Ala Leu Pro Met Phe Arg	
	530	535	540
Glu Pro Arg Gln		Arg Ser Thr Arg Lys Gln Leu Glu Lys Asp Arg	
	545	550	555
Leu Asp Pro Leu		Lys Ser His Lys Pro Glu Pro Pro Val Ala Gly	
	560	565	570
Pro Gly Arg Gly		Gly Arg Val Gly Thr His Gly Gly Thr Leu Ser	
	575	580	585
Ser Tyr Ile Val		Lys Asn Ile Ala Leu Asp Lys Thr Asp Asp Ser	
	590	595	600
Asn Pro Arg Glu		Ala Ile Leu Arg His Ala Lys Ala Ala Glu Asp	
	605	610	615
Ser Pro Tyr Trp		Val Ser Pro Ala Tyr Ser Lys Thr Gln Pro Lys	
	620	625	630

Thr Met Phe Ala Gln Val Glu Ser Asp Asp Glu Glu Ala Lys Asn  
                   635                  640                  645  
 Glu Pro Glu Trp Lys Lys Arg Lys Ile  
                   650

<210> 14  
 <211> 180  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2012970CD1

<400> 14  
 Met Glu Ala Asn Met Pro Lys Arg Lys Glu Pro Gly Arg Ser Leu  
   1                  5                  10                  15  
 Arg Ile Lys Val Ile Ser Met Gly Asn Ala Glu Val Gly Lys Ser  
                   20                  25                  30  
 Cys Ile Ile Lys Arg Tyr Cys Glu Lys Arg Phe Val Ser Lys Tyr  
                   35                  40                  45  
 Leu Ala Thr Ile Gly Ile Asp Tyr Gly Val Thr Lys Val His Val  
                   50                  55                  60  
 Arg Asp Arg Glu Ile Lys Val Asn Ile Phe Asp Met Ala Gly His  
                   65                  70                  75  
 Pro Phe Phe Tyr Glu Val Arg Asn Glu Phe Tyr Lys Asp Thr Gln  
                   80                  85                  90  
 Gly Val Ile Leu Val Tyr Asp Val Gly Gln Lys Asp Ser Phe Asp  
                   95                  100                  105  
 Ala Leu Asp Ala Trp Leu Ala Glu Met Lys Gln Glu Leu Gly Pro  
                   110                  115                  120  
 His Gly Asn Met Glu Asn Ile Ile Phe Val Val Cys Ala Asn Lys  
                   125                  130                  135  
 Ile Asp Cys Thr Lys His Arg Cys Val Asp Glu Ser Glu Gly Arg  
                   140                  145                  150  
 Leu Trp Ala Glu Ser Lys Gly Phe Leu Tyr Phe Glu Thr Ser Ala  
                   155                  160                  165  
 Gln Thr Gly Glu Gly Ile Asn Glu Met Phe Gln Ile His Leu Gly  
                   170                  175                  180

<210> 15  
 <211> 374  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2254315CD1

<400> 15  
 Met Ala Ala Ser Ala Ala Ala Glu Leu Gln Ala Ser Gly Gly  
   1                  5                  10                  15  
 Pro Arg His Pro Val Cys Leu Leu Val Leu Gly Met Ala Gly Ser

	20		25		30
Gly Lys Thr Thr Phe Val Gln Arg Leu Thr Gly His Leu His Ala					
	35		40		45
Gln Gly Thr Pro Pro Tyr Val Ile Asn Leu Asp Pro Ala Val His					
	50		55		60
Glu Val Pro Phe Pro Ala Asn Ile Asp Ile Arg Asp Thr Val Lys					
	65		70		75
Tyr Lys Glu Val Met Lys Gln Tyr Gly Leu Gly Pro Asn Gly Gly					
	80		85		90
Ile Val Thr Ser Leu Asn Leu Phe Ala Thr Arg Phe Asp Gln Val					
	95		100		105
Met Lys Phe Ile Glu Lys Ala Gln Asn Met Ser Lys Tyr Val Leu					
	110		115		120
Ile Asp Thr Pro Gly Gln Ile Glu Val Phe Thr Trp Ser Ala Ser					
	125		130		135
Gly Thr Ile Ile Thr Glu Ala Leu Ala Ser Ser Phe Pro Thr Val					
	140		145		150
Val Ile Tyr Val Met Asp Thr Ser Arg Ser Thr Asn Pro Val Thr					
	155		160		165
Phe Met Ser Asn Met Leu Tyr Ala Cys Ser Ile Leu Tyr Lys Thr					
	170		175		180
Lys Leu Pro Phe Ile Val Val Met Asn Lys Thr Asp Ile Ile Asp					
	185		190		195
His Ser Phe Ala Val Glu Trp Met Gln Asp Phe Glu Ala Phe Gln					
	200		205		210
Asp Ala Leu Asn Gln Glu Thr Thr Tyr Val Ser Asn Leu Thr Arg					
	215		220		225
Ser Met Ser Leu Val Leu Asp Glu Phe Tyr Ser Ser Leu Arg Val					
	230		235		240
Val Gly Val Ser Ala Val Leu Gly Thr Gly Leu Asp Glu Leu Phe					
	245		250		255
Val Gln Val Thr Ser Ala Ala Glu Glu Tyr Glu Arg Glu Tyr Arg					
	260		265		270
Pro Glu Tyr Glu Arg Leu Lys Lys Ser Leu Ala Asn Ala Glu Ser					
	275		280		285
Gln Gln Gln Arg Glu Gln Leu Glu Arg Leu Arg Lys Asp Met Gly					
	290		295		300
Ser Val Ala Leu Asp Ala Gly Thr Ala Lys Asp Ser Leu Ser Pro					
	305		310		315
Val Leu His Pro Ser Asp Leu Ile Leu Thr Arg Gly Thr Leu Asp					
	320		325		330
Glu Glu Asp Glu Glu Ala Asp Ser Asp Thr Asp Asp Ile Asp His					
	335		340		345
Arg Val Thr Glu Glu Ser His Glu Glu Pro Ala Phe Gln Asn Phe					
	350		355		360
Met Gln Glu Ser Met Ala Gln Tyr Trp Lys Arg Asn Asn Lys					
	365		370		

&lt;210&gt; 16

&lt;211&gt; 649

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2415545CD1

&lt;400&gt; 16

```

Met Glu Gly Ala Gly Tyr Arg Val Val Phe Glu Lys Gly Gly Val
  1          5          10          15
Tyr Leu His Thr Ser Ala Lys Lys Tyr Gln Asp Arg Asp Ser Leu
          20          25          30
Ile Ala Gly Val Ile Arg Val Val Glu Lys Asp Asn Asp Val Leu
          35          40          45
Leu His Trp Ala Pro Val Glu Glu Ala Gly Asp Ser Thr Gln Ile
          50          55          60
Leu Phe Ser Lys Lys Asp Ser Ser Gly Gly Asp Ser Cys Ala Ser
          65          70          75
Glu Glu Glu Pro Thr Phe Asp Pro Gly Tyr Glu Pro Asp Trp Ala
          80          85          90
Val Ile Ser Thr Val Arg Pro Gln Pro Cys His Ser Glu Pro Thr
          95          100          105
Arg Gly Ala Glu Pro Ser Cys Pro Gln Gly Ser Trp Ala Phe Ser
          110          115          120
Val Ser Leu Gly Glu Leu Lys Ser Ile Arg Arg Ser Lys Pro Gly
          125          130          135
Leu Ser Trp Ala Tyr Leu Val Leu Val Thr Gln Ala Gly Gly Ser
          140          145          150
Leu Pro Ala Leu His Phe His Arg Gly Gly Thr Arg Ala Leu Leu
          155          160          165
Arg Val Leu Ser Arg Tyr Leu Leu Leu Ala Ser Ser Pro Gln Asp
          170          175          180
Ser Arg Leu Tyr Leu Val Phe Pro His Asp Ser Ser Ala Leu Ser
          185          190          195
Asn Ser Phe His His Leu Gln Leu Phe Asp Gln Asp Ser Ser Asn
          200          205          210
Val Val Ser Arg Phe Leu Gln Asp Pro Tyr Ser Thr Thr Phe Ser
          215          220          225
Ser Phe Ser Arg Val Thr Asn Phe Phe Arg Gly Ala Leu Gln Pro
          230          235          240
Gln Pro Glu Gly Ala Ala Ser Asp Leu Pro Pro Pro Pro Asp Asp
          245          250          255
Glu Pro Glu Pro Gly Phe Glu Val Ile Ser Cys Val Glu Leu Gly
          260          265          270
Pro Arg Pro Thr Val Glu Arg Gly Pro Pro Val Thr Glu Glu Glu
          275          280          285
Trp Ala Arg His Val Gly Pro Glu Gly Arg Leu Gln Gln Val Pro
          290          295          300
Glu Leu Lys Asn Arg Ile Phe Ser Gly Gly Leu Ser Pro Ser Leu
          305          310          315
Arg Arg Glu Ala Trp Lys Phe Leu Leu Gly Tyr Leu Ser Trp Glu
          320          325          330
Gly Thr Ala Glu Glu His Lys Ala His Ile Arg Lys Lys Thr Asp
          335          340          345
Glu Tyr Phe Arg Met Lys Leu Gln Trp Lys Ser Val Ser Pro Glu
          350          355          360
Gln Glu Arg Arg Asn Ser Leu Leu His Gly Tyr Arg Ser Leu Ile
          365          370          375
Glu Arg Asp Val Ser Arg Thr Asp Arg Thr Asn Lys Phe Tyr Glu

```

	380		385		390
Gly Pro Glu Asn	Pro Gly Leu Gly Leu	Leu Asn Asp Ile Leu Leu			
	395		400		405
Thr Tyr Cys Met	Tyr His Phe Asp Leu	Gly Tyr Val Gln Gly Met			
	410		415		420
Ser Asp Leu Leu	Ser Pro Ile Leu Tyr	Val Ile Gln Asn Glu Val			
	425		430		435
Asp Ala Phe Trp	Cys Phe Cys Gly Phe	Met Glu Leu Val Gln Gly			
	440		445		450
Asn Phe Glu Glu	Ser Gln Glu Thr Met	Lys Arg Gln Leu Gly Arg			
	455		460		465
Leu Leu Leu Leu	Leu Arg Val Leu Asp	Pro Leu Leu Cys Asp Phe			
	470		475		480
Leu Asp Ser Gln	Asp Ser Gly Ser Leu	Cys Phe Cys Phe Arg Trp			
	485		490		495
Leu Leu Ile Trp	Phe Lys Arg Glu Phe	Pro Phe Pro Asp Val Leu			
	500		505		510
Arg Leu Trp Glu	Val Leu Trp Thr Gly	Leu Pro Gly Pro Asn Leu			
	515		520		525
His Leu Leu Val	Ala Cys Ala Ile Leu	Asp Met Glu Arg Asp Thr			
	530		535		540
Leu Met Leu Ser	Gly Phe Gly Ser Asn	Glu Ile Leu Lys His Ile			
	545		550		555
Asn Glu Leu Thr	Met Lys Leu Ser Val	Glu Asp Val Leu Thr Arg			
	560		565		570
Ala Glu Ala Leu	His Arg Gln Leu Thr	Ala Cys Thr Arg Ala Ala			
	575		580		585
Pro Gln Arg Ala	Gly Asp Pro Gly Ala	Gly Pro Ala Thr Gln Ser			
	590		595		600
Pro Thr Ala Pro	Arg Pro Pro Pro Pro	Arg Cys Leu Cys Thr Pro			
	605		610		615
Thr Arg Ala Pro	Pro Thr Pro Pro Pro	Ser Thr Asp Thr Ala Pro			
	620		625		630
Gln Pro Asp Ser	Ser Leu Glu Ile Leu	Pro Glu Glu Glu Asp Glu			
	635		640		645
Gly Ala Asp Ser					

&lt;210&gt; 17

&lt;211&gt; 698

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2707969CD1

&lt;400&gt; 17

Met Cys His Asp	Asp Asp Lys Asp	Pro Val Leu Arg Val Phe
1	5	10 15
Asp Ser Arg Val	Asp Lys Ile Arg Leu	Leu Asn Val Arg Thr Pro
	20	25 30
Thr Leu Arg Thr	Ser Met Tyr Gln Lys	Cys Thr Thr Val Asp Glu
	35	40 45
Ala Glu Lys Ala	Ile Glu Leu Arg Leu	Ala Lys Ile Asp His Thr

Ala	Ile	His	Pro	His	Leu	Leu	Asp	Met	Lys	Ile	Gly	Gln	Gly	Lys	50	55	60
															65	70	75
Tyr	Glu	Pro	Gly	Phe	Phe	Pro	Lys	Leu	Gln	Ser	Asp	Val	Leu	Ser	80	85	90
Thr	Gly	Pro	Ala	Ser	Asn	Lys	Trp	Thr	Lys	Arg	Asn	Ala	Pro	Ala	95	100	105
Gln	Trp	Arg	Arg	Lys	Asp	Arg	Gln	Lys	Gln	His	Thr	Glu	His	Leu	110	115	120
Arg	Leu	Asp	Asn	Asp	Gln	Arg	Glu	Lys	Tyr	Ile	Gln	Glu	Ala	Arg	125	130	135
Thr	Met	Gly	Ser	Thr	Ile	Arg	Gln	Pro	Lys	Leu	Ser	Asn	Leu	Ser	140	145	150
Pro	Ser	Val	Ile	Ala	Gln	Thr	Asn	Trp	Lys	Phe	Val	Glu	Gly	Leu	155	160	165
Leu	Lys	Glu	Cys	Arg	Asn	Lys	Thr	Lys	Arg	Met	Leu	Val	Glu	Lys	170	175	180
Met	Gly	Arg	Glu	Ala	Val	Glu	Leu	Gly	His	Gly	Glu	Val	Asn	Ile	185	190	195
Thr	Gly	Val	Glu	Glu	Asn	Thr	Leu	Ile	Ala	Ser	Leu	Cys	Asp	Leu	200	205	210
Leu	Glu	Arg	Ile	Trp	Ser	His	Gly	Leu	Gln	Val	Lys	Gln	Gly	Lys	215	220	225
Ser	Ala	Leu	Trp	Ser	His	Leu	Leu	His	Tyr	Gln	Asp	Asn	Arg	Gln	230	235	240
Arg	Lys	Leu	Thr	Ser	Gly	Ser	Leu	Ser	Thr	Ser	Gly	Ile	Leu	Leu	245	250	255
Asp	Ser	Glu	Arg	Arg	Lys	Ser	Asp	Ala	Ser	Ser	Leu	Met	Pro	Pro	260	265	270
Leu	Arg	Ile	Ser	Leu	Ile	Gln	Asp	Met	Arg	His	Ile	Gln	Asn	Ile	275	280	285
Gly	Glu	Ile	Lys	Thr	Asp	Val	Gly	Lys	Ala	Arg	Ala	Trp	Val	Arg	290	295	300
Leu	Ser	Met	Glu	Lys	Lys	Leu	Leu	Ser	Arg	His	Leu	Lys	Gln	Leu	305	310	315
Leu	Ser	Asp	His	Glu	Leu	Thr	Lys	Lys	Leu	Tyr	Lys	Arg	Tyr	Ala	320	325	330
Phe	Leu	Arg	Cys	Asp	Asp	Glu	Lys	Glu	Gln	Phe	Leu	Tyr	His	Leu	335	340	345
Leu	Ser	Phe	Asn	Ala	Val	Asp	Tyr	Phe	Cys	Phe	Thr	Asn	Val	Phe	350	355	360
Thr	Thr	Ile	Leu	Ile	Pro	Tyr	His	Ile	Leu	Ile	Val	Pro	Ser	Lys	365	370	375
Lys	Leu	Gly	Gly	Ser	Met	Phe	Thr	Ala	Asn	Pro	Trp	Ile	Cys	Ile	380	385	390
Ser	Gly	Glu	Leu	Gly	Glu	Thr	Gln	Ile	Met	Gln	Ile	Pro	Arg	Asn	395	400	405
Val	Leu	Glu	Met	Thr	Phe	Glu	Cys	Gln	Asn	Leu	Gly	Lys	Leu	Thr	410	415	420
Thr	Val	Gln	Ile	Gly	His	Asp	Asn	Ser	Gly	Leu	Tyr	Ala	Lys	Trp	425	430	435
Leu	Val	Glu	Tyr	Val	Met	Val	Arg	Asn	Glu	Ile	Thr	Gly	His	Thr	440	445	450
Tyr	Lys	Phe	Pro	Cys	Gly	Arg	Trp	Leu	Gly	Lys	Gly	Met	Asp	Asp	455	460	465

Gly	Ser	Leu	Glu	Arg	Ile	Leu	Val	Gly	Glu	Leu	Leu	Thr	Ser	Gln	
				470					475					480	
Pro	Glu	Val	Asp	Glu	Arg	Pro	Cys	Arg	Thr	Pro	Pro	Leu	Gln	Gln	
				485					490					495	
Ser	Pro	Ser	Val	Ile	Arg	Arg	Leu	Val	Thr	Ile	Ser	Pro	Asn	Asn	
				500					505					510	
Lys	Pro	Lys	Leu	Asn	Thr	Gly	Gln	Ile	Gln	Glu	Ser	Ile	Gly	Glu	
				515					520					525	
Ala	Val	Asn	Gly	Ile	Val	Lys	His	Phe	His	Lys	Pro	Glu	Lys	Glu	
				530					535					540	
Arg	Gly	Ser	Leu	Thr	Leu	Leu	Leu	Cys	Gly	Glu	Cys	Gly	Leu	Val	
				545					550					555	
Ser	Ala	Leu	Glu	Gln	Ala	Phe	Gln	His	Gly	Phe	Lys	Ser	Pro	Arg	
				560					565					570	
Leu	Phe	Lys	Asn	Val	Phe	Ile	Trp	Asp	Phe	Leu	Glu	Lys	Ala	Gln	
				575					580					585	
Thr	Tyr	Tyr	Glu	Thr	Leu	Glu	Lys	Asn	Glu	Val	Val	Pro	Glu	Glu	
				590					595					600	
Asn	Trp	His	Thr	Arg	Ala	Arg	Asn	Phe	Cys	Arg	Phe	Val	Thr	Ala	
				605					610					615	
Ile	Asn	Asn	Thr	Pro	Arg	Asn	Ile	Gly	Lys	Asp	Gly	Lys	Phe	Gln	
				620					625					630	
Met	Leu	Val	Cys	Leu	Gly	Ala	Arg	Asp	His	Leu	Leu	His	His	Trp	
				635					640					645	
Ile	Ala	Leu	Leu	Ala	Asp	Cys	Pro	Ile	Thr	Ala	His	Met	Tyr	Glu	
				650					655					660	
Asp	Val	Ala	Leu	Ile	Lys	Asp	His	Thr	Leu	Val	Asn	Ser	Leu	Ile	
				665					670					675	
Arg	Val	Leu	Gln	Thr	Leu	Gln	Glu	Phe	Asn	Ile	Thr	Leu	Glu	Thr	
				680					685					690	
Ser	Leu	Val	Lys	Gly	Ile	Asp	Ile								
				695											

&lt;210&gt; 18

&lt;211&gt; 396

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2817769CD1

&lt;400&gt; 18

Met	Pro	Pro	Lys	Lys	Gly	Gly	Asp	Gly	Ile	Lys	Pro	Pro	Pro	Ile	
1				5					10					15	
Ile	Gly	Arg	Phe	Gly	Thr	Ser	Leu	Lys	Ile	Gly	Ile	Val	Gly	Leu	
				20					25					30	
Pro	Asn	Val	Gly	Lys	Ser	Thr	Phe	Phe	Asn	Val	Leu	Thr	Asn	Ser	
				35					40					45	
Gln	Ala	Ser	Ala	Glu	Asn	Phe	Pro	Phe	Cys	Thr	Ile	Asp	Pro	Asn	
				50					55					60	
Glu	Ser	Arg	Val	Pro	Val	Pro	Asp	Glu	Arg	Phe	Asp	Phe	Leu	Cys	
				65					70					75	
Gln	Tyr	His	Lys	Pro	Ala	Ser	Lys	Ile	Pro	Ala	Phe	Leu	Asn	Val	
				80					85					90	

Val Asp Ile Ala Gly Leu Val Lys Gly Ala His Asn Gly Gln Gly	95	100	105
Leu Gly Asn Ala Phe Leu Ser His Ile Ser Ala Cys Asp Gly Ile	110	115	120
Phe His Leu Thr Arg Ala Phe Glu Asp Asp Asp Ile Thr His Val	125	130	135
Glu Gly Ser Val Asp Pro Ile Arg Asp Ile Glu Ile Ile His Glu	140	145	150
Glu Leu Gln Leu Lys Asp Glu Glu Met Ile Gly Pro Ile Ile Asp	155	160	165
Lys Leu Glu Lys Val Ala Val Arg Gly Gly Asp Lys Lys Leu Lys	170	175	180
Pro Glu Tyr Asp Ile Met Cys Lys Val Lys Ser Trp Val Ile Asp	185	190	195
Gln Lys Lys Pro Val Arg Phe Tyr His Asp Trp Asn Asp Lys Glu	200	205	210
Ile Glu Val Leu Asn Lys His Leu Phe Leu Thr Ser Lys Pro Met	215	220	225
Val Tyr Leu Val Asn Leu Ser Glu Lys Asp Tyr Ile Arg Lys Lys	230	235	240
Asn Lys Trp Leu Ile Lys Ile Lys Glu Trp Val Asp Lys Tyr Asp	245	250	255
Pro Gly Ala Leu Val Ile Pro Phe Ser Gly Ala Leu Glu Leu Lys	260	265	270
Leu Gln Glu Leu Ser Ala Glu Glu Arg Gln Lys Tyr Leu Glu Ala	275	280	285
Asn Met Thr Gln Ser Ala Leu Pro Lys Ile Ile Lys Ala Gly Phe	290	295	300
Ala Ala Leu Gln Leu Glu Tyr Phe Phe Thr Ala Gly Pro Asp Glu	305	310	315
Val Arg Ala Trp Thr Ile Arg Lys Gly Thr Lys Ala Pro Gln Ala	320	325	330
Ala Gly Lys Ile His Thr Asp Phe Glu Lys Gly Phe Ile Met Ala	335	340	345
Glu Val Met Lys Tyr Glu Asp Phe Lys Glu Glu Gly Ser Glu Asn	350	355	360
Ala Val Lys Ala Ala Gly Lys Tyr Arg Gln Gln Gly Arg Asn Tyr	365	370	375
Ile Val Glu Asp Gly Asp Ile Ile Phe Phe Lys Phe Asn Thr Pro	380	385	390
Gln Gln Pro Lys Lys Lys	395		

&lt;210&gt; 19

&lt;211&gt; 634

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2917557CD1

&lt;400&gt; 19

Met Ser Ser Asp Ser Glu Tyr Asp Ser Asp Asp Arg Thr Lys



1	5	10	15
Glu Glu Arg Ala Tyr Asp Lys Ala Lys Arg Arg Ile Glu Lys Arg			
	20	25	30
Arg Leu Glu His Ser Lys Asn Val Asn Thr Glu Lys Leu Arg Ala			
	35	40	45
Pro Ile Ile Cys Val Leu Gly His Val Asp Thr Gly Lys Thr Lys			
	50	55	60
Ile Leu Asp Lys Leu Arg His Thr His Val Gln Asp Gly Glu Ala			
	65	70	75
Gly Gly Ile Thr Gln Gln Ile Gly Ala Thr Asn Val Pro Leu Glu			
	80	85	90
Ala Ile Asn Glu Gln Thr Lys Met Ile Lys Asn Phe Asp Arg Glu			
	95	100	105
Asn Val Arg Ile Pro Gly Met Leu Ile Ile Asp Thr Pro Gly His			
	110	115	120
Glu Ser Phe Ser Asn Leu Arg Asn Arg Gly Ser Ser Leu Cys Asp			
	125	130	135
Ile Ala Ile Leu Val Val Asp Ile Met His Gly Leu Glu Pro Gln			
	140	145	150
Thr Ile Glu Ser Ile Asn Leu Leu Lys Ser Lys Lys Cys Pro Phe			
	155	160	165
Ile Val Ala Leu Asn Lys Ile Asp Arg Leu Tyr Asp Trp Lys Lys			
	170	175	180
Ser Pro Asp Ser Asp Val Ala Ala Thr Leu Lys Lys Gln Lys Lys			
	185	190	195
Asn Thr Lys Asp Glu Phe Glu Glu Arg Ala Lys Ala Ile Ile Val			
	200	205	210
Glu Phe Ala Gln Gln Gly Leu Asn Ala Ala Leu Phe Tyr Glu Asn			
	215	220	225
Lys Asp Pro Arg Thr Phe Val Ser Leu Val Pro Thr Ser Ala His			
	230	235	240
Thr Gly Asp Gly Met Gly Ser Leu Ile Tyr Leu Leu Val Glu Leu			
	245	250	255
Thr Gln Thr Met Leu Ser Lys Arg Leu Ala His Cys Glu Glu Leu			
	260	265	270
Arg Ala Gln Val Met Glu Val Lys Ala Leu Pro Gly Met Gly Thr			
	275	280	285
Thr Ile Asp Val Ile Leu Ile Asn Gly Arg Leu Lys Glu Gly Asp			
	290	295	300
Thr Ile Ile Val Pro Gly Val Glu Gly Pro Ile Val Thr Gln Ile			
	305	310	315
Arg Gly Leu Leu Leu Pro Pro Pro Met Lys Glu Leu Arg Val Lys			
	320	325	330
Asn Gln Tyr Glu Lys His Lys Glu Val Glu Ala Ala Gln Gly Val			
	335	340	345
Lys Ile Leu Gly Lys Asp Leu Glu Lys Thr Leu Ala Gly Leu Pro			
	350	355	360
Leu Leu Val Ala Tyr Lys Glu Asp Glu Ile Pro Val Leu Lys Asp			
	365	370	375
Glu Leu Ile His Glu Leu Lys Gln Thr Leu Asn Ala Ile Lys Leu			
	380	385	390
Glu Glu Lys Gly Val Tyr Val Gln Ala Ser Thr Leu Gly Ser Leu			
	395	400	405
Glu Ala Leu Leu Glu Phe Leu Lys Thr Ser Glu Val Pro Tyr Ala			
	410	415	420

Gly Ile Asn Ile	Gly Pro Val His Lys	Lys Asp Val Met Lys	Ala
425		430	435
Ser Val Met Leu	Glu His Asp Pro Gln Tyr	Ala Val Ile Leu	Ala
440		445	450
Phe Asp Val Arg	Ile Glu Arg Asp Ala Gln	Glu Met Ala Asp	Ser
455		460	465
Leu Gly Val Arg	Ile Phe Ser Ala Glu Ile	Ile Tyr His Leu	Phe
470		475	480
Asp Ala Phe Thr	Lys Tyr Arg Gln Asp Tyr	Lys Lys Gln Lys	Gln
485		490	495
Glu Glu Phe Lys	His Ile Ala Val Phe Pro	Cys Lys Ile Lys	Ile
500		505	510
Leu Pro Gln Tyr	Ile Phe Asn Ser Arg Asp	Pro Ile Val Met	Gly
515		520	525
Val Thr Val Glu	Ala Gly Gln Val Lys Gln	Gly Thr Pro Met	Cys
530		535	540
Val Pro Ser Lys	Asn Phe Val Asp Ile Gly	Ile Val Thr Ser	Ile
545		550	555
Glu Ile Asn His	Lys Gln Val Asp Val Ala	Lys Lys Gly Gln	Glu
560		565	570
Val Cys Val Lys	Ile Glu Pro Ile Pro Gly	Glu Ser Pro Lys	Met
575		580	585
Phe Gly Arg His	Phe Glu Ala Thr Asp Ile	Leu Val Ser Lys	Ile
590		595	600
Ser Arg Gln Ser	Ile Asp Ala Leu Lys Asp	Trp Phe Arg Asp	Glu
605		610	615
Met Gln Lys Ser	Asp Trp Gln Leu Ile Val	Glu Leu Lys Lys	Val
620		625	630
Phe Glu Ile Ile			

&lt;210&gt; 20

&lt;211&gt; 196

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3421335CD1

&lt;400&gt; 20

Met Gly Ser Val	Asn Ser Arg Gly His Lys	Ala Glu Ala Gln	Val
1	5	10	15
Val Met Met Gly	Leu Asp Ser Ala Gly Lys	Thr Thr Leu Leu	Tyr
20		25	30
Lys Leu Lys Gly	His Gln Leu Val Glu Thr	Leu Pro Thr Val	Gly
35		40	45
Phe Asn Val Glu	Pro Leu Lys Ala Pro Gly	His Val Ser Leu	Thr
50		55	60
Leu Trp Asp Val	Gly Gly Gln Ala Pro Leu	Arg Ala Ser Trp	Lys
65		70	75
Asp Tyr Leu Glu	Gly Thr Asp Ile Leu Val	Tyr Val Leu Asp	Ser
80		85	90
Thr Asp Glu Ala	Arg Leu Pro Glu Ser Ala	Ala Glu Leu Thr	Glu
95		100	105

Val	Leu	Asn	Asp	Pro	Asn	Met	Ala	Gly	Val	Pro	Phe	Leu	Val	Leu
				110					115					120
Ala	Asn	Lys	Gln	Glu	Ala	Pro	Asp	Ala	Leu	Pro	Leu	Leu	Lys	Ile
				125					130					135
Arg	Asn	Arg	Leu	Ser	Leu	Glu	Arg	Phe	Gln	Asp	His	Cys	Trp	Glu
				140					145					150
Leu	Arg	Gly	Cys	Ser	Ala	Leu	Thr	Gly	Glu	Gly	Leu	Pro	Glu	Ala
				155					160					165
Leu	Gln	Ser	Leu	Trp	Ser	Leu	Leu	Lys	Ser	Arg	Ser	Cys	Met	Cys
				170					175					180
Leu	Gln	Ala	Arg	Ala	His	Gly	Ala	Glu	Arg	Gly	Asp	Ser	Lys	Arg
				185					190					195

Ser

&lt;210&gt; 21

&lt;211&gt; 446

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 605761CD1

&lt;400&gt; 21

Met	Ala	Ala	Arg	Lys	Gly	Arg	Arg	Arg	Thr	Cys	Glu	Thr	Gly	Glu
1				5					10					15
Pro	Met	Glu	Ala	Glu	Ser	Gly	Asp	Thr	Ser	Ser	Glu	Gly	Pro	Ala
				20					25					30
Gln	Val	Tyr	Leu	Pro	Gly	Arg	Gly	Pro	Pro	Leu	Arg	Glu	Gly	Glu
				35					40					45
Glu	Leu	Val	Met	Asp	Glu	Glu	Ala	Tyr	Val	Leu	Tyr	His	Arg	Ala
				50					55					60
Gln	Thr	Gly	Ala	Pro	Cys	Leu	Ser	Phe	Asp	Ile	Val	Arg	Asp	His
				65					70					75
Leu	Gly	Asp	Asn	Arg	Thr	Glu	Leu	Pro	Leu	Thr	Leu	Tyr	Leu	Cys
				80					85					90
Ala	Gly	Thr	Gln	Ala	Glu	Ser	Ala	Gln	Ser	Asn	Arg	Leu	Met	Met
				95					100					105
Leu	Arg	Met	His	Asn	Leu	His	Gly	Thr	Lys	Pro	Pro	Pro	Ser	Glu
				110					115					120
Gly	Ser	Asp	Glu	Glu	Glu	Glu	Glu	Glu	Asp	Glu	Glu	Asp	Glu	Glu
				125					130					135
Glu	Arg	Lys	Pro	Gln	Leu	Glu	Leu	Ala	Met	Val	Pro	His	Tyr	Gly
				140					145					150
Gly	Ile	Asn	Arg	Val	Arg	Val	Ser	Trp	Leu	Gly	Glu	Glu	Pro	Val
				155					160					165
Ala	Gly	Val	Trp	Ser	Glu	Lys	Gly	Gln	Val	Glu	Val	Phe	Ala	Leu
				170					175					180
Arg	Arg	Leu	Leu	Gln	Val	Val	Glu	Glu	Pro	Gln	Ala	Leu	Ala	Ala
				185					190					195
Phe	Leu	Arg	Asp	Glu	Gln	Ala	Gln	Met	Lys	Pro	Ile	Phe	Ser	Phe
				200					205					210
Ala	Gly	His	Met	Gly	Glu	Gly	Phe	Ala	Leu	Asp	Trp	Ser	Pro	Arg
				215					220					225

```

Val Thr Gly Arg Leu Leu Thr Gly Asp Cys Gln Lys Asn Ile His
      230                      235                      240
Leu Trp Thr Pro Thr Asp Gly Gly Ser Trp His Val Asp Gln Arg
      245                      250                      255
Pro Phe Val Gly His Thr Arg Ser Val Glu Asp Leu Gln Trp Ser
      260                      265                      270
Pro Thr Glu Asn Thr Val Phe Ala Ser Cys Ser Ala Asp Ala Ser
      275                      280                      285
Ile Arg Ile Trp Asp Ile Arg Ala Ala Pro Ser Lys Ala Cys Met
      290                      295                      300
Leu Thr Thr Ala Thr Ala His Asp Gly Asp Val Asn Val Ile Ser
      305                      310                      315
Trp Ser Arg Arg Glu Pro Phe Leu Leu Ser Gly Gly Asp Asp Gly
      320                      325                      330
Ala Leu Lys Ile Trp Asp Leu Arg Gln Phe Lys Ser Gly Ser Pro
      335                      340                      345
Val Ala Thr Phe Lys Gln His Val Ala Pro Val Thr Ser Val Glu
      350                      355                      360
Trp His Pro Gln Asp Ser Gly Val Phe Ala Ala Ser Gly Ala Asp
      365                      370                      375
His Gln Ile Thr Gln Trp Asp Leu Ala Val Glu Arg Asp Pro Glu
      380                      385                      390
Ala Gly Asp Val Glu Ala Asp Pro Gly Leu Ala Asp Leu Pro Gln
      395                      400                      405
Gln Leu Leu Phe Val His Gln Gly Glu Thr Glu Leu Lys Glu Leu
      410                      415                      420
His Trp His Pro Gln Cys Pro Gly Leu Leu Val Ser Thr Ala Leu
      425                      430                      435
Ser Gly Phe Thr Ile Phe Arg Thr Ile Ser Val
      440                      445

```

&lt;210&gt; 22

&lt;211&gt; 265

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 483862CD1

&lt;400&gt; 22

```

Met Ser Ser Gly Leu Arg Ala Ala Asp Phe Pro Arg Trp Lys Arg
  1          5          10          15
His Ile Ser Glu Gln Leu Arg Arg Arg Asp Arg Leu Gln Arg Gln
      20          25          30
Ala Phe Glu Glu Ile Ile Leu Gln Tyr Asn Lys Leu Leu Glu Lys
      35          40          45
Ser Asp Leu His Ser Val Leu Ala Gln Lys Leu Gln Ala Glu Lys
      50          55          60
His Asp Val Pro Asn Arg His Glu Ile Ser Pro Gly His Asp Gly
      65          70          75
Thr Trp Asn Asp Asn Gln Leu Gln Glu Met Ala Gln Leu Arg Ile
      80          85          90
Lys His Gln Glu Glu Leu Thr Glu Leu His Lys Lys Arg Gly Glu

```

	95		100		105
Leu Ala Gln Leu	Val Ile Asp Leu Asn	Asn Gln Met Gln Arg	Lys		
	110		115		120
Asp Arg Glu Met	Gln Met Asn Glu Ala	Lys Ile Ala Glu Cys	Leu		
	125		130		135
Gln Thr Ile Ser	Asp Leu Glu Thr Glu	Cys Leu Asp Leu Arg	Thr		
	140		145		150
Lys Leu Cys Asp	Leu Glu Arg Ala Asn	Gln Thr Leu Lys Asp	Glu		
	155		160		165
Tyr Asp Ala Leu	Gln Ile Thr Phe Thr	Ala Leu Glu Gly Lys	Leu		
	170		175		180
Arg Lys Thr Thr	Glu Glu Asn Gln Glu	Leu Val Thr Arg Trp	Met		
	185		190		195
Ala Glu Lys Ala	Gln Glu Ala Asn Arg	Leu Asn Ala Glu Asn	Glu		
	200		205		210
Lys Asp Ser Arg	Arg Arg Gln Ala Arg	Leu Gln Lys Glu Leu	Ala		
	215		220		225
Glu Ala Ala Lys	Glu Pro Leu Pro Val	Glu Gln Asp Asp Asp	Ile		
	230		235		240
Glu Val Ile Val	Asp Glu Thr Ser Asp	His Thr Glu Glu Thr	Ser		
	245		250		255
Pro Val Arg Ala	Ile Ser Arg Ala Ala	Thr			
	260		265		

&lt;210&gt; 23

&lt;211&gt; 185

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1256777CD1

&lt;400&gt; 23

Met Leu Lys Ala Lys	Ile Leu Phe Val	Gly Pro Cys Glu Ser	Gly
1	5	10	15
Lys Thr Val Leu Ala	Asn Phe Leu Thr	Glu Ser Ser Asp Ile	Thr
	20	25	30
Glu Tyr Ser Pro Thr	Gln Gly Val Arg	Ile Leu Glu Phe Glu	Asn
	35	40	45
Pro His Val Thr Ser	Asn Asn Lys Gly	Thr Gly Cys Glu Phe	Glu
	50	55	60
Leu Trp Asp Cys Gly	Gly Asp Ala Lys	Phe Glu Ser Cys Trp	Pro
	65	70	75
Ala Leu Met Lys Asp	Ala His Gly Val	Val Ile Val Phe Asn	Ala
	80	85	90
Asp Ile Pro Ser His	Arg Lys Glu Met	Glu Met Trp Tyr Ser	Cys
	95	100	105
Phe Val Gln Gln Pro	Ser Leu Gln Asp	Thr Gln Cys Met Leu	Ile
	110	115	120
Ala His His Lys Pro	Gly Ser Gly Asp	Asp Lys Gly Ser Leu	Ser
	125	130	135
Leu Ser Pro Pro Leu	Asn Lys Leu Lys	Leu Val His Ser Asn	Leu
	140	145	150

Glu Asp Asp Pro	Glu Glu Ile Arg Met	Glu Phe Ile Lys Tyr Leu
155	160	165
Lys Ser Ile Ile Asn Ser Met Ser Glu Ser Arg Asp Arg Glu Glu		
170	175	180
Met Ser Ile Met Thr		
185		

&lt;210&gt; 24

&lt;211&gt; 554

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2198779CD1

&lt;400&gt; 24

Met Gly Ser Arg Asn Ser Ser Ser Ala Gly Ser Gly Ser Gly Asp		
1	5	10
Pro Ser Glu Gly Leu Pro Arg Arg Gly Ala Gly Leu Arg Arg Ser		
20	25	30
Glu Glu Glu Glu Glu Glu Asp Glu Asp Val Asp Leu Ala Gln Val		
35	40	45
Leu Ala Tyr Leu Leu Arg Arg Gly Gln Val Arg Leu Val Gln Gly		
50	55	60
Gly Gly Ala Ala Asn Leu Gln Phe Ile Gln Ala Leu Leu Asp Ser		
65	70	75
Glu Glu Glu Asn Asp Arg Ala Trp Asp Gly Arg Leu Gly Asp Arg		
80	85	90
Tyr Asn Pro Pro Val Asp Ala Thr Pro Asp Thr Arg Glu Leu Glu		
95	100	105
Phe Asn Glu Ile Lys Thr Gln Val Glu Leu Ala Thr Gly Gln Leu		
110	115	120
Gly Leu Arg Arg Ala Ala Gln Lys His Ser Phe Pro Arg Met Leu		
125	130	135
His Gln Arg Glu Arg Gly Leu Cys His Arg Gly Ser Phe Ser Leu		
140	145	150
Gly Glu Gln Ser Arg Val Ile Ser His Phe Leu Pro Asn Asp Leu		
155	160	165
Gly Phe Thr Asp Ser Tyr Ser Gln Lys Ala Phe Cys Gly Ile Tyr		
170	175	180
Ser Lys Asp Gly Gln Ile Phe Met Ser Ala Cys Gln Asp Gln Thr		
185	190	195
Ile Arg Leu Tyr Asp Cys Arg Tyr Gly Arg Phe Arg Lys Phe Lys		
200	205	210
Ser Ile Lys Ala Arg Asp Val Gly Trp Ser Val Leu Asp Val Ala		
215	220	225
Phe Thr Pro Asp Gly Asn His Phe Leu Tyr Ser Ser Trp Ser Asp		
230	235	240
Tyr Ile His Ile Cys Asn Ile Tyr Gly Glu Gly Asp Thr His Thr		
245	250	255
Ala Leu Asp Leu Arg Pro Asp Glu Arg Arg Phe Ala Val Phe Ser		
260	265	270
Ile Ala Val Ser Ser Asp Gly Arg Glu Val Leu Gly Gly Ala Asn		
275	280	285

Asp Gly Cys Leu Tyr Val Phe Asp Arg	Glu Gln Asn Arg Arg Thr	
290	295	300
Leu Gln Ile Glu Ser His Glu Asp Asp	Val Asn Ala Val Ala Phe	
305	310	315
Ala Asp Ile Ser Ser Gln Ile Leu Phe	Ser Gly Gly Asp Asp Ala	
320	325	330
Ile Cys Lys Val Trp Asp Arg Arg Thr	Met Arg Glu Asp Asp Pro	
335	340	345
Lys Pro Val Gly Ala Leu Ala Gly His	Gln Asp Gly Ile Thr Phe	
350	355	360
Ile Asp Ser Lys Gly Asp Ala Arg Tyr	Leu Ile Ser Asn Ser Lys	
365	370	375
Asp Gln Thr Ile Lys Leu Trp Asp Ile	Arg Arg Phe Ser Ser Arg	
380	385	390
Glu Gly Met Glu Ala Ser Arg Gln Ala	Ala Thr Gln Gln Asn Trp	
395	400	405
Asp Tyr Arg Trp Gln Gln Val Pro Lys	Lys Gly Phe Thr Leu His	
410	415	420
Pro Tyr Pro Ala Trp Arg Lys Leu Lys	Leu Pro Gly Asp Ser Ser	
425	430	435
Leu Met Thr Tyr Arg Gly His Gly Val	Leu His Thr Leu Ile Arg	
440	445	450
Cys Arg Phe Ser Pro Ile His Ser Thr	Gly Gln Gln Phe Ile Tyr	
455	460	465
Ser Gly Cys Ser Thr Gly Lys Val Val	Val Tyr Asp Leu Leu Ser	
470	475	480
Gly His Ile Val Lys Lys Leu Thr Asn	His Lys Ala Cys Val Arg	
485	490	495
Asp Val Ser Trp His Pro Phe Glu Glu	Lys Ile Val Ser Ser Ser	
500	505	510
Trp Asp Gly Asn Leu Arg Leu Trp Gln	Tyr Arg Gln Ala Glu Tyr	
515	520	525
Phe Gln Asp Asp Met Pro Glu Ser Glu	Glu Cys Ala Ser Ala Pro	
530	535	540
Ala Pro Val Pro Gln Ser Ser Thr Pro	Phe Ser Ser Pro Gln	
545	550	

&lt;210&gt; 25

&lt;211&gt; 434

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2226116CD1

&lt;400&gt; 25

Met Arg Pro Ser Ser Ser Val Ser Val Ser	Cys Pro Ala Leu Asn
1	5 10 15
Gln Val Ser His Phe Ala Asn Leu Thr Ser	Val Gly Ala Met Ala
20	25 30
Pro Ala Arg Cys Phe Ser Ala Arg Leu Arg	Thr Val Phe Gln Gly
35	40 45
Val Gly His Trp Ala Leu Ser Thr Trp Ala	Gly Leu Lys Pro Ser

Arg	Leu	Leu	Pro	Gln	Arg	Ala	Ser	Pro	Arg	Leu	Leu	Ser	Val	Gly	50	55	60
															65	70	75
Arg	Ala	Asp	Leu	Ala	Lys	His	Gln	Glu	Leu	Pro	Gly	Lys	Lys	Leu			
															80	85	90
Leu	Ser	Glu	Lys	Lys	Leu	Lys	Arg	Tyr	Phe	Val	Asp	Tyr	Arg	Arg			
															95	100	105
Val	Leu	Val	Cys	Gly	Gly	Asn	Gly	Gly	Ala	Gly	Ala	Ser	Cys	Phe			
															110	115	120
His	Ser	Glu	Pro	Arg	Lys	Glu	Phe	Gly	Gly	Pro	Asp	Gly	Gly	Asp			
															125	130	135
Gly	Gly	Asn	Gly	Gly	His	Val	Ile	Leu	Arg	Val	Asp	Gln	Gln	Val			
															140	145	150
Lys	Ser	Leu	Ser	Ser	Val	Leu	Ser	Arg	Tyr	Gln	Gly	Phe	Ser	Gly			
															155	160	165
Glu	Asp	Gly	Gly	Ser	Lys	Asn	Cys	Phe	Gly	Arg	Ser	Gly	Ala	Val			
															170	175	180
Leu	Tyr	Ile	Arg	Val	Pro	Val	Gly	Thr	Leu	Val	Lys	Glu	Gly	Gly			
															185	190	195
Arg	Val	Val	Ala	Asp	Leu	Ser	Cys	Val	Gly	Asp	Glu	Tyr	Ile	Ala			
															200	205	210
Ala	Leu	Gly	Gly	Ala	Gly	Gly	Lys	Gly	Asn	Arg	Phe	Phe	Leu	Ala			
															215	220	225
Asn	Asn	Asn	Arg	Ala	Pro	Val	Thr	Cys	Thr	Pro	Gly	Gln	Pro	Gly			
															230	235	240
Gln	Gln	Arg	Val	Leu	His	Leu	Glu	Leu	Lys	Thr	Val	Ala	His	Ala			
															245	250	255
Gly	Met	Val	Gly	Phe	Pro	Asn	Ala	Gly	Lys	Ser	Ser	Leu	Leu	Arg			
															260	265	270
Ala	Ile	Ser	Asn	Ala	Arg	Pro	Ala	Val	Ala	Ser	Tyr	Pro	Phe	Thr			
															275	280	285
Thr	Leu	Lys	Pro	His	Val	Gly	Ile	Val	His	Tyr	Glu	Gly	His	Leu			
															290	295	300
Gln	Ile	Ala	Val	Ala	Asp	Ile	Pro	Gly	Ile	Ile	Arg	Gly	Ala	His			
															305	310	315
Gln	Asn	Arg	Gly	Leu	Gly	Ser	Ala	Phe	Leu	Arg	His	Ile	Glu	Arg			
															320	325	330
Cys	Arg	Phe	Leu	Leu	Phe	Val	Val	Asp	Leu	Ser	Gln	Pro	Glu	Pro			
															335	340	345
Trp	Thr	Gln	Val	Asp	Leu	Lys	Tyr	Glu	Leu	Glu	Met	Tyr	Glu				
															350	355	360
Lys	Gly	Leu	Ser	Ala	Arg	Pro	His	Ala	Ile	Val	Ala	Asn	Lys	Ile			
															365	370	375
Asp	Leu	Pro	Glu	Ala	Gln	Ala	Asn	Leu	Ser	Gln	Leu	Arg	Asp	His			
															380	385	390
Leu	Gly	Gln	Glu	Val	Ile	Val	Leu	Ser	Ala	Leu	Thr	Gly	Glu	Asn			
															395	400	405
Leu	Glu	Gln	Leu	Leu	Leu	His	Leu	Lys	Val	Leu	Tyr	Asp	Ala	Tyr			
															410	415	420
Ala	Glu	Ala	Glu	Leu	Gly	Gln	Gly	Arg	Gln	Pro	Leu	Arg	Trp				
															425	430	

&lt;210&gt; 26

&lt;211&gt; 826



&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2504472CD1

&lt;400&gt; 26

```

Met Val Ala Pro Val Leu Glu Thr Ser His Val Phe Cys Cys Pro
 1          5          10          15
Asn Arg Val Arg Gly Val Leu Asn Trp Ser Ser Gly Pro Arg Gly
 20          25          30
Leu Leu Ala Phe Gly Thr Ser Cys Ser Val Val Leu Tyr Asp Pro
 35          40          45
Leu Lys Arg Val Val Val Thr Asn Leu Asn Gly His Thr Ala Arg
 50          55          60
Val Asn Cys Ile Gln Trp Ile Cys Lys Gln Asp Gly Ser Pro Ser
 65          70          75
Thr Glu Leu Val Ser Gly Gly Ser Asp Asn Gln Val Ile His Trp
 80          85          90
Glu Ile Glu Asp Asn Gln Leu Leu Lys Ala Val His Leu Gln Gly
 95          100         105
His Glu Gly Pro Val Tyr Ala Val His Ala Val Tyr Gln Arg Arg
 110         115         120
Thr Ser Asp Pro Ala Leu Cys Thr Leu Ile Val Ser Ala Ala Ala
 125         130         135
Asp Ser Ala Val Arg Leu Trp Ser Lys Lys Gly Pro Glu Val Met
 140         145         150
Cys Leu Gln Thr Leu Asn Phe Gly Asn Gly Phe Ala Leu Ala Leu
 155         160         165
Cys Leu Ser Phe Leu Pro Asn Thr Asp Val Pro Ile Leu Ala Cys
 170         175         180
Gly Asn Asp Asp Cys Arg Ile His Ile Phe Ala Gln Gln Asn Asp
 185         190         195
Gln Phe Gln Lys Val Leu Ser Leu Cys Gly His Glu Asp Trp Ile
 200         205         210
Arg Gly Val Glu Trp Ala Ala Phe Gly Arg Asp Leu Phe Leu Ala
 215         220         225
Ser Cys Ser Gln Asp Cys Leu Ile Arg Ile Trp Lys Leu Tyr Ile
 230         235         240
Lys Ser Thr Ser Leu Glu Thr Gln Asp Asp Asp Asn Ile Arg Leu
 245         250         255
Lys Glu Asn Thr Phe Thr Ile Glu Asn Glu Ser Val Lys Ile Ala
 260         265         270
Phe Ala Val Thr Leu Glu Thr Val Leu Ala Gly His Glu Asn Trp
 275         280         285
Val Asn Ala Val His Trp Gln Pro Val Phe Tyr Lys Asp Gly Val
 290         295         300
Leu Gln Gln Pro Val Arg Leu Leu Ser Ala Ser Met Asp Lys Thr
 305         310         315
Met Ile Leu Trp Ala Pro Asp Glu Glu Ser Gly Val Trp Leu Glu
 320         325         330
Gln Val Arg Val Gly Glu Val Gly Gly Asn Thr Leu Gly Phe Tyr
 335         340         345
Asp Cys Gln Phe Asn Glu Asp Gly Ser Met Ile Ile Ala His Ala

```

	350		355		360
Phe His Gly Ala	Leu His Leu Trp Lys	Gln Asn Thr Val Asn	Pro		
	365		370		375
Arg Glu Trp Thr	Pro Glu Ile Val Ile	Ser Gly His Phe Asp	Gly		
	380		385		390
Val Gln Asp Leu	Val Trp Asp Pro Glu	Gly Glu Phe Ile Ile	Thr		
	395		400		405
Val Gly Thr Asp	Gln Thr Thr Arg Leu	Phe Ala Pro Trp Lys	Arg		
	410		415		420
Lys Asp Gln Ser	Gln Val Thr Trp His	Glu Ile Ala Arg Pro	Gln		
	425		430		435
Ile His Gly Tyr	Asp Leu Lys Cys Leu	Ala Met Ile Asn Arg	Phe		
	440		445		450
Gln Phe Val Ser	Gly Ala Asp Glu Lys	Val Leu Arg Val Phe	Ser		
	455		460		465
Ala Pro Arg Asn	Phe Val Glu Asn Phe	Cys Ala Ile Thr Gly	Gln		
	470		475		480
Ser Leu Asn His	Val Leu Cys Asn Gln	Asp Ser Asp Leu Pro	Glu		
	485		490		495
Gly Ala Thr Val	Pro Ala Leu Gly Leu	Ser Asn Lys Ala Val	Phe		
	500		505		510
Gln Gly Asp Ile	Ala Ser Gln Pro Ser	Asp Glu Glu Glu Leu	Leu		
	515		520		525
Thr Ser Thr Gly	Phe Glu Tyr Gln Gln	Val Ala Phe Gln Pro	Ser		
	530		535		540
Ile Leu Thr Glu	Pro Pro Thr Glu Asp	His Leu Leu Gln Asn	Thr		
	545		550		555
Leu Trp Pro Glu	Val Gln Lys Leu Tyr	Gly His Gly Tyr Glu	Ile		
	560		565		570
Phe Cys Val Thr	Cys Asn Ser Ser Lys	Thr Leu Leu Ala Ser	Ala		
	575		580		585
Cys Lys Ala Ala	Lys Lys Glu His Ala	Ala Ile Ile Leu Trp	Asn		
	590		595		600
Thr Thr Ser Trp	Lys Gln Val Gln Asn	Leu Val Phe His Ser	Leu		
	605		610		615
Thr Val Thr Gln	Met Ala Phe Ser Pro	Asn Glu Lys Phe Leu	Leu		
	620		625		630
Ala Val Ser Arg	Asp Arg Thr Trp Ser	Leu Trp Lys Lys Gln	Asp		
	635		640		645
Thr Ile Ser Pro	Glu Phe Glu Pro Val	Phe Ser Leu Phe Ala	Phe		
	650		655		660
Thr Asn Lys Ile	Thr Ser Val His Ser	Arg Ile Ile Trp Ser	Cys		
	665		670		675
Asp Trp Ser Pro	Asp Ser Lys Tyr Phe	Phe Thr Gly Ser Arg	Asp		
	680		685		690
Lys Lys Val Val	Val Trp Gly Glu Cys	Asp Ser Thr Asp Asp	Cys		
	695		700		705
Ile Glu His Asn	Ile Gly Pro Cys Ser	Ser Val Leu Asp Val	Gly		
	710		715		720
Gly Ala Val Thr	Ala Val Ser Val Cys	Pro Val Leu His Pro	Ser		
	725		730		735
Gln Arg Tyr Val	Val Ala Val Gly Leu	Glu Cys Gly Lys Ile	Cys		
	740		745		750
Leu Tyr Thr Trp	Lys Lys Thr Asp Gln	Val Pro Glu Ile Asn	Asp		
	755		760		765

```

Trp Thr His Cys Val Glu Thr Ser Gln Ser Gln Ser His Thr Leu
770 775 780
Ala Ile Arg Lys Leu Cys Trp Lys Asn Cys Ser Gly Lys Thr Glu
785 790 795
Gln Lys Glu Ala Glu Gly Ala Glu Trp Leu His Phe Ala Ser Cys
800 805 810
Gly Glu Asp His Thr Val Lys Ile His Arg Val Asn Lys Cys Ala
815 820 825
Leu

```

```

<210> 27
<211> 618
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 3029920CD1

```

```

<400> 27
Met Lys Lys Asp Val Arg Ile Leu Leu Val Gly Glu Pro Arg Val
1 5 10 15
Gly Lys Thr Ser Leu Ile Met Ser Leu Val Ser Glu Glu Phe Pro
20 25 30
Glu Glu Val Pro Pro Arg Ala Glu Glu Ile Thr Ile Pro Ala Asp
35 40 45
Val Thr Pro Glu Arg Val Pro Thr His Ile Val Asp Tyr Ser Glu
50 55 60
Ala Glu Gln Ser Asp Glu Gln Leu His Gln Glu Ile Ser Gln Ala
65 70 75
Asn Val Ile Cys Ile Val Tyr Ala Val Asn Asn Lys His Ser Ile
80 85 90
Asp Lys Val Thr Ser Arg Trp Ile Pro Leu Ile Asn Glu Arg Thr
95 100 105
Asp Lys Asp Ser Arg Leu Pro Leu Ile Leu Val Gly Asn Lys Ser
110 115 120
Asp Leu Val Glu Tyr Ser Ser Met Glu Thr Ile Leu Pro Ile Met
125 130 135
Asn Gln Tyr Thr Glu Ile Glu Thr Cys Val Glu Cys Ser Ala Lys
140 145 150
Asn Leu Lys Asn Ile Ser Glu Leu Phe Tyr Tyr Ala Gln Lys Ala
155 160 165
Val Leu His Pro Thr Gly Pro Leu Tyr Cys Pro Glu Glu Lys Glu
170 175 180
Met Lys Pro Ala Cys Ile Lys Ala Leu Thr Arg Ile Phe Lys Ile
185 190 195
Ser Asp Gln Asp Asn Asp Gly Thr Leu Asn Asp Ala Glu Leu Asn
200 205 210
Phe Phe Gln Arg Ile Cys Phe Asn Thr Pro Leu Ala Pro Gln Ala
215 220 225
Leu Glu Asp Val Lys Asn Val Val Arg Lys His Ile Ser Asp Gly
230 235 240
Val Ala Asp Ser Gly Leu Thr Leu Lys Gly Phe Leu Phe Leu His
245 250 255

```

Thr	Leu	Phe	Ile	Gln	Arg	Gly	Arg	His	Glu	Thr	Thr	Trp	Thr	Val
				260					265					270
Leu	Arg	Arg	Phe	Gly	Tyr	Asp	Asp	Asp	Leu	Asp	Leu	Thr	Pro	Glu
				275					280					285
Tyr	Leu	Phe	Pro	Leu	Leu	Lys	Ile	Pro	Pro	Asp	Cys	Thr	Thr	Glu
				290					295					300
Leu	Asn	His	His	Ala	Tyr	Leu	Phe	Leu	Gln	Ser	Thr	Phe	Asp	Lys
				305					310					315
His	Asp	Leu	Asp	Arg	Asp	Cys	Ala	Leu	Ser	Pro	Asp	Glu	Leu	Lys
				320					325					330
Asp	Leu	Phe	Lys	Val	Phe	Pro	Tyr	Ile	Pro	Trp	Gly	Pro	Asp	Val
				335					340					345
Asn	Asn	Thr	Val	Cys	Thr	Asn	Glu	Arg	Gly	Trp	Ile	Thr	Tyr	Gln
				350					355					360
Gly	Phe	Leu	Ser	Gln	Trp	Thr	Leu	Thr	Thr	Tyr	Leu	Asp	Val	Gln
				365					370					375
Arg	Cys	Leu	Glu	Tyr	Leu	Gly	Tyr	Leu	Gly	Tyr	Ser	Ile	Leu	Thr
				380					385					390
Glu	Gln	Glu	Ser	Gln	Ala	Ser	Ala	Val	Thr	Val	Thr	Arg	Asp	Lys
				395					400					405
Lys	Ile	Asp	Leu	Gln	Lys	Lys	Gln	Thr	Gln	Arg	Asn	Val	Phe	Arg
				410					415					420
Cys	Asn	Val	Ile	Gly	Val	Lys	Asn	Cys	Gly	Lys	Ser	Gly	Val	Leu
				425					430					435
Gln	Ala	Leu	Leu	Gly	Arg	Asn	Leu	Met	Arg	Gln	Lys	Lys	Ile	Arg
				440					445					450
Glu	Asp	His	Lys	Ser	Tyr	Tyr	Ala	Ile	Asn	Thr	Val	Tyr	Val	Tyr
				455					460					465
Gly	Gln	Glu	Lys	Tyr	Leu	Leu	Leu	His	Asp	Ile	Ser	Glu	Ser	Glu
				470					475					480
Phe	Leu	Thr	Glu	Ala	Glu	Ile	Ile	Cys	Asp	Val	Val	Cys	Leu	Val
				485					490					495
Tyr	Asp	Val	Ser	Asn	Pro	Lys	Ser	Phe	Glu	Tyr	Cys	Ala	Arg	Ile
				500					505					510
Phe	Lys	Gln	His	Phe	Met	Asp	Ser	Arg	Ile	Pro	Cys	Leu	Ile	Val
				515					520					525
Ala	Ala	Lys	Ser	Asp	Leu	His	Glu	Val	Lys	Gln	Glu	Tyr	Ser	Ile
				530					535					540
Ser	Pro	Thr	Asp	Phe	Cys	Arg	Lys	His	Lys	Met	Pro	Pro	Pro	Gln
				545					550					555
Ala	Phe	Thr	Cys	Asn	Thr	Ala	Asp	Ala	Pro	Ser	Lys	Asp	Ile	Phe
				560					565					570
Val	Lys	Leu	Thr	Thr	Met	Ala	Met	Tyr	Pro	His	Val	Thr	Gln	Ala
				575					580					585
Asp	Leu	Lys	Ser	Ser	Thr	Phe	Trp	Leu	Arg	Ala	Ser	Phe	Gly	Ala
				590					595					600
Thr	Val	Phe	Ala	Val	Leu	Gly	Phe	Ala	Met	Tyr	Lys	Ala	Leu	Leu
				605					610					615
Lys	Gln	Arg												

&lt;210&gt; 28

&lt;211&gt; 596

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<223> Incyte ID No: 3332415CD1

Met	Glu	Pro	Glu	Leu	Asp	Ala	Gln	Lys	Gln	Pro	Arg	Pro	Arg	Arg
1				5					10					15
Arg	Ser	Arg	Arg	Ala	Ser	Gly	Leu	Ser	Thr	Glu	Gly	Ala	Thr	Gly
				20					25					30
Pro	Ser	Ala	Asp	Thr	Ser	Gly	Ser	Glu	Leu	Asp	Gly	Arg	Cys	Ser
				35					40					45
Leu	Arg	Arg	Gly	Ser	Ser	Phe	Thr	Phe	Leu	Thr	Pro	Gly	Pro	Asn
				50					55					60
Trp	Asp	Phe	Thr	Leu	Lys	Arg	Lys	Arg	Arg	Glu	Lys	Asp	Asp	Asp
				65					70					75
Val	Val	Ser	Leu	Ser	Ser	Leu	Asp	Leu	Lys	Glu	Pro	Ser	Asn	Lys
				80					85					90
Arg	Val	Arg	Pro	Leu	Ala	Arg	Val	Thr	Ser	Leu	Ala	Asn	Leu	Ile
				95					100					105
Ser	Pro	Val	Arg	Asn	Gly	Ala	Val	Arg	Arg	Phe	Gly	Gln	Thr	Ile
				110					115					120
Gln	Ser	Phe	Thr	Leu	Arg	Gly	Asp	His	Arg	Ser	Pro	Ala	Ser	Ala
				125					130					135
Gln	Lys	Phe	Ser	Ser	Arg	Ser	Thr	Val	Pro	Thr	Pro	Ala	Lys	Arg
				140					145					150
Arg	Ser	Ser	Ala	Leu	Trp	Ser	Glu	Met	Leu	Asp	Ile	Thr	Met	Lys
				155					160					165
Glu	Ser	Leu	Thr	Thr	Arg	Glu	Ile	Arg	Arg	Gln	Glu	Ala	Ile	Tyr
				170					175					180
Glu	Met	Ser	Arg	Gly	Glu	Gln	Asp	Leu	Ile	Glu	Asp	Leu	Lys	Leu
				185					190					195
Ala	Arg	Lys	Ala	Tyr	His	Asp	Pro	Met	Leu	Lys	Leu	Ser	Ile	Met
				200					205					210
Ser	Glu	Glu	Glu	Leu	Thr	His	Ile	Phe	Gly	Asp	Leu	Asp	Ser	Tyr
				215					220					225
Ile	Pro	Leu	His	Glu	Asp	Leu	Leu	Thr	Arg	Ile	Gly	Glu	Ala	Thr
				230					235					240
Lys	Pro	Asp	Gly	Thr	Val	Glu	Gln	Ile	Gly	His	Ile	Leu	Val	Ser
				245					250					255
Trp	Leu	Pro	Arg	Leu	Asn	Ala	Tyr	Arg	Gly	Tyr	Cys	Ser	Asn	Gln
				260					265					270
Leu	Ala	Ala	Lys	Ala	Leu	Leu	Asp	Gln	Lys	Lys	Gln	Asp	Pro	Arg
				275					280					285
Val	Gln	Asp	Phe	Leu	Gln	Arg	Cys	Leu	Glu	Ser	Pro	Phe	Ser	Arg
				290					295					300
Lys	Leu	Asp	Leu	Trp	Ser	Phe	Leu	Asp	Ile	Pro	Arg	Ser	Arg	Leu
				305					310					315
Val	Lys	Tyr	Pro	Leu	Leu	Leu	Lys	Glu	Ile	Leu	Lys	His	Thr	Pro
				320					325					330
Lys	Glu	His	Pro	Asp	Val	Gln	Leu	Leu	Glu	Asp	Ala	Ile	Leu	Ile
				335					340					345
Ile	Gln	Gly	Val	Leu	Ser	Asp	Ile	Asn	Leu	Lys	Lys	Gly	Glu	Ser

Gln Arg Asp Pro Arg Ile Glu Ala Ser Lys Val Leu Leu Cys His		
380	385	390
Gly Glu Leu Arg Ser Lys Ser Gly His Lys Leu Tyr Ile Phe Leu		
395	400	405
Phe Gln Asp Ile Leu Val Leu Thr Arg Pro Val Thr Arg Asn Glu		
410	415	420
Arg His Ser Tyr Gln Val Tyr Arg Gln Pro Ile Pro Val Gln Glu		
425	430	435
Leu Val Leu Glu Asp Leu Gln Asp Gly Asp Val Arg Met Gly Gly		
440	445	450
Ser Phe Arg Gly Ala Phe Ser Asn Ser Glu Lys Ala Lys Asn Ile		
455	460	465
Phe Arg Ile Arg Phe His Asp Pro Ser Pro Ala Gln Ser His Thr		
470	475	480
Leu Gln Ala Asn Asp Val Phe His Lys Gln Gln Trp Phe Asn Cys		
485	490	495
Ile Arg Ala Ala Ile Ala Pro Phe Gln Ser Ala Gly Ser Pro Pro		
500	505	510
Glu Leu Gln Gly Leu Pro Glu Leu His Glu Glu Cys Glu Gly Asn		
515	520	525
His Pro Ser Ala Arg Lys Leu Thr Ala Gln Arg Arg Ala Ser Thr		
530	535	540
Val Ser Ser Val Thr Gln Val Glu Val Asp Glu Asn Ala Tyr Arg		
545	550	555
Cys Gly Ser Gly Met Gln Met Ala Glu Asp Ser Lys Ser Leu Lys		
560	565	570
Thr His Gln Thr Gln Pro Gly Ile Arg Arg Ala Arg Asp Lys Ala		
575	580	585
Leu Ser Gly Gly Lys Arg Lys Glu Thr Leu Val		
590	595	

&lt;210&gt; 29

&lt;211&gt; 589

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 4031536CD1

&lt;400&gt; 29

Met Ser Lys Pro Gly Lys Pro Thr Leu Asn His Gly Leu Val Pro		
1	5	10
Val Asp Leu Lys Ser Ala Lys Glu Pro Leu Pro His Gln Thr Val		
20	25	30
Met Arg Ile Phe Ser Ile Ser Ile Ile Ala Gln Gly Leu Pro Phe		
35	40	45
Cys Arg Arg Arg Met Lys Arg Lys Leu Asp His Gly Ser Glu Val		
50	55	60
Arg Ser Phe Ser Leu Gly Lys Lys Pro Cys Lys Val Ser Glu Tyr		
65	70	75
Thr Ser Thr Thr Gly Leu Val Pro Cys Ser Ala Thr Pro Thr Thr		
80	85	90
Phe Gly Asp Leu Arg Ala Ala Asn Gly Gln Gly Gln Gln Arg Arg		

	95	100	105
Arg Ile Thr Ser Val Gln Pro Pro Thr Gly Leu Gln Glu Trp Leu			
	110	115	120
Lys Met Phe Gln Ser Trp Ser Gly Pro Glu Lys Leu Leu Ala Leu			
	125	130	135
Asp Glu Leu Ile Asp Ser Cys Glu Pro Thr Gln Val Lys His Met			
	140	145	150
Met Gln Val Ile Glu Pro Gln Phe Gln Arg Asp Phe Ile Ser Leu			
	155	160	165
Leu Pro Lys Glu Leu Ala Leu Tyr Val Leu Ser Phe Leu Glu Pro			
	170	175	180
Lys Asp Leu Leu Gln Ala Ala Gln Thr Cys Arg Tyr Trp Arg Ile			
	185	190	195
Leu Ala Glu Asp Asn Leu Leu Trp Arg Glu Lys Cys Lys Glu Glu			
	200	205	210
Gly Ile Asp Glu Pro Leu His Ile Lys Arg Arg Lys Val Ile Lys			
	215	220	225
Pro Gly Phe Ile His Ser Pro Trp Lys Ser Ala Tyr Ile Arg Gln			
	230	235	240
His Arg Ile Asp Thr Asn Trp Arg Arg Gly Glu Leu Lys Ser Pro			
	245	250	255
Lys Val Leu Lys Gly His Asp Asp His Val Ile Thr Cys Leu Gln			
	260	265	270
Phe Cys Gly Asn Arg Ile Val Ser Gly Ser Asp Asp Asn Thr Leu			
	275	280	285
Lys Val Trp Ser Ala Val Thr Gly Lys Cys Leu Arg Thr Leu Val			
	290	295	300
Gly His Thr Gly Gly Val Trp Ser Ser Gln Met Arg Asp Asn Ile			
	305	310	315
Ile Ile Ser Gly Ser Thr Asp Arg Thr Leu Lys Val Trp Asn Ala			
	320	325	330
Glu Thr Gly Glu Cys Ile His Thr Leu Tyr Gly His Thr Ser Thr			
	335	340	345
Val Arg Cys Met His Leu His Glu Lys Arg Val Val Ser Gly Ser			
	350	355	360
Arg Asp Ala Thr Leu Arg Val Trp Asp Ile Glu Thr Gly Gln Cys			
	365	370	375
Leu His Val Leu Met Gly His Val Ala Ala Val Arg Cys Val Gln			
	380	385	390
Tyr Asp Gly Arg Arg Val Val Ser Gly Ala Tyr Asp Phe Met Val			
	395	400	405
Lys Val Trp Asp Pro Glu Thr Glu Thr Cys Leu His Thr Leu Gln			
	410	415	420
Gly His Thr Asn Arg Val Tyr Ser Leu Gln Phe Asp Gly Ile His			
	425	430	435
Val Val Ser Gly Ser Leu Asp Thr Ser Ile Arg Val Trp Asp Val			
	440	445	450
Glu Thr Gly Asn Cys Ile His Thr Leu Thr Gly His Gln Ser Leu			
	455	460	465
Thr Ser Gly Met Glu Leu Lys Asp Asn Ile Leu Val Ser Gly Asn			
	470	475	480
Ala Asp Ser Thr Val Lys Ile Trp Asp Ile Lys Thr Gly Gln Cys			
	485	490	495
Leu Gln Thr Leu Gln Gly Pro Asn Lys His Gln Ser Ala Val Thr			
	500	505	510

Cys	Leu	Gln	Phe	Asn	Lys	Asn	Phe	Val	Ile	Thr	Ser	Ser	Asp	Asp
				515					520					525
Gly	Thr	Val	Lys	Leu	Trp	Asp	Leu	Lys	Thr	Gly	Glu	Phe	Ile	Arg
				530					535					540
Asn	Leu	Val	Thr	Leu	Glu	Ser	Gly	Gly	Ser	Gly	Gly	Val	Val	Trp
				545					550					555
Arg	Ile	Arg	Ala	Ser	Asn	Thr	Lys	Leu	Val	Cys	Ala	Val	Gly	Ser
				560					565					570
Arg	Asn	Gly	Thr	Glu	Glu	Thr	Lys	Leu	Leu	Val	Leu	Asp	Phe	Asp
				575					580					585

Val Asp Met Lys

&lt;210&gt; 30

&lt;211&gt; 3375

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 708398CB1

&lt;400&gt; 30

```

gggggagaagg gagcccgag gatcaggggt cagagttagg gggttccct cctgctgcac 60
cctcatctca gggccgcaa cttccagctg cagcggcgac tttcagttc atttccacgg 120
accctcctgc ctgggcccgc agccgcccgc gcgatgccc gtaagttag ctgccggcag 180
ctccgggagg cgggccagtg ttccgagagt ttccgtggtc ttccgggact ggacatggag 240
acagatcgcg agcggctgcg gaccatttat aaccgcgact tcaagatcag ctttgggacc 300
ccgcccctg gcttctctc catgctgtat ggaatgaaga ttgcaaatc ggctacgtc 360
accaagactc gggtcaggtt cttcagactc gaccgctggg ccgacgtgcg gttcccagaa 420
aagaggagaa tgaagctggg gtcagatc agcaaacc acaagtcact gctagccaag 480
atcttttatg acagggtga gtatcttcat gggaaacatg gtgtggatgt ggaagtccag 540
gggccccatg aagcccgaga tgggcagctc cttatccgcc tggatttgaa ccgcaaagag 600
gtgctgacct tgaggcttcg gaatggcgga acccagctcg ttaccctcac tcacctcttc 660
ccactctgcc ggacacccca gtttgccttc tacaatgaag accaggagtt gccctgtcca 720
ctgggcccgc gtgaatgcta tgaactccat gtccattgta agaccagctt tgtgggctac 780
ttcccagcca cagtgtctcg ggagctgctg ggacctgggg agtcgggttc agaaggagcc 840
ggcacattct acattgcccg cttcttggct gccgtcgccc acagccccct ggctgcacag 900
ctgaagccca tgaactcctt caagcggacc cggatcaccg gaaaccctgt ggtgaccaat 960
cggatagagg aaggagagag acctgaccgc gctaagggtc atgacctgga gttaagtatg 1020
gcgctgggga catactacc acctccccgc ctcaggcagc tgctccccat gcttcttcag 1080
ggaacaagta tcttactgc ccctaaggag atcgccagaga tcaaggccca gctggagaca 1140
gccctgaagt ggaggaacta tgaggatgaag ctgcggctgc tgctgcacct ggaggaactg 1200
cagatggagc atgatatccg gcaactatgac ctggagtcgg tgcccatgac ctgggacctt 1260
gtggaccaga accccaggct gctcacgctg gaggttctcg gactgactga gagccgcccc 1320
tcagtgtctc gggcgacca cctgtttgcc cttttgtcct cggagacaca ccaggaggac 1380
cccatcacat ataagggtt tgtgcacaag gtggaattgg accgtgtcaa gctgagcttt 1440
tccatgagcc tctgagccg ctttgtggat gggctgacct tcaagggtgaa ctttaccttc 1500
aaccgcccgc cgctgcgagt ccagcaccgt gccctggagc tgacagggcg ctggctgctg 1560
tggcccatgc tcttctctgt ggcacctcgg gacgtcccgc tgctgcctc agatgtgaaa 1620
ctcaagctgt acgaccggag tctggagtca aaccagagc agctgcaggc catgaggcac 1680
attgttacgg gcaccaccg tccagcccc tacatcatc ttgggcctcc aggcaccggc 1740
aagactgtca cgttagtgga ggcaattaag caggtggtga agcacttgcc caaagccac 1800
atcttggcct gcgtccatc caactcagg gctgacctac tctgtcaaag gctccgggtc 1860
caccttcta gctccatcta ccgctcctg gcccacgca gggacatccg catggtacct 1920

```



```

gaggacatca agccctgctg caactgggac gcaaagaagg gggagtatgt atttcccgcc 1980
aagaagaagc tgcaggaata ccgggtctta attaccaccc tcatcactgc cggcagggtg 2040
gtctcggccc agtttcccat tgatcacttc acacacatct tcatcgatga ggctggccac 2100
tgcatggagc ctgagagtct ggtagctata gcagggctga tggaaagtaa ggaaacagg 2160
gatccaggag ggcagctggg gctggcagga gaccctcggc agctggggcc tgtgctgct 2220
tccccactga cccagaagca tggactggga tactcactgc tggagcggct gctcatctac 2280
aactccctgt acaagaaggg ccctgatggc tatgaccccc agttcataac caagctgctc 2340
cgcaactaca ggtctcatcc caccatcctg gacattccta accagctcta ttatgaagg 2400
gagctgcagg cctgtgctga tgtcgtggat cgagaacgct tctgccgctg ggcgggccta 2460
cctcgacagg gctttcccat catctttcac ggcgtaatgg gcaaagatga gctgaaggc 2520
aacagcccat ccttcttcaa ccctgaagag gctgccacag tgacttcta cctgaagctg 2580
ctcctggccc ctcctccaa gaagggcaaa gctcgcctga gccctcgaag tgtgggcgtc 2640
atctcccggt accggaacaa ggtggagaaa atccgttact gcatcaccaa acttgacagg 2700
gagcttcgag gactggatga catcaaggac ttgaagggtg gttcagtaga agaattccaa 2760
ggccaagaac gaagcgtcat cctcatctcc accgtgcgaa gcagccagag cttgtgtag 2820
ctggatctgg actttaatct gggtttcctt aagaacccca agagggtcaa ttagctgtg 2880
accegaggcca aggcctgct catcatcgtg ggaaccccc ttctcctggg ccatgacct 2940
gactggaaag tattctgga gttctgtaaa gaaaacggag ggtataccgg gtgtccctt 3000
cctgccaac tggacctgca acagggacag aatttactgc aaggctctg caagctcagc 3060
ccctctacct caggggccca cagccatgac tacctcccc aggagcggga gggtagagg 3120
ggcctgctc tgcaagtga gccagagtgg aggaatgagc tctgaagaca cagcaccag 3180
ccttctcgca ccagccaagc cttaactgcc tgccagacc tgaaccagaa cccagctgaa 3240
ctgcccctcc aaggacaggg aaggctgggg gagggagttt acaaccaag ccattccacc 3300
ccctccctg ctggggagaa tgacacatca agctgctaac aattggggga aggggaagg 3360
agaaaactct gaaac 3375

```

&lt;210&gt; 31

&lt;211&gt; 2434

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1259937CB1

&lt;400&gt; 31

```

caaggatccg atgggtatat ggagtgtgag gtaatggatc attcatgtgg aaggatgcag 60
ggggtttttg agaccagggt ttggaagaga gttcagcact gctggtagtt ttgggaatca 120
cccatgtgca ggcgacacat gaggcagtaa ggaactctgc aggggtccct gagatttgga 180
aatgtaggga agagcaatgg attgaggtec gaacctggag gatctgctat acgcagagct 240
gggaggaggg acagagtcag taccagagtc ggaaaaaagc aggggtggga ggggaacctg 300
agtcaggaga cttgcctggc aggcgctgcc ctgccagcag aggcctgaca gtggtttcca 360
tgaactgcat ccctgctgtg ggctgggaca gggccactga cacagtatcg gagcacagaa 420
ggggaaagga gcaggaggga ttccaactct gccagttagc agctgtgtgg ctttgggcat 480
gttacttaac ctctctgagc ctcatattatt tcatccataa aatggaaata aaaataatac 540
ttttgtcaaa ggcgcattgt gaattattag atcctcagaa taatgcctgg cttgtagcaa 600
atggtagctg gaggaaaagg aagagaaaac caaagtcagc agctgaagga ttttcatatt 660
agaactgctc tggacctatc tggcagatgc agaagcacac acacacggag gggcatggat 720
ttgccccgcc cttagacatg ttgtgtcttc tcctggatcc ttggtcccag gtgccttacc 780
tgagctcagg tgaatgtggc aagcagagcc ctctgggtgt gtgaatgctg tgtggcggcc 840
gtgctcctgg tgacacaggg acctcacaat ccctccctcc acggtctcct ctcagtctct 900
cccagcctta ttttctcgtt cctcttcttc ccaggcccgg aacttgctct tttggctccc 960
caaccaggac gagccccctc ctggcagcag ctgtgccatc caagtggggg ataaagtccc 1020
ctatgacatc tgcgggccag accactcagt gttgaccctg cagctgcctg tgacagcctc 1080

```

```

cgtgagagag gtgatggcag cgttggccca ggaggatggc tggaccaagg ggcagggtgct 1140
ggtgaaggtc aattctgcag gtgatgccat tggcctgcag ccagatgccg gtggtgtggc 1200
cacatctctg gggctcaatg agcgtctctt tgttgtcaac ccacaggaag tgcattgagct 1260
gatccacacac cctgaccagc tggggcccaac tgtgggctct gctgaggggc tggacctggt 1320
gagtgccaaag gacctggcag gccagctgac ggaccacgac tggagcctct tcaacagtat 1380
ccaccagggtg gagctgatcc actatgtgct gggcccccag catctgcggg atgtcaccac 1440
cgccaacctg gagcgcttca tgcgccgctt caatgagctg cagtactggg tggccaccga 1500
gctgtgtctc tgccccgtgc ccggcccccg ggcccagctg ctcaggaaat tcatatagct 1560
ggcgccccac ctcaaggagc agaagaatct caattccttc tttgccgtca tgtttggcct 1620
cagcaactcg gccatcagcc gcctagccca cacctgggag cggctgcctc acaaagtccg 1680
gaagctgtac tccgccctcg agaggtgct ggatccctca tgggaaccac gggatataccg 1740
actggccctc gccaaagctct ccctcctgt catcccttc atgccccttc ttctcaaaga 1800
catgaccttc attcatgagg gaaaccacac actagtggag aatctcatca actttgagaa 1860
gatgagaatg atggccagag ccgcgcggat gctgcaccac tgccgaagcc acaaccctgt 1920
gcctctctca ccactcagaa gccgagtttc ccacctccac gaggacagcc aggtggcgag 1980
gatttccaca tgctcggagc agtccctgag caccggaggt ccagccagca cctgggctta 2040
tgtccagcag ctgaaggctc ttgacaacca gcgggaactc tcccgctct cccgagagct 2100
ggagccatga ggaggggctg ggactggagc tggagcaggc acttgacagc gggaaagcca 2160
gggtgtgccc ggccaagata ctcacaggct ggccacagct gggcaaggct ctccgtggag 2220
tggactcgag tccctggagc aggcagtgtg gaggcagcca tccctgtga tgactggcag 2280
ctaaggagga cctcggagtg gacccgagcc aggaataacg aatgaccaa ggccaaggaa 2340
gggaggacag agaggcccca ggagtgggtg gagagtggag tgcgctggga cgttgtgtgc 2400
aatagagagg tctccacacc agaaaaaaaa aaaa 2434

```

<210> 32

<211> 892

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 1452285CB1

<400> 32

```

cacgcctctc tctgcaccta cacttgcgct ccccaagtct ctctcgtgcg cagagcccag 60
gctgcgcttc cctgggtcagg cacggcacgt ctggccggcc gccaggatgc agggcccgcg 120
caaggagcac ctgtacaagt tgctggtgat tggcgacctg ggcgtgggga agaccagtat 180
catcaagcgc tacgtgcacc agaacttctc ctcgcactac cgggccacaa tcggcgtgga 240
cttcgcgctc aaggtgctcc actgggaccc ggagactgtg gtgcgcctgc agctctggga 300
tategcaggt caagaaagat ttggaaacat gacgagggtc tattaccgag aagctatggg 360
tgcatattat gtcttcgatg tcaccaggcc agccacattt gaagcagtgg caaagtggaa 420
aaatgatttg gactccaagt taagtctccc taatggcaaa ccggtttcag tggttttgtt 480
ggccaacaaa tgtgaccagg ggaaggatgt gctcatgaac aatggcctca agatggacca 540
gttctgcaag gagcacggtt tcgtaggatg gtttgaaaca tcagcaaagg aaaatataaa 600
cattgatgaa gcctccagat gcctggtgaa acacatactt gcaaatgagt gtgacctaat 660
ggagtctatt gagccggagc tcgtgaagcc catctcaca tcaaccaagg ttgccagctg 720
ctctggctgt gccaaatcct agtaggcacc tttgctggtg tctggttagga atgacctcat 780
tgttccacaa attgtgcctc tatttttacc attttgggta aacgtcagga tagagatacc 840
acatgtggca agccaaagat ctatgcctcc atatgtgcct ttctgttagc tt 892

```

<210> 33

&lt;211&gt; 2288

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1812894CB1

&lt;400&gt; 33

```
eggctcgagc ccagatggag gcaacagtac taggttgcag gacttgctaa gccggtaggt 60
ggcctggggg aagagatggg aagagaggct gatccctgtc cccacagca ctggaggact 120
cccgggtcca ggaaggggca aatggtgagg ccgagtcagg tgagctcagc cggcttcggg 180
ctgagctggc aggcgcctcg gcagaaatgg aaaccatgaa ggctgtggca gaggtgagcg 240
agagcacgaa ggccgaggct gtggctgcgg tgcagcggca gtgccaagag gaggtggcct 300
cgctgcaggc catcctgaaa gactccatca gcagctatga agcccagatc accgccctga 360
agcaggagcg acagcagcag cagcaggact gtgaggagaa ggagcgggag ctgggcccgc 420
tgaagcagct gctgtcccgg gcctaccccc tggactccct ggagaagcag atggaaaagg 480
cccacgagga ctgggagaag ctgcgggaga tcgtactgcc catggaaaag gagatcgagg 540
agctgaaggc gaagctgctg agggccgagg agctgattca ggagatccag agacgtcccc 600
ggcatgcccc ttccctgcac ggctccacgg agttgctgcc cctgtcccgg gatccatcgc 660
ccccgctgga gcctctggag gagctgagcg gagatggggg tccagccgct gaggccttcg 720
ctcacaactg cgatgacagc gcctccatct cctccttctc ccttggcggg ggggtcggca 780
gcagctcctc cctgccccaa agccgcccagg gcctgagccc tgaacaggaa gagacggcct 840
cgctggtgtc tacggggcacc ctgggttccc agggcatcta cctgccccct cctggctacc 900
agctcgtccc agacactcag tgggagcagc tgcagacaga gggccgacag ctgcagaagg 960
acctggagag cgtcagtcgc gagcgggacg agctccaaga gggcctgaga cggagcaatg 1020
aggactgtgc caagcagatg caggtgtctc tggcccaggc ccagaactca gagcagctgc 1080
tgcgggaccct gcaagggacc gtgagccagg cccaggagcg ggtgcagctg cagatggcgg 1140
agctggtcac caccacaag tgctgcacc atgaggtaaa gcggttgaat gaggaaaacc 1200
aagggtcccg ggccgagcag ctgccatcct cagcccccca gggctcgag caggagcagg 1260
gcgaggagga atcactgccc agctctgtgc cagagctgca gcagctgctg tgctgcacgc 1320
ggcaagaggc gagggcccgg ctgcaggccc aggagcacgg ggccgagcgc ctgcggatcg 1380
agatcgtgac gctgcgggag gctctggagg aggagacagt ggccagggcc agcctggagg 1440
ggcagctgag ggtgcagcgg gaggagacag aggtgctgga ggccctccctg tgcagcctga 1500
ggacagagat ggagcgggtg cagcaggaac agagcaaggc ccagctccca gacctcctct 1560
cagaacagag ggccaagggt ctgcccgtgc aggcagagct ggagaccagt gagcaggtgc 1620
agagggattt cgtgcgactg tcccaggccc tgcaggtgcg cctagagcgg atccgccagg 1680
ctgagaccct ggagcaagtg cgcagcatca tggatgaggc gccactcacg gacgtcaggg 1740
acatcaagga cacctgaggg gtcaggatat cccaccccc accctgggaa agacgccttt 1800
ccccactcct gaaccatgag gcctcgtctt ggggtcttgg atggcttttc caccgtccct 1860
gagactgggg ttgaggggac tgacgggggc caccaccgcc ccgccctcca gcgcctcctc 1920
ccaggggtggc tgggcctcct gttctcaggg atcacacctg ggtgaggggc ccaagccctc 1980
cccgaacca aaggtgcagg ctccaggcctg cggctttctg gctgctgtgc tgcctcctgg 2040
gctccagccc tcccctgccc ccagcccgtc ccctgcccag ggcacagcgg agccatgggg 2100
gctgggagtc cccatcagag gcagtgaggt gggccccggc cctgggacag gcagctgcct 2160
tctggtctgc atgacactaa gacgcttgtc cacagcggcg acccaggcct ccaagcttgc 2220
acagaggcaa ggccagactt ttccgtcggt tattttcaat aaataagcag ctcagcgcaa 2280
aaaaaaaa
```

&lt;210&gt; 34

&lt;211&gt; 1813

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> unsure  
 <222> 1708, 1711, 1713, 1715  
 <223> Incyte ID No: a o r g o r c o r t, unknown, or other

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3074884CB1

<400> 34  
 gcacgaagga ggccccgctt caggtggccc tggcggagat gccggaagat gcggacgaga 60  
 acgccgagga ggagctgctg cggggagagc ctctgctgcc ggccggggacc cagcgctgt 120  
 gtctggttca ccctgacgtc aagtggggcc cggggaagtc gcagatgact cgagccgagt 180  
 ggcaggtggc ggaggccaca gcgctggtgc acacgctgga cggctggtcc gtggtgcaga 240  
 caatggtcgt gtccaccaa acgccggaca ggaagctcat ctttggcaaa gggaactttg 300  
 agcacctgac agaaaagatc cgagggtctc cagacgtcac gtgctcttc ctgaacgtgg 360  
 agaggatggc tgccccgacc aagaaagaac tggagccgc ctggggcgtg gaggtgtttg 420  
 accgcttcac ggtcgtcctg cacatcttc gctgtaacgc ccgcacgaag gagggccggc 480  
 ttcaggtggc cctggcggag atgccgctgc acaggtcgaa cttgaaaagg gacgtcgccc 540  
 acctgtaccg aggagtggc tcgctgctaca tcatggggtc aggagaatcc ttcattgcagc 600  
 tgcagcagcg tctcctgaga gagaaggagg ccaagatcag gaaggccttg gacaggcttc 660  
 gcaagaagag gcacctgctc cgccggcagc ggacgaggcg ggagttcccc gtgatctccg 720  
 tgggtggggt caccaactgc ggaaagacca cgctgatcaa ggcactgacg ggcgatgccg 780  
 ccatccagcc acgggaccag ctgtttgccg cgctggacgt cacggcccac gcgggcacgc 840  
 tgccctcacg catgacgctc ctgtacgtgg acaccatcgg ctctctctcc cagctgccgc 900  
 acggcctcat cgagtccttc tccgccaccc tggagacgt ggcccactcg gatctcatct 960  
 tgcacgtgag ggacgtcagc caccgccagg cggagctcca gaaatgcagc gttctgtcca 1020  
 cgctgctgag cctgcagctg cccgccccgc tccctggactc catggtggag gttcacaaca 1080  
 aggtggacct cgtgcccggg tacagccca cggaaccgaa cgtcgtgccc gtgtctgccc 1140  
 tgcggggcca cgggctccag gagctgaaa ctgagctcga tgcggcggtt ttgaaggcga 1200  
 cggggagaca gatectcact ctccgtgtga ggctcgcagg ggcgcagctc agctggctgt 1260  
 ataaggaggc cacagttcag gaggtggacg tgatccctga ggacggggcg gccgacgtga 1320  
 gggatcatcat cagcaactca gcctacggca aattccgga gctctttcca ggatgaacgg 1380  
 acgccacag aggcctgcgg ggtgggggca tcgctgcctg gggagctgag gcgttaccgc 1440  
 tgtgttggg gcagcttggg gtcaggtgca gcagggtcct ccttgtctgg ttctgcaccc 1500  
 gtctcgctcc cagccatttg ctgggatgac cgtgcaggcc ggtgacacgg ccgcacctgc 1560  
 cccaaagcgg gccgcccgag cgtccactcc aagcctgagc atccacacaa ttccagtggg 1620  
 ccctcgggtc ctgctgtgaa ctgctttccc tcggaatgtt tccgtaacag gacattaaac 1680  
 ctttgttttt acttccgtga aaaaaaanac ngngnaaaaa aaaaaggggc ggcccgtcc 1740  
 tagaggattc caagccttac cgtaacgcgt tgcattggcg agcggtcata agcttcttct 1800  
 aatagggggt cac 1813

<210> 35  
 <211> 1733  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3452277CB1

<400> 35  
 ctacggcctg gaccgagtga ccaatccgaa tgaagtcaag gtaaaccaga aacaaacagt 60  
 cgttgctgtc aaaaaagaga tcatgtatta ccaacaggcc ttgatgaggt ccacagtga 120

gtcttctgtg tccctgggag ggattgtgaa atacagttag cagttctcat ccaacgatgc 180  
catcatgtca ggctgcctcc ccagcaaccc ctggatcacc gatgacaccc agttctggga 240  
cttaaatgcc aaattgggtg aaatcccaac caagatgcga gtggaacgat gggccttcaa 300  
cttcagcgaa ttgatccgag accccaaagg tcgacagagc ttccagtact tcctcaagaa 360  
agaattcagt ggagagaatc tgggattctg ggaagcctgc gaggatctga agtatggaga 420  
tcagtcctaaa gtcaaggaga aagcagagga gatttacaag ctgttcctgg ccccgggggc 480  
gaggcgctgg atcaacatag atggcaaaac catggacatc acagtgaagg ggctgaagca 540  
ccccaccgc tatgtgctgg acgcccacac aacccacatt tacatgctca tgaagaagga 600  
ttottatgct cgctatttaa aatctccgat ctataaggac atgctggcca aagctattga 660  
acctcaggaa accaccaaga aaagctccac cctccctttt atgcgcgctc acctgcgctc 720  
cagcccaagc cctgtcatcc tgagacagct ggaagaggaa gccaaaggccc gagaagcagc 780  
caacactgtg gacatcacc agccggggcca gcacatggct cccagcccc atctgaccgt 840  
gtacaccggg acctgcatgc ccccgctctc ttctagcccc ttctcctcct cctgccgctc 900  
ccccaggaag cctttcgctt caccagccg cttcatccgg cgacccagca ccaccatctg 960  
cccctcacc atcagagtgg ccttgaggag ctcacggggc ttggagcaga aaggggagtg 1020  
cagcgggtcc atggcccccc gtggggccctc tgtcaccgag agcagcgagg cctccctcga 1080  
cacctcctgg cctcgagcc ggcccagggc cctcctaag gcccgcatgg ctctgtcctt 1140  
cagcaggttt ctgagacgag gctgtctggc ctcacctgtc ttgcccaggc tctacccaa 1200  
gtgccctgct gtgtcccacg ggagggtgca gcccctgggg gacgtggggc agcagctgcc 1260  
acgattgaaa tccaagagag tagcaaaact ttccagatc aaaatggatg tgcccacggg 1320  
gagcgggacc tgcctgatgg actcggagga tgcctggaaca ggagagtcgg gtgaccgggc 1380  
cacagaaaag gaggtcatct gcccctggga gagcctgtaa ggaaagaggc aggctgagct 1440  
gggggctctg gaccaggaag atgctctgac agatgccatg gtatggggcca caggacacac 1500  
ttgctcgaga accaaagtgc atttgggtga catttgaaga ttggggagac aagatgggtg 1560  
agattgtggc aaagaatgct ctggctggtt accaggggcc aactccttct cctcttctctg 1620  
accctccctc ccttgggcag aagaaacgca tgtggaccag aagactttcc ctgctgcctt 1680  
aaaaccaata aaaggttaac ttttaagtttc ttggaaaaaa aaaaaaaaag ggg 1733

&lt;210&gt; 36

&lt;211&gt; 1776

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 4203832CE1

&lt;400&gt; 36

cccagccgag cccagcctag cccagccca gccgagcgga accgcgagcc ccaagcccga 60  
gccgcgcccc gccgagcag agccctccag ccgctcacc cgctgcccac cccagcgacc 120  
ctcagccgct ctctgccctt ctctcgcccc cgcccccgc ctcgcccgc ctctgcccga 180  
tgaaactggc cgcatgac aagaagatgt gccgagcgga ctcgagctg agtatcccgg 240  
ccaagaactg ctatcgcatg gtcacctctg gctcgtccaa ggtgggcaag acggccatcg 300  
tgtcgcgctt cctcaccggc cgcttcgagg acgctacac gcctaccatc gaggacttcc 360  
accgcaagtt ctactccatc cgcgcgagg tctaccagct cgacatcctc gacacgtccg 420  
gcaaccacc gttccccgcc atgcggtgcc tctccatcct cacaggagac gttttcatcc 480  
tggtgttcag tctggacaac cgcgactcct tcgaggaggt gcagcggctc aggcagcaga 540  
tctctgacac caagtcttgc ctcaagaaca aaaccaagga gaacgtggac gtgcccctgg 600  
tcattctgcg caacaaggtt gaccgcgact tctaccgcga ggtggaccag cgcgagatcg 660  
agcagctggt gggcgacgac cccagcgct gcgctactt cgagatctcg gccagaaga 720  
acagcagcct ggaccagatg ttccgcgcgc tcttcgccat ggccaagctg cccagcgaga 780  
tgagcccaga cctgcaccgc aaggtctcgg tgagtagctg cgacgtgctg cacaagaagg 840  
cgctcgga caagaagctg ctgcggggcg gcagcgcgcg cgccggcgcg gaccggggcg 900  
acgcctttgg catcgtggca cccttcgcgc gccggcccag cgtacacagc gacctcatgt 960

```

acatccgcga gaaggccagc gccggcagcc aggccaagga caaggagcgc tgcgtcatca 1020
gctaggagcc ccgccgcgct ggcgacacaa cctaaggagg acctttttgt taagtcaaat 1080
ccaacggccc ggtgcgcccc aggccgggag cgcgcgcgga ctggcgtctc cctcccgcc 1140
gatccgcccc cagcactggg gaggcgccac tgaaccgaga agggacggtc atctgctccg 1200
gaaggaaaga gaacgggcca agactgggac tattccccac ccccggtccc ccattgaggc 1260
ccgccacccc cataactttg ggagcgaggg ccagcccgag ggtggattta tcttctcaaa 1320
gacctaagag tgagcgcggg gtgggggagg gatgtgaagt tatccagcct ctgctaggct 1380
tcaagaaacc gtcatgcccg cttgagggtc aggacccacg gggcattatc ttgtctgtga 1440
ttccgggttg ctgtgacagc cggtagagcc tctgccctcc cgaaactaag cgggggggcg 1500
tgggtcaaat catagccaag tgacttgttt acatgtgagt gaaactgcac aaaggaacac 1560
aaaaaaaaac ttgacttta acggtagtgc cgggtgtcaac atggacacga acaaaacctt 1620
accaggtgt ttatactgtg tgtgtgtgag gtctttaaag ttattgcttt atttggtttt 1680
ttaatatata ataaaataat taaaatgga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa gaaaaaaaaa aaaaaaa 1776

```

&lt;210&gt; 37

&lt;211&gt; 1316

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 104368CB1

&lt;400&gt; 37

```

cggacgcgtg gggcggtttt tctcttttagc gctcagggcg ctgaccact gctcttctc 60
ttaagaaagt gtcattcc ttccggcgcc cggagctgct ggcccaaagg gatccggagc 120
gagctagggc agacaccatg accacccttg atgataagtt gctgggggag aaactgcagt 180
actactatag cagcagttag gatgaggaca gtgaccacga ggacaaggac cgaggcagat 240
gtgccccagc cagcagttct gtgcctgcag aggtgagct ggcaggcgaa ggcattctcag 300
ttaacacagg cccaaaaggt gtgatcaatg actggcgccg cttcaagcag ttggagacag 360
agcagaggga ggagcagtgc cgggagatgg aaaggctgat caagaagctg tcaatgactt 420
gcaggtocca tctggatgaa gaggaggagc aacagaaaca gaaagacctc caggagaaga 480
tcagtgggaa gatgactctg aaggagttag ccataatgaa tgaggacca gatgatgaag 540
agtttctgca gcagtaccgg aagcagcgaa tggaagagat gcggcagcag cttcacaagg 600
ggccccaatt caagcaggtt tttagatct ccagtggaga agggttttta gacatgattg 660
ataaagaaca gaaaagcatt gtcacatggt ttcataatga tgaggatggc attccaggga 720
ccgaagccat gaatggttgc atgatctgcc ttgccgcaga gtaccagct gtcaagtctt 780
gcaagggtgaa gagctcagtt attggcgcca gcagtcagtt caccaggaat gcccttcctg 840
cctgctgat ctataagggg ggtgaattga tcggcaattt tgttcgtgtt actgaccagc 900
tgggggatga tttctttgct gtggaccttg aagcttttct ccagggaattt ggattactcc 960
cagaaaagga agtcttggtg ctgacatctg tgcgtaactc tgccacgtgt cacagtgagg 1020
atagcgacct ggaaatagat tgaactgata gtctagtgtc atagatttct cattgtttgg 1080
gttggaatac acgtcattgt ttatttttgt tcctttgtct tctggctttt cagctgttct 1140
ttgtagtccc ttttattatg cataaaataa agaaattctt agattaaatc agaatgctga 1200
ataaccttgt agctagcaat aaggtgactt acagttgtat aaacaggaag ccaggctttt 1260
gaactgttta cttaaagattc tgggtgtga catctctgtt attgtttcca gtcaat 1316

```

&lt;210&gt; 38

&lt;211&gt; 1554

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1441680CB1

&lt;400&gt; 38

```

gtggcttggtg gagggtggcgc cgttagtgag gcggttgctg agacagacgc tgaggcgggt 60
aggaggagcc cgagccgtaa ggaagccgt gatgagggcc gtgttgacgt ggagagataa 120
agccgagcac tgtataaatg acatcgcat taagcctgat ggaactcaac tgattttggc 180
tgccggaagc agattactgg tttatgacac ctctgatggc accttacttc agccctcaa 240
gggacacaaa gacactgtgt actgtgtggc atatgcgaag gatggcaagc gctttgcttc 300
tggatcagct gacaaaagcg ttattatctg gacatcaaaa ctggaaggca ttctgaagta 360
cacgcacaat gatgtctatac aatgtgtctc ctacaatcct attactcatc aactggcatc 420
ttgttctctc agtgactttg ggttggtggtc tcctgaacag aagtctgtct ccaaacacaa 480
atcaagcagc aagatcatct gctgcagctg gacaaatgat ggtcagtacc tggcgctggg 540
gatgttcaat gggatcatca gcatacggaa caaaaatggc gaggagaaag taaagatcga 600
gcgccggggg ggctccctct cgccaatatg gtccatctgc tggaaacctt caagagagga 660
acgtaatgac atcctggctg tggtgactg gggacagaaa gtttccttct accagctgag 720
tggaaaacag attggaagg atcgggcact gaactttgac ccctgctgca tcagctactt 780
tactaaaggc gagtacattt tgctgggggg ttcagacaag caagtatctc ttttcaccaa 840
ggatggagtg cggcttgga ctggtgggga gcagaactcc tgggtgtgga cgtgtcaagc 900
gaaaccggat tccaactatg tgggtggtcgg ctgccaggac ggcaccattt ccttctacca 960
gcttattttc agcacagtcc atggagttaa caaggaccgc tatgcctaca gggatagcat 1020
gactgacgtc attgtgcagc acctgatcac tgagcagaaa gtccggatta aatgcaaaga 1080
gcttgtcaag aagattgcca tctacagaaa tcgattggct atccaactgc cagagaaaat 1140
cctcatctat gagtgtgatt cagaggactt atcagacatg cattaccggg taaaggagaa 1200
gattatcaag aagtttgagt gcaacctcct ggtggtgtgt gccaatcaca tcatcctgtg 1260
ccaggagaaa cggctgcagt gcctgtcctt cagcggagtg aaggagcggg agtggcagat 1320
ggagtctctc attcgttaca tcaaggatgat cgggtggcct cctggaagag aaggcctctt 1380
agtggggctg aagaagatgt acttgttagt gtattcatc atattgattg taaaggatta 1440
tttttctc agtactgatg tccttggaat tcttacctgg aaacatgtt gcaaaaaaca 1500
ttattgggtc tttcatcttt tttcttggtt ttacatatt gtccaataaa aata 1554

```

&lt;210&gt; 39

&lt;211&gt; 2320

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1494955CB1

&lt;400&gt; 39

```

gggcgccccg gtactcacta gctgaggtgg cagtgggtcc accaactagg agctctcgca 60
gatgtcggag ctcatggggc tgctgggtgt gcttgggctg ctggccctga tggcgacggc 120
ggcggtagcg cgggggtggc tgcgcgcggg ggaggagagg agcggccggc ccgcctgcc 180
aaaagcaaat ggatttccac ctgacaaatc ttcgggatcc aagaagcaga aacaatatca 240
gcggattcgg aaggagaagc ctcaacaaca caacttcacc caccgcctcc tggctgcagc 300
tctgaagagc cacagcggga acatatcttg catggacttt agcagcaatg gcaaatacct 360
ggctacctgt gcagatgatc gcaccatccg catctggagc accaaggact tctgcagcg 420
agagcaccgc agcatgagag ccaacgtgga gctggaccac gccaccctgg tgcgcttcag 480
ccctgactgc agagccttca tcgtctggct ggccaacggg gacaccctcc gtgtcttcaa 540
gatgaccaag cgggaggatg ggggctacac cttcacagcc accccagagg acttccttaa 600
aaagcacaag gcgcctgtca tcgacattgg cattgtctaac acagggaagt ttatcatgac 660
tgctccagc gacaccactg tcctcatctg gagcctgaag ggtcaagtgc tgtctacat 720

```

```

caacaccaac cagatgaaca acacacacgc tgctgtatct ccctgtggca gatttgtagc 780
ctcgtgtggc ttcaccccag atgtgaaggt ttgggaagtc tgctttggaa agaaggggga 840
gttccaggag gtggtgcgag ccttcgaact aaagggccac tccgggctg tgcactcgtt 900
tgctttctcc aacgactcac ggaggatggc ttctgtctcc aaggatggta catggaaact 960
gtgggacaca gatgtggaat acaagaagaa gcaggacccc tacttgctga agacaggccg 1020
ctttgaagag gcggcgggtg ccgcgcgctg ccgcctggcc ctctccccc aacgcccagg 1080
cttggccttg gccagtggca gtagtattca tctctacaat acccggcggg gcgagaagga 1140
ggagtgtctt gagcgggtcc atggcgagtg tatcgccaac ttgtcctttg acatcactgg 1200
ccgctttctg gcctcctgtg gggaccgggc ggtgcggctg tttcacaaca ctccctggcc 1260
ccgagccatg gtggaggaga tgcaggcca cctgaagcgg gcctccaacg agagcaccgg 1320
ccagaggctg cagcagcagc tgaccaggc ccaagagacc ctgaagagcc tgggtgcctt 1380
gaagaagtga ctctgggagg gcccgcgca gaggattgag gaggagggat ctggcctcct 1440
catggcgctg ctgccatctt tcctcccagg tggaaagcctt tcagaaggag tctcctgggt 1500
ttcttactgg tggcctgtct tcttccatt gaaactactc ttgtctactt aggtctctct 1560
cttctgtgtg gctgtgactc ctccctgact agtggccaag gtgcttttct tctcccagg 1620
cccagtgggt ggaatctgtc cccacctggc actgaggaga atggtagaga ggagaggaga 1680
gagagagaga atgtgatttt tggcctgtg gcagcacatc ctcacacca aagaagtttg 1740
taaagtgtcc agaacaacct agagaacacc tgagtactaa gcagcagttt tgcaaggatg 1800
ggagactggg atagcttccc atcacagaac tgtgttccat caaaaagaca ctaagggtat 1860
tccttctggg cctcagttct atttgtaaga tggagaataa tcctctctgt gaactccttg 1920
caaagatgat atgaggctaa gagaatatca agtccccagg tctggaagaa aagtagaaaa 1980
gagtagtact attgtccaat gtcataaaag tggtaaaagt gggaaccagt gtgctttgaa 2040
accaaattag aaacacattc cttgggaagg caaagttttc tgggacttga tcatacattt 2100
tatatggttg ggacttctct cttcgggaga tgatatcttg tttaaggaga cctcttttca 2160
gttcatcaag ttcatacagat atttgagtgc ccactctgtg cccaaataaa tatgagctgg 2220
ggattaaata cgaataagac atggtttctg ccatcaaaga tggctggtgg gagagagaga 2280
tacaccctta ttaagtgtt tgtgttagtt tattcatagc 2320

```

<210> 40

<211> 879

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 1508161CB1

<400> 40

```

gaagaatttg ttcaggcgtt cgtgcagaag gacccttttg ataatgacaa gagttgctac 60
agtgaacgga agaaaaacacg aaacttagaa gcttacgtgg aatgggttaa tcgcctcagc 120
tacttggttg ctacagaaat ctgtatgcct gttaagaaaa aacaccgagc aagaatgatt 180
gagtatttca ttgacgtagc tcgggagtgt tttaacattg gcaacttcaa ctccctgatg 240
gcgataatct ctggtatgaa tatgagccca gtctctcgac taaaaaaaac ttggggccaa 300
gtgaagactg caaaatttga cattcttgag catcagatgg acccttcaag caatttctat 360
aattatcgaa cagctcttcg tggggcagca caaagggtctt taactgctca tagtagtaga 420
gaaaagattg tgataccatt cttcagtcct ttaatcaaag atatttatct cctcaatgag 480
ggttgtgcca accgccttcc caatggccat gtcaattttg agaaattttg ggaactggcc 540
aaacaagtga gtgaatttat gacatggaaa caagtggagt gtccatttga gagggaccgg 600
aagatcttgc agtatctgct cacagtacca gtcttcagtg aagatgctct ctacttggct 660
tcttatgaga gtgaaggacc tgaaaatcat atagagaaag acagatggaa gtctttaagg 720
tcgagcctct taggcagagt ttaacacatg ggagctgcct gcctgctgct gctgctgctt 780
cctgcagatc atggaggggc tggcctttgt tttctggcat ctcgtaccac gaacactcat 840
gaagaccctg cagtcattgg agcaccggg tcagcaaaag 879

```



<210> 41  
<211> 2248  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 1811877CB1

<400> 41  
ggaggaccag gaggacatca ctgcctttga cctcagccct gacaacgagg tgctgggtgac 60  
agccagtcgg gcattgctgc tggctcagtg ggcctggcaa gagggcagcg ttaccgcct 120  
gtggaaggcg atacacacgg cccccgtggc caccatggcc ttcgacccca cctccactct 180  
gctagccaca ggtggctgtg atggggccgt gcgcgtctgg gacatcgtgc ggactacgg 240  
gacacaccac ttccgaggct cggccggtgt cgtgcaccta gtggccttcc acccggaacc 300  
tacacgcctg ctgctcttct cctcggccac ggatgccgcc atccgcgtgt ggtcactgca 360  
ggaccggtca tgcctggctg tgctgactgc cactacagc gccgtcacct cactggcctt 420  
cagcgccgac ggccacacca tgctcagctc cggccgtgac aagatatgta tcatctggga 480  
ccttcagagc tgccaggcca cgaggaccgt gcctgtgttt gagagcgtgg aggtcgtgt 540  
gctgttgcca gaggagccag tgtcccagct ggggtgtaag tccccagggc tgtactttct 600  
gacagctggc gaccaaggca ctctgcgct gtgggaggca gcttctgggc agtgtgtgta 660  
cacgcaggcc cagccgcccgg gccctgggca ggagctgacc cactgcaccc tggcacacac 720  
cgccggcgtg gtcctcaccg ccaccgccga ccacaacctg ttgctctacg aggtcgcctc 780  
cctgcggctg cagaaacagt tcgctggcta cagtgaggag gttttggatg tccggtttct 840  
tgggcccag gactccacg ttgtcgtggc ctccaatagc ccctgcctaa aagtgtttga 900  
gctgcagacg tcagcctgcc agatcctcca cggccacacg gatatcgtcc tggccctgga 960  
tgtgttccgg aagggtggc tctttgccag ctgtgccaag gatcagagcg tccgtatctg 1020  
gagaatgaac aaggctggcc aggtgatgtg cgtggctcag ggttccggtc acacacacag 1080  
tgtgggcacc gtctgctgct ctaggctgaa ggagtccttc ctggtgacag gcagccagga 1140  
ctgcactgtg aagctgtggc ctcttcccaa agccttgctg tccaagaaca cagccccaga 1200  
caacggccct atcctcctgc agggccagac cactcagcgc tgccatgata aggacatcaa 1260  
cagcgtggct attgccccca acgacaagct gctggccaca ggctcacagg accgcacggc 1320  
caagctctgg gccctgccac agtgccagct gctgggtgtc ttctcaggcc accggcgtgg 1380  
cctctggctg gtccagttct ctcccatgga ccagggtgtg gccacggcct cagctgatgg 1440  
caccatcaag ctctgggcac tccaggactt cagctgtctc aagacatttg aggggcacga 1500  
tgcttctgtg ctgaagggtg cctttgtgag ccgtggcacg cagctgctgt ccagcggtt 1560  
ggatggcctc gtgaagctct ggaccatcaa gaacaacgag tgtgtgcgga cgctggatgc 1620  
ccacgaggac aaggtctggg ggctgcactg cagccggctg gacgaccacg ccctcactgg 1680  
ggccagtga tcccagatca tcctctggaa ggatgtgacc gaggcggagc aggcagagga 1740  
gcaggccagg caagaggagc aggtgggtcag gcagcaagag ctggacaacc tgctgcatga 1800  
gaagcggtac ctgcccggcg tgggcctggc catctccctg gatcggcccc acaccgtgct 1860  
gactgtcatc caggccatcc ggagggaccc tgaggcctgc gagaagctgg aagccaccat 1920  
gctccgactg cggcgcgacc agaaagaggc cctgctgcgc ttctgcgtca cgtggaacac 1980  
caactcgcgg cactgccacg agggccaggc cgtgctgggt gtgctcttga ggcgagaggc 2040  
ccccgaggag ctgctggcct acgaaggcgt gcgggcagcg cttgaggccc tgctgcccta 2100  
cactgagcgg cactttcagc ggctcagcag gacctccag gccgcgctt tcttgactt 2160  
cctgtggcac aacatgaagc tccctgtgcc ggccgcgcc cccacccctt gggaaaccca 2220  
taaaggcgca ctgccctaaa aaaaaaaa 2248

<210> 42  
<211> 2146  
<212> DNA  
<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1848674CB1

&lt;400&gt; 42

```
gttattggca agttccccctg cagttgtttg ggctgtccct gtggctggtt ctgggggtgtg 60
cggccagcca tggagcgctc tgggccagc gaagtgcagc gctcagacgc gtcgggaccg 120
gacccgcagc ttgcggtcac catgggcttc acgggggttcg gtaaaaaagc tcgcacattt 180
gacttggaag caatgtttga acaaaactcga aggacagctg tggaaagaag tcgcaaaaaca 240
ctggaagcaa gagaaaaaga ggaagaaatg aacagagaga aagaattaag aagacaaaat 300
gaagatattg agccaacatc ctcaagatca aatgtggtca gagattgtc caaatcatct 360
tccagggata cgagcagcag tgaaagtga cagagttctg actcttctga tgatgagtta 420
attggccctc ctttaccctc taaaatggta ggaaaaccag ttaattttat ggaggaagat 480
atcctcggtc ctttaccctc acctcttaat gaagaagaag aagaagcaga ggaagaaga 540
gaggaagagg aggaagagga aaatcctgtt cacaagattc ctgactcgca tgagataacg 600
ctgaagcatg gcactaaaac agtgtctgct ttgggtctgg atccctcagg tgcccgtttg 660
gtgacaggag gatatgacta tgatgttaag ttttgggatt ttgctggaat ggatgcttct 720
tttaaggcat ttcatccctc tcagccctgt gagtgccatc agatcaagtc attacagtat 780
agtaacacag gagacatgat tcttgttgta tctggaagct ctcaggccaa ggtgattgac 840
agagatggtt ttgaagtaat ggaatgtata aaaggagacc agtatattgt ggacatggcc 900
aacaccaagg gtcatacagc aatgcttcat actggctcat ggcattccaa aataaaggga 960
gaatttatga cttgctcaaa tgatgcgact gtgaggacgt gggaagttga aaatccaaag 1020
aagcaaaaaa gtgtgtttta accacggacg atgcaaggca aaaaagtcatt tccactacg 1080
tgcacatata gtagagatgg aaacctcata gcagctgcct gccagaatgg aagcatacag 1140
atctgggacc gaaatttgac tgttcatcct aagttccact ataaacaggc tcatgactcg 1200
ggcacagaca cttcttgctg gactttttcc tatgatggta atgtccttgc ctctcgtgga 1260
ggtgacgatt cattaataat atgggacatc cgacaattta ataaaccact tttttcagcc 1320
tcgggtcttc ccaccatgtt ccaatgact gactgctgtt tcagtccaga tgataagctc 1380
atagtcaact gtacatctat tcaaagagga tgtggcagcg gcaaacttgt tttctttgag 1440
cgtaggactt tccaaagggt gtatgaaata gacatcacag atgcgagtggt tgttcgctgc 1500
ctgtggcatc caaagctgaa ccagatcatg gttggaactg gaaatggatt ggctaaagtc 1560
tattacgacc ccaacaagag tcagagggga gcaaaattat gtgtgggtta aaccacagcg 1620
aaggcaaaac aagctgagac tctaactcag gactacatca tccccctca tgccttgctc 1680
atgttccgtg agccccgcca acggagtaca aggaacagc tggagaagga cagactggat 1740
cccctgaagt cgcataaacc tgaacctcct gtagcaggcc caggctcgtgg tggccgagtt 1800
ggaacccacg ggggcactct ctcttcctat attgtgaaga acattgcttt ggacaagacc 1860
gatgacagta atcctcggga agccattttg cgtcatgcc aagcagcaga agacagccca 1920
tattgggttt ctccagcata ttccaagact cagcccaaaa ccatgtttgc ccaagttgaa 1980
tctgatgatg aggaagcaaa gaatgagcca gaatggaaaa aacgtaaaaat ttgaagaatc 2040
tcatttgaga gctgtttgca tgagtgggag ggggtatggg caggtttggg tttttttttt 2100
atgtcatga aattaaaaat tcatttttat gaaaaaaaaa aaaaaa 2146
```

&lt;210&gt; 43

&lt;211&gt; 714

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2012970CB1

&lt;400&gt; 43

```
ggatggcgag cagcggaggc gaggcgggtga cgagagcagc ggctccgcca ttggacgagg 60
```

```

aggcctgagg gacggggccag cgggtgcacaa gaagagaccg aggcgggtgg ccccgagaga 120
gccagggcca tggaggccaa catgccgaag cggaaggagc ctggcaggtc tctccgtatc 180
aaagtcattc ccatgggcaa cgccgaagtg gggaaaagct gtattataaa gcgatactgt 240
gagaaaagat tcgtgtctaa atacctggca acaattggaa ttgactatgg agtcacaaag 300
gtacacgtca gagacagaga aatcaaagtt aacatctttg atatggctgg acatcccttc 360
ttctatgagg ttcgaaatga gttttacaag gacacacagg gtgtgatact ggtctatgat 420
gttgggcaga aagactcctt tgacgccctt gatgcgtggc tggcagaaat gaagcaagag 480
cttggacctc atggaaacat ggaaaatatt atattttag tttgtgcaa caagattgat 540
tgtacaaaac atcgctgtgt agatgaaagt gaaggacgtc tttgggctga aagcaaagg 600
ttcctgtact ttgaaacttc agcacaact ggagaaggca ttaatgagat gttccagata 660
catcttggat agaactaatg gataaattag tctgttttaa aaagaaaaaa aaaa 714

```

&lt;210&gt; 44

&lt;211&gt; 1779

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2254315CB1

&lt;400&gt; 44

```

caggaggaag atggcggcgt ccgcagctgc cgctgagctc caggcttctg ggggtccgcg 60
gcacccagtg tgtctgttgg ttttgggaat ggcgggatcc gggaaaacca cttttgtaca 120
gaggctcaca ggacacctgc atgcccagg cactccaccg tatgtgatca acctggatcc 180
agcagtacat gaagtccctt ttctgccaat tattgatatt cgtgatactg taaagtataa 240
agaagtaatg aaacaatatg gacttggacc caatggcggc atagtacact cactcaatct 300
ctttgctacc agatttgatc aggtgatgaa atttattgag aaggcccaga acatgtccaa 360
atatgtgttg attgacacac ctggacagat tgaggatttc acctggctag cttctgggac 420
aattatcact gaagcccttg catcctcatt tccaacagtt gtcattctatg taatggacac 480
atcgagaagt accaaccag tgaccttcatt gtccaacatg ctctatgcct gcagcatctt 540
atacaaaacc aagctgcctt tcattgtggg catgaataaa actgacatca ttgaccacag 600
ctttgcagtg gaatggatgc aggattttga ggctttccaa gatgccttga atcaagagac 660
tacatacgtc agtaacctga ctgcttcaat gagcctgggt ttagatgagt tttacagctc 720
actcaggggt gtgggtgtct ctgctgttct gggacttgga ttagatgaac tctttgtgca 780
agttaccagt gctgccgaag aatatgaaag ggagtatcgt cctgaatatg aacgtctgaa 840
aaaatcactg gccaacgcag agagccaaca gcagagagaa caactggaac gccttcgaaa 900
agatatgggt tctgtagcct tggatgcagg gactgccaaa gacagcttat ctctgtgtct 960
gcaccttctt gatttgatcc tgactcgagg aaccttggat gaagaggatg aggaagcaga 1020
cagcgatact gatgacattg accacagagt tacagaggaa agccatgaag agccagcatt 1080
ccagaatttt atgcaagaat cgatggcaca atactggaag agaaacaata aataggagac 1140
tttagcacac ttacttggt tctagaagtc cagaattttg gacctccacg tgaaagaact 1200
gttcttacct ctgaactggg ggctcccata agggataatt ttctcagag tagcaaagtt 1260
tctcttatta gagaaatctt gtgactcaga tgaagtcagg gatagaagac ccttggacct 1320
ggcagggtta tgctgattat tccttggcct ttcccttgta tttatgcaag gaaggatata 1380
ctgagctgat actcttccaa gcctacaact tcaagtttta tcatttgaac tcaagtactt 1440
ttgctgctga ggaatggaat caaaagaacg tagtctcctg gtgaccacct cagatctcta 1500
ttattaggct agatgtatag cctctactcc ccagcttct tgctcttgac cctgcactgt 1560
aagttgccct tctattagca gccaaaggaa agggaaacat gagcttatcc agaacggtgg 1620
cagatctccc ttggcaatca accaacgttg ctatgaaata tgccctcacac tgtatagctc 1680
attataggac gtcaggtttg ttgaaaaaag tgggcaagac atgattaatg aatcagaatc 1740
ctgtttcatt ggtgacttgg ataaagactt ttttaatttt 1779

```

<210> 45  
<211> 2234  
<212> DNA  
<213> Homo sapiens  
  
<220>  
<221> misc\_feature  
<223> Incyte ID No: 2415545CB1

<400> 45  
ccccttctga aaaatgggtt caccgcgtcc ttctctagaa cgggtcgggc cgctaccact 60  
gtccggcccc gaggggaact gttttctccg gaagtgaaca cacgctgact aggaaaagga 120  
ggaggcgggg cagtggggcc ttccggcgcg actatggaag gagccggcta cagggtggtg 180  
tttgagaagg gcggagtgtg cctgcacacc agcgctaaga agtatcagga ccgagactct 240  
ctcatcgctg gtgtcatccg tgctgtggaa aaggacaatg acgtcctcct gactgggct 300  
cctgtagagg aggtctggaga ttccacccaa atcctcttct ccaagaagga ctccagtggg 360  
ggtgactcat gtgcttctga ggaggaacca acctttgacc ccggtatga acctgactgg 420  
gctgtcatca gcaactgtgc gccacagccc tgccactcag agcccacgag aggtgcagag 480  
cccagctgcc cccagggtcc ctgggccttc tcagtgcgtc tgggggagct aaagtccatc 540  
cgccgctcca agccaggcct cagctgggccc tacctgggtc tggtgaccca ggctggaggt 600  
tccttgcccc cactgcactt ccaccgcggg ggcacccgcg ccctgctcgc cgtcctcagc 660  
cgctacctgc tgttgccag ctccccgcag gactcccgcc tctaccttgt cttccccac 720  
gactcctctg ctctctccaa ctcttccac cacctgcagc tctttgacca ggacagctcc 780  
aatgtggtgt cacgcttccct ccaggatccc tactccacca ccttcagcag cttctccca 840  
gtgaccaact tcttccgggg tgccctgcag ccacagcctg agggagccgc ctccgacctt 900  
ccccgccac ccgacgatga gcccgagcct ggattcgagg tcatttctctg tgtggagctg 960  
gggcctcggc caaccgtgga gcggggccct ccagttacag aggaggagtg ggcacgccac 1020  
gtgggcccct aaggtcgcct gcagcaggtc cctgagctga agaaccggat cttctcgggg 1080  
ggctgtgagc ccagcctgcg gcgcgaggcc tggaaagtcc tcctagggta cctcagctgg 1140  
gaaggcacag ctgaggagca caaggccac atacgcaaga aaacggatga gtatttccgc 1200  
atgaagctgc agtggaaatc tgtgagccct gagcaggagc ggagaaactc acttctgcat 1260  
ggataccgca gcctcatcga aagggtgtgt agccgcactg acaggaccaa caagttctac 1320  
gagggtcccc agaaccgggg gctgggcccgt ctgaacgata tcctcctcac ctactgcatg 1380  
tatcacttgc acctcggtta cgtccagggc atgagtgatc ttctctcccc gatcctctac 1440  
gtcattcaga acgaggtgga tgctttctgg tgtttctgtg gcttcatgga gctcgtgcaa 1500  
gggaactttg aagagagcca ggagaccatg aagcggcaac tcgggcgact gctgctgctc 1560  
ctgagggtgc tggacccccct gctctgcgac ttccctggatt cccaggactc cggctctctc 1620  
tgcttctgtt tccggtggct gctcatctgg ttcaagaggg aattccccct cccgatgtc 1680  
cttcggctgt gggaggtgct gtggacaggg ctccctggcc ccaatctgca cctgctgggtg 1740  
gcctgcgcca tcctggacat ggagagggac accctcatgc tgtccggctt cggctccaat 1800  
gagatcctca agcacatcaa cgagctgact atgaagctga gcgtggagga cgtgctgacc 1860  
cgcgccgagg ccctgcaccg ccagctaacc gcctgcaccc gagctgcccc acaacgtgca 1920  
ggagatcctg gggctggccc cgccacgcag agccccacag cccctcgccc accgcctccc 1980  
cgctgcctct gtacgcccac ccggggccccg cccacccgcg cgccctccac ggacacagcc 2040  
ccgcagcccc acagcagcct ggagatcctg cccgaggagg aggacgaggg cgccgactcc 2100  
taaccccgcc aggcagcctc gttctgcaca ggcactttag cccgagccag gcacacctgc 2160  
gagggggcag gtgtgctcgc ccgcccgtgt gataagctgg cttcattaaa ctgacacttc 2220  
tcaaaaaaaaa aaaa 2234

<210> 46  
<211> 3150  
<212> DNA  
<213> Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 96, 97, 99, 3070-3072, 3074, 3078, 3080-3082, 3085-3087, 3091,

&lt;222&gt; 3099, 3100, 3103, 3107, 3110-3112, 3114, 3115, 3121, 3123, 3125,

&lt;222&gt; 3128, 3136, 3138, 3140, 3141, 3143, 3145, 3147, 3149

&lt;223&gt; Incyte ID No: a or g or c or t, unknown, or other

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2707969CB1

&lt;400&gt; 46

```

acacaggagc aatgcaaaat ttgataaagc attttttctgt cagatcagct gagccctact 60
gcccttcctc tcaagattcc tggagaccca gatgtnnngna tcttttcattg acaacaaaat 120
aatgtgtcat gatgatgatg ataaagaccc tgtactccgg gtattttgatt cccgagttga 180
caagatcagg ctgttgaatg ttcggacacc tactctccgt acatccatgt accagaagt 240
taccactgtg gatgaagcag agaaagcaat tgagctgcgt ctggcaaaaa ttgaccatac 300
tgcaattcac ccacatttac ttgacatgaa gattggacaa gggaaatatg agccgggctt 360
cttccttaag ctgcagtctg atgtactttc cactgggcca gccagcaaca agtggacgaa 420
aaggaatgcc cctgcccagt ggaggcggaa agatcggcag aagcagcaca cagaacacct 480
gcgtttagat aatgaccaga gggagaagta catccaggaa gccaggacta tgggcagcac 540
tatccgccag cccaaactgt ccaacctctc tccatcagtg attgccaga ccaattggaa 600
gtttgtagag ggctgtctga aggaatgccg caataagacc aagaggatgc tgggtgaaaa 660
gatgggccga gaagctgtgg agctagggca tggggagggtg aacatcacag ggggtggaaga 720
gaacaccctg attgccagcc tttgtgatct cctggaaagg atctggagtc atggactaca 780
agtgaacag gggaaatcag ctttatggtc ccacctgtta cattatcagg acaaccggca 840
gagaaaactc acatcaggaa gcctcagtac ctcagggaata cttcttgatt cagaacgtag 900
gaagtctgat gccagctcac tcatgcctcc cctgaggatc tccctgattc aggatatgag 960
gcacatccag aacatcgggg aaatcaagac tgatgtggga aaggccagag catgggtgctg 1020
actgtccatg gaaaaaaagt tactttccag acacctgaag cagctcctct cagaccatga 1080
gtcaccaaaa agttatata agcgtatgc cttcctgcgc tgtgatgacg agaaggagca 1140
gttctctat cacctcctgt ctttcaatgc cgtcgattac ttttgcttca ccaatgtctt 1200
cacaactatc ctgatcccg accacattct gatcgtagca agcaagaagc tggggggctc 1260
catgttctac gccaaacct ggatctgtat atcaggagaa ttgggtgaga cacagatcat 1320
gcagattccc aggaatgtgc tagagatgac cttcgagtgc cagaacttgg ggaagcttac 1380
tactgtccag attggccatg ataactctgg gctgtatgcc aaatggctgg tggagtatgt 1440
gatggtcagg aatgagatca caggacatac ctacaagttc ccgtgtggcc ggtggttagg 1500
gaagggcatg gatgatggaa gcctggagcg gatcctagtt ggggagctgc tcacatccca 1560
gcctgagggtg gatgagaggc catgccggac cccgccgctg cagcagctcc ccagtgtcat 1620
ccggaggctt gttaccatct caccacaaca caagcccaag ctgaacactg ggcagatcca 1680
ggagtccatc ggggaggcag tcaatggcat tgtgaagcac ttccataagc ctgagaaaga 1740
gcgaggcagt ctgacgctgt tgctctgtgg agagtgtggc cttgtctcgg ccttggaaaca 1800
ggctttccag catggattta aatcgccccg gctcttcaaa aatgtcttca tttgggattt 1860
cctggaaaaa gcacaaacct attatgagac attagagaag aatgaagtag tccctgagga 1920
aaactggcat acaagagccc ggaacttctg ccgatttctc actgcaatca acaatactcc 1980
ccggaacatc ggcaaggatg gcaagtttca gatgctgggtg tgcttgggag ccagagatca 2040
ctcctacac cactggattg ccctgctggc tgactgcccc atcactgcac acatgtatga 2100
ggatgtggca ctgatcaaag accatacact tgtcaattcc ttgattcgtg tgctgcagac 2160
attgcaggag ttcaacatca cgctggagac gtcccttctc aagggcatcg acatctgacc 2220
tcccagcacc agccagcagc aggactgaga aagactcacc ctgcagctct gacctttttt 2280
cccaaaagga cttaagcgat tgtgcaggag taggagacaa aatgtacact cactgtaaaa 2340
agagaactag aggatttttg gaataaataa tctatttttag agtttatttg ctgatttgct 2400
ttttacacac tttcatgtga aagagtgata gggagaggga gcgaggctgg tgccgcttat 2460
tttgaagctg gtgccctccc tcgccgtggc cacatgctgg aagcctgagg cctccctgga 2520
ctgagcctgt ggcactgcgt gcgggacagt tatgtttcct tgccccgtcg cattaatgag 2580

```

```

gcccttccac atcattttta aactaatgtt tttctatatt aacattatta tggatatttg 2640
gctttcatag gccacacaca ggtgtgctgc gcgggaagcc ccatgctcca atcaaaggga 2700
tttttagtag tgcctctaag caagcaccga tgagtcagtc ccacgtattt tcttttttgt 2750
cagtattgtt tgggaaggag acatgccggg atgtgtcatc gtgccaaata ccacatttcc 2820
tgttggcaca gtttcacaga agtaaacata agcatgtttt aacaggtttt tcttttcttt 2880
tttctttttt aaaatgtttt atttatttaa cccgccattg tgtgttttta agtattttct 2940
ttttttaagg aaaggaaaag cttgtcacaa tctaactggc tatgttatta ttattaaatt 3000
tatgttttgc aacttagaaa ccagctacag tatggcccac ttaataaaac acctgaaaca 3060
aaaaaaaaagn nngngggngn nngtnnngag naggaggggn ggngggnggn nngnngggag 3120
ntnanttntg ggggtgngngn ngngnangnt 3150

```

&lt;210&gt; 47

&lt;211&gt; 1806

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2817769CB1

&lt;400&gt; 47

```

gtctgcgcgc aggtgccgct cggcgcccgg gccgcccgtt cgcgggctgt cgccgccgtc 60
gtgcgtgccg ctgcggcgag gggacgggccc tgcgttctct cctccttctt ccccgctccc 120
agctgccggc aggaccttct tctcgctgcc gctgggaccc cgtgtcatcg ccaggccga 180
gcacgatgcc cctaataaag ggaggtgatg gaattaaacc accccaatc attggaagat 240
ttggaacctc actgaaaatt ggtattgttg gattgcaaaa tgttgggaaa tctactttct 300
tcaatgtgtt aaccaatagt caggcttcag cagaaaactt cccgttctgc actattgatc 360
ctaagagag cagagtacct gtgccagatg aaagggttga ctttctttgt caataccaca 420
aaccagcaag caaaattcct gcctttctaa atgtggttga tattgctggc cttgtgaaag 480
gagctcacia tgggcagggc ctgggggaatg cttttttatc tcatattagt gcctgtgatg 540
gcatctttca tctaacacgt gcttttgaag atgatgatat cacgcacgtt gaaggaagtg 600
tagatcctat tcgagatata gaaataatac atgaagagct tcagcttaaa gatgaggaaa 660
tgattgggccc cattatagat aaactagaaa aggtggctgt gagaggagga gataaaaaac 720
taaaacctga atatgatata atgtgcaaag taaaatcctg gggtatagat caaaagaaac 780
ctgttcgctt ctatcatgat tggaatgaca aagagattga agtgttgaat aaacacttat 840
ttttgacttc aaaaccaatg gtctacttgg ttaatctttc tgaaaaagac tacattagaa 900
agaaaaacaa atggttgata aaaattaaag agtgggtgga caagtatgac ccagggtgctt 960
tggtcattcc ttttagtggg gccttggaac tcaagttgca agaattgagt gctgaggaga 1020
gacagaagta tctggaagcg aacatgacac aaagtgtttt gccaaagatc attaaggctg 1080
ggtttgcagc actccaacta gaatactttt tctactgcagg ccagatgaa gtgcgtgcat 1140
ggaccatcag gaaagggact aaggctcctc aggtgcagg aaagattcac acagattttg 1200
aaaagggatt cattatggct gaagtaatga aatacgaaga ttttaaagag gaaggttctg 1260
aaaatgcagt caaggctgct ggaaagtaca gacaacaagg cagaaattat attgttgaag 1320
atggagatat tatcttcttc aaatttaaca cacctcaaca accgaagaag aaataaaatt 1380
tagttattgc tcagataaac atacaacttc caaaaggcat ctgattttta aaaaattaaa 1440
atctctgaaa accaatgcga caaataaagt tggggagatg ggaatctttg acaaacaaat 1500
tatttttatt tgttttaaaa ttaaaatact gtgtaccccc cccactcca tgaaatgcag 1560
gttactaaa tgtgaacagc tttgcttttc acgtgattaa gaccctactc caaattgtag 1620
aagcttttca ggaaccatat tactctcatg atacttcatt aatctccatc atgtatgcca 1680
agcctgacac atttgacagt gaggacaatg tggcttgctc ctttttgaat ctacagataa 1740
tgcatgtttt acagtactcc agatgtctac actcaataaa acatttgaca aaacaaaaaa 1800
aaaaaa 1806

```

<210> 48  
<211> 2880  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 2917557CB1

<400> 48  
gaggaggagg aggaggaaga agaggaagaa gaagatgaag aaagtgaaga agaggaggaa 60  
gaggagggag aaagtgaagg cagtgaagg gatgaggaag atgaaaagg gtcagatgag 120  
aaggattcag ggaagacatt agataaaaaag ccaagtaaag aaatgagctc agattctgaa 180  
tatgactctg atgatgatcg gactaaagaa gaaagggcct atgacaaaagc aaaacggagg 240  
attgagaaac ggcgacttga acatagtaaa aatgtaaaca ccgaaaagct aagagcccct 300  
attatctcgc tacttgggca tgtggacaca gggaagacaa aaattctaga taagctccgt 360  
cacacacatg tacaagatgg tgaagcagg ggtatcacac aacaaattgg ggccaccaat 420  
gttcctcttg aagctattaa tgaacagact aagatgatta aaaattttga tagagagaat 480  
gtacggattc caggaatgct aattattgat actcctgggc atgaatcttt cagtaatctg 540  
agaaatagag gaagctctct ttgtgacatt gccattttag ttgttgatat tatgcattgg 600  
ttggagcccc agacaattga gtctatcaac ctctctcaaat ctaaaaaatg tcccttcatt 660  
gttgactca ataagattga taggttatat gattggaaaa agagtcctga ctctgatgtg 720  
gctgctactt taaagaagca gaaaaagaat acaaaagatg aatttgagga gcgagcaaa 780  
gctattattg tagaatttgc acagcagggt ttgaatgctg ctttgtttta tgagaataaa 840  
gatccccgca cttttgtgtc tttgtacct acctctgcac atactggtga tggcatggga 900  
agtctgatct acctcttgt agagttaact cagaccatgt tgagcaagag acttgcacac 960  
tgtgaagagc tgagagcaca ggtgatggag gttaaagctc tcccggggat gggcaccact 1020  
atagatgtca tcttgatcaa tgggcgtttg aaggaaggag atacaatcat tgttcctgga 1080  
gtagaagggc ccattgtaac tcagattcga ggcctcctgt tacctcctcc tatgaaggaa 1140  
ttacgagtga agaaccagta tgaaaagcat aaagaagtag aagcagctca gggggtaaa 1200  
attccttgaa aagacctgga gaaaacattg gctgggttac ccctccttgt ggcttataaa 1260  
gaagatgaaa tccctgttct taaagatgaa ttgatccatg agttaaagca gacactaaat 1320  
gctatcaaat tagaagaaaa aggagtctat gtccaggcat ctacactggg ttctttggaa 1380  
gctctactgg aatttctgaa aacatcagaa gtgccctatg caggaattaa cattggccca 1440  
gtgcataaaa aagatgttat gaaggcttca gtgatgttg aacatgaccc tcagtatgca 1500  
gtaattttgg ccttcgatgt gagaattgaa cgagatgcac aagaaatggc tgatagttaa 1560  
ggagttagaa tttttagtgc agaaattatt tatcatttat ttgatgcctt taaaaatat 1620  
agacaagact acaagaaaca gaaacaagaa gaatttaagc acatagcagt atttcctgc 1680  
aagataaaaa tccctcctca gtacattttt aattctcgag atccgatagt gatgggggtg 1740  
acggtggaag caggctcagg gaaacagggg acacccatgt gtgtcccaag caaaaatttt 1800  
gttgacatcg gaatagtaac aagtattgaa ataaaccata aacaagtgga tgttgcaaaa 1860  
aaaggacaag aagtttgtgt aaaaatagaa cctatccctg gtgagtcacc caaaatgttt 1920  
ggaagacatt ttgaagctac agatattcct gttagtaaga tcagccggca gtccattgat 1980  
gcactcaaag actggttcag agatgaaatg cagaagagtg actggcagct tattgtggag 2040  
ctgaagaaag tatttgaaat catctaattt ttccacatgg agcaggaact ggagtaaag 2100  
caatactgtg ttgtaatatc ccaacaaaaa tcagacaaaa aatggaacag acgtatttgg 2160  
acactgatgg acttaagtat ggaaggaaga aaaatagggt tataaaatgt tttccatgag 2220  
aaaccaagaa acttacactg gtttgacagt ggtcagttac atgtcccccac agttccaatg 2280  
tgectgttca ctcacctctc ccttccccaa ccctctctca cttggctgct gttttaaagt 2340  
ttgcccttcc ccaaatttgg atttttatta cagatctaaa gctctttcga ttttatactg 2400  
attaaatcag tactgcagta tttgattaac caagcttctg cagattttgt gattcctggg 2460  
acttttttga cgtaagaaat acttctttat ttatgcatat tcttcccaca gtgatttttc 2520  
cagcattcct ctgccatag cctttagggc ttttataaaa tagaaaatta ggcattctga 2580  
tatttcttta gctgctttgt gtgaaacat ggtgtaaaag cacagctggc tgctttttac 2640  
tgcttgtgta gtcacgagtc cattgtaatc atcacattc taaaccaaac taccaataaa 2700

gaaaacagac atccaccagt aagcaagctc tgtaggctt ccatgttagt gtagcttctc 2760  
 tcccacaagt tgcctccta ggacaagaat tatcttacia actaaactat catcacacta 2820  
 ccttgatgc cagcacctgg taacagtaga gatttttata cattaatctt gatctgtttt 2880

<210> 49  
 <211> 1109  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3421335CB1

<400> 49  
 cccacgcgtc cgctcgtctt tgggtcatgc ctggccagca gaaagcagct ccatagggga 60  
 ggagagccac gcaggatctc acagctgcag tctaatagta acacagagga ttcagcagt 120  
 gccaccatgg gttctgtgaa ttccagaggt cacaaggcgg aagcccaggt ggtgatgatg 180  
 ggcttgact cggcgggcaa gaccacgctc ctttacaagc tgaagggcca ccagctggtg 240  
 gagaccctgc ccactgttgg tttaacgtg gagcctctga aagctcctgg gcacgtgtca 300  
 ctgactctct gggacgttgg gggcaggcc cgcctcagag ccagctggaa ggactatctg 360  
 gaaggcacag atatcctcgt gtacgtgctg gacagcacag atgaagcccg cttaccgag 420  
 tcggcggtc agctcacaga agtctgaac gacccaaca tggctggcgt ccccttcttg 480  
 gtgctggcca acaagcagga ggacactgat gcacttcgc tgcttaagat cagaaacagg 540  
 ctgagtctag agagattcca ggacactgc tgggagctcc ggggctgcag tgccctcact 600  
 ggggaggggc tgcccgaggc cctgcagagc ctgtggagcc tcctgaaatc tcgcagctgc 660  
 atgtgtctgc aggcgagagc ccatggggct gagcgaggag acagcaagag atcttgatcc 720  
 agacagagca gcatactttt gctcatacaa actagaagaa ccagctgac cttgagaaat 780  
 ttacgcttag tctatcaaac aagaaatgct ggcttgcccc ggtggctcat gcctgtaatc 840  
 ccagcactgt gggagaccac ggtgggggaa tcccttgagc ccaggagtgt gagagcaaca 900  
 tcacaacacc ccatttctac taataatcaa aaaattggcc gggcatggtg gcatgtgcct 960  
 gtagtcccag ctacttggga ggctgaggca ggagaatcgc ttgagcccaa gaggtagagg 1020  
 ttgcagttag ccaagatgc gccactgcac tccagtctgg gcaacagagt gagaccctgt 1080  
 tctagtgtg ataataataa tgatgtagt 1109

<210> 50  
 <211> 2407  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 605761CB1

<400> 50  
 ctttcgctgg cgccattacc tgagttctcc tccagcgttt ccgcaccctc tccgattagc 60  
 ggtcccagga gtttccaagg taaccgcgca gtagggcgga tctcattagg cggaaagcga 120  
 aaccgggaag tgacgtctt accgggtgtc agcagcgaga gggttcgaag atggcggcgc 180  
 gcaagggtcg gcgtcgacg tgtgaaaccg gggaacccat ggaagccgag tccggcgaca 240  
 caagttccga gggcccgcc caggtctacc tgcccgccg ggggcccgcg ctacgcgaag 300  
 gggaggagct ggtcatggac gaggaggcct atgtgtctta ccaccgagcg cagactggcg 360  
 cccctgtct cagctttgac atagtccggg atcacctggg agacaaccgg acagagcttc 420  
 ctcttacact ttacttgtgt gctgggaccc aggtcgagag cgcccagagc aacagactga 480  
 tgatgcttcg gatgcacaat ctgcatggga caaagcccc accctcagag ggcagtgatg 540



```

aagaagaaga ggaggaagat gaagaggatg aagaagagcg gaaacctcag ctggagctgg 600
ccatggtgcc ccactatggt ggcatcaacc gagttcgggt gtcatggctg ggtgaagagc 660
ctgtggctgg ggtgtggtca gagaagggcc aggtggaggt gtttgcgctg cggcggttc 720
tgcaggtggt ggaggagccc caggccctgg cagccttcct ccgggatgag caggcccaaa 780
tgaagcccat cttctccttc gctggacaca tgggagaggg ctttgccttc gactgggtccc 840
cccgggtgac cggtcgcctg ctgaccggtg actgtcaaaa gaacatccac ctctggacac 900
ctacggagcg cggctcctgg cagctggacc agcggccatt cgtgggccac acacgctctg 960
tggaggacct gcagtgggtca ccgactgaga acacgggtgt tgctcctgc tcagctgacg 1020
cctccatccg catctgggac atccgggcag ccccagcaa ggcttgcag ctccaccacg 1080
ccaccgccc tgatggggac gtcaatgtca tcagctggag ccgcccggag cccttcctgc 1140
tcagtggcgg ggatgatggg gccctcaaga tctgggacct tcggcagttc aagtctgggt 1200
ccccagtggc cacttcaag cagcacgtgg ccccgtgac ctccgtcgag tggcaccccc 1260
aggacagcgg ggtctttgca gcctcgggtg cagaccacca gatcacacag tgggacctgg 1320
cagtggagcg ggacctgag gcgggcgacg tggaggccga ccccgactg gccgacctcc 1380
cgacgagcgt gctgttcgtg caccagggcg agaccgagct gaaggagctg cactggcacc 1440
cgcagtgcct agggctcctg gtcagcacgg cgctgtcagg cttcaccatc ttccgcacca 1500
tcagcgtctg aggcgtccca ctggctctga tcttgcttc tgcttggaac ctgaagtcca 1560
attgggctcc cctggaaggg gttcattcag gtctgttgac tgagactggc cggcctgtgg 1620
gctgccgtga tggattctgt ttgacgtatt gttctctaga aggcctggct ctgatccagt 1680
gaccctctc accaaagaac tcggtttaac cagggtctctg taagaccact cccaccacga 1740
gacttgtgtg ccctgggtgt gcctgtgtgt cggattcctt cctgtcagct gtgaccatt 1800
tgacctgtgt cccagaacc cagttttttg tttgtttgt tgagacggag tcttgggtctg 1860
tcgcccaggc tggagtgcag tagcacgatc ttggctcact gcaacctccg cctcctgggt 1920
taaagtgatt ctctcagctc agtctccag gtagctggga ttacaggcat gtgccaccac 1980
accccgtaa tttttgtatt tttagtagag acggggtttc accatgttgg ccaggctgggt 2040
ctcaaattct tgatctcaag tgatctgtcc gcccggcct cccagagtgc tgggttggga 2100
ttacaggcgt gagccaccgc gtccgggtca ggaccagtt ttggctgctg gttcccagca 2160
ggggactcgg gggatataca gtggctgcac caaattggag gtgtgggttc ctccaacaca 2220
atttcttct gccctgtgtc ttctgccag ctgggtttgg ccaggatttc tccgtgtggg 2280
ggctacatgc gacctctcc cctcctccct gacttttagag gctggtgctg tgcgggagg 2340
aaggtcaggg ctctgagca gcaataaagg accaggaaga ggcctgaggt gtaaaaaaaa 2400
aaaaaaa

```

&lt;210&gt; 51

&lt;211&gt; 1158

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 483862CB1

&lt;400&gt; 51

```

ggaagaccgt cccggatggc ctccgggact gccagtgtgt ggaggtgagc tccgggattg 60
ccggcattcc cgcttctgct ggttgcttca tgctgcaggc tgcggccgct agccctcgct 120
cgattgggtg gcgctgaggt gccggggcag caagtgcacat gtcgtcgggc ctccgcgcgcg 180
ctgacttccc ccgctggaag cgccacatct cggagcaact gaggcgcggg gaccggctgc 240
agagacaggc gttcgaggag atcatcctgc agtataacaa attgctggaa aagtcagatc 300
ttcattcagt gttggccag aaactacagg ctgaaaagca tgacgtacca aacaggcacg 360
agataagtcc cggacatgat ggcacatgga atgacaatca gctacaagaa atggcccaac 420
tgaggattaa gcaccaagag gaactgactg aattacacaa gaaacgtggg gagttagctc 480
aactgggtgat tgacctgaat aaccaaagc agcggaagga caggagagatg cagatgaatg 540
aagcaaaaat tgcagaatgt ttgcagacta tctctgacct ggagacggag tgcctagacc 600
tgcgactaa gctttgtgac cttgaaagag ccaaccagac cctgaaggat gaatatgatg 660

```

```

ccctgcagat cacttttact gccttggagg gaaaactgag gaaaactacg gaagagaacc 720
aggagctggt caccagatgg atggctgaga aagcccagga agccaatcgg cttaatgcag 780
agaatgaaaa agactccagg aggcggcaag cccggctgca gaaagagctt gcagaagcag 840
caaaggaacc tctaccagtc gaacaggatg atgacattga ggtcattgtg gatgaaactt 900
ctgatcacac agaagagacc tctcctgtgc gagccatcag cagagcagcc acgtaagtag 960
gcaggtttgg gccagggaaa agacagcttg aggagcaata tgaaggcaca tctgtggaca 1020
tgacaaagaa tgcagtcaga tgcacccaac cccttactcc ttttctggga caccagcgt 1080
cgaacacacc acagaggtgt ctagtcttcc tcagttcacc tctgcttaat gggagggaaag 1140
cagaacacgg gtggcttc                                     1158

```

&lt;210&gt; 52

&lt;211&gt; 1026

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1256777CB1

&lt;400&gt; 52

```

ctgcgggcct ctctccgtcg ccatggaaac gaaagcggcc aagtagagct ccgtcctgac 60
gcgcgcctc ccgtagggctc cggccggcta agccgcggcg gacaactatg ctgaaagcca 120
agatcctctt cgtggggcct tgcgagagtg gaaaaactgt tttggccaac tttctgacag 180
aatcttctga catcactgaa tacagcccaa cccaaggagt gaggatccta gaatttgaga 240
acccgcatgt taccagcaac aacaaaggca cgggctgtga attcgagcta tgggactgtg 300
gtggcgatgc taagtttgag tctgctggc cggccctgat gaaggatgct catggagtgg 360
tgatcgtctt caatgctgac atcccaagcc accggaagga aatggagatg tggatttcct 420
gctttgtcca acagccgtcc ttacaggaca cacagtgtat gctaattgca caccacaaac 480
caggctctgg agatgataaa ggaagcctgt ctttgtcgcc acccttgaac aagctgaagc 540
tggtgcactc aaacctggaa gatgacctg aggagatccg gatggaattc ataaagtatt 600
taaaaagcat aatcaactcc atgtctgaga gcagagacag ggaggagatg tcaattatga 660
cctagccagc cttcacctgg gactgccaca tccccagtga aatcagcatg tttctcggtg 720
cagatctgaa atcacatcca gctcctgatg ttttcttctc cctctgactg cagaggaagt 780
gttctacact gcaggaaggc acctgtcaca caggcggttc actcagacca tctgtgctct 840
gccctgagtt cagttgagaa aatcctatta tcaaatttgg atttctggc cccagaactt 900
cccaaagacc tgtaaaatgg agggatttac cacctcacat atgtccagtt aaacagtttg 960
tggacttgta accgtcgcag cccaatgata caacagtagt ttaatcacgt gaaaaaaaaa 1020
aaaaaa

```

&lt;210&gt; 53

&lt;211&gt; 2456

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2198779CB1

&lt;400&gt; 53

```

gacgagcgac gagatgacgg aggagcgggt ggccaacgca tgccggcagt cgggtgtaaac 60
aaggcctcgc gccgctgcgg gtcctgcgac cgctcctggc tgggatttcg attggtcgg 120
cagagaggtt acctggaaat ccaacaccgc ccaacacccc tcccgtccc cagtccgggg 180
acttcgatag gattggagaa ggagttgaca ggaggagccc ccgcacagga cctaagaatg 240

```

```

ctgtgaccag aagatgggat cgcggaacag cagcagtga ggatccgggt ccggagaccc 300
ctccgagggc ttgccccgaa gaggggctgg cctgcgtcgg agtgaggaag aggaagaaga 360
ggatgaagat gtggatctgg cccaggtact ggccatcttc ctccgcagag gccaaagtga 420
gttggtgcag ggaggaggtg cagcaaattt acaattcatt caggccctct tggactcaga 480
ggaagagaat gacagagctt gggatggtcg tcttggggat cgatacaacc cacctgtgga 540
tgctaccctt gacaccggg agctggaatt caatgagatc aagacacaag tggaaactggc 600
cacagggcag ctggggctta ggcgggcccgc ccagaagcac agctttcctc gaatgttgca 660
ccagagagaa cggggctctt gccatcgggg aagcttctcc cttggagaac agtctcgagt 720
gatattctac ttcttgccca atgatctggg cttcactgat agctactctc agaaggcttt 780
ctgtggcatc tacagcaaag atgggtcaa atcatgtct gcttgccaag accagacaat 840
ccgactctat gactgccgat atggccgttt ccgtaaattc aagagcatca aggcccgca 900
tgtaggctgg agcgtcttgg atgtggcctt caccctgat gggaaccact tcctctactc 960
tagctggtct gattacattc atatctgcaa tatctatggt gagggagata cacacactgc 1020
cctggatctc aggccagatg agcgtcgctt tgctgtcttc tccattgctg tctcctcaga 1080
tggacgagaa gtactaggag gggccaatga tggctgcctg tatgtctttg accgagaaca 1140
gaaccggcgc acccttcaga ttgagtccca tgaggatgat gtgaatgcag tggcctttgc 1200
tgatataagc tcccaaacc tgttctctgg gggagatgat gccatctgca aagtgtggga 1260
tcgacgcacc atgcgggagg atgaccccaa gcctgtgggt gcaactggctg gacaccagga 1320
tggcatcacc ttcatcgaca gcaagggtga tgcccggat ctgatctcca actctaaaga 1380
ccagaccatc aaactctggg atatccgacg cttttccagc cggaaggcca tggaaacttc 1440
acgccaggct gccacacagc aaaactggga ctatcggtgg cagcaagtgc ccaaaaaagg 1500
gtttactctg catccctacc cagcctggcg gaagctgaag ctcccagggg acagctcctt 1560
gatgacctac cggggccacg gagtgctgca caccctcatc cgctgccggg tctcccccat 1620
tcatagcact ggccagcagt tcatctacag tggctgctcc actggcaaag tggttgtgta 1680
cgaccttcta agtggccaca ttgtgaagaa gctgaccaac cacaaggcct gtgtgcgtga 1740
cgtcagttgg caccctttg aagagaagat tgtcagcagt tcgtgggacg ggaacctgctg 1800
tctgtggcag taccgccagg ctgagtactt ccaggatgac atgccagaat ctgaggaatg 1860
tgccagcgcc cctgccccag tgccccaatc ctctacaccc ttttctcac cccagtagat 1920
ccaacctcca gcccatata ggggtgaacct cttgataagc tctctgcctc ctctccctt 1980
tctccctgtt ggggaatgtt tggaggaatc actggcattt gatggggaat aacataagcc 2040
tgggctctga gcctcagctg agccctggaa gattctcccc atggggcaga gtggtctcct 2100
tacgtgctca caccagtcga gcttgggtcc ctatctctgg ccagagtttg gcaaggactgc 2160
cattatctgg ggtgtggcct ctgccagcaa gagaagtgtc ctgggtgttt ttaatcatgt 2220
ttgaatgtta ggggttggat cctagagtag atgcctgagg ccacatctga acagacctgt 2280
cagccaggcc tgccaggtct tcacgttagg gattcaactg gccaatcaca ggacaggtgt 2340
cctggccttt ctctctgagg tctctagggg aggggcatgg gtaagggtgt tctctcagca 2400
ccctcctggg gtggggatta tgtctgctgt catgtctggg tctttaagggt aggaca 2456

```

<210> 54

<211> 1771

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 2226116CB1

<400> 54

```

cggtctgagt taatatcttc gttgagcgga accttgetat tccataagag gatgtgtcca 60
gtgttgtgga agatttcatt ttttaaattc tttgtacaga aatcctgctc ccaagtcaca 120
gataggctga cggtctgagc ggcaagacgt gaccaggggc cgagaggggt agtgaccagg 180
aaaatcgcat tcatcagttc acttgtttgt ttcagaaacg tgcacaaaga cctgctgcat 240
gaggccctcg tcttcagttt ctgtttcatg cccagcatta aaccaagtat ctcatcttgc 300
caatttgact tctgtagggg ccatggcacc tgcaagggtg ttctcagcaa gattgaggac 360

```

```

cgtgttttcag ggcgtggggc attgggcttt gtccacatgg gctggcctga agcccagccg 420
gctactgcca cagcgggctt ctcccaggct gctctcggtc ggccgtgcgg acctcgccaa 480
gcatcaggaa ctcccgggga agaagctgct ctctgagaaa aagctgaaaa ggtactttgt 540
ggactatcgg agagtgtctg tctgtggagg aaacggaggc gctggggcaa gctgcttcca 600
cagtgaagccc cgaaggagt ttggaggccc tgatggaggg gacggaggca acggtggaca 660
cgtcattctg agagttgacc agcaagtcaa gtccctgtcg tcggctctgt cgcggtacca 720
gggtttcagt ggagaagatg gagggagtaa aaactgcttc gggcgagtg gcgcccgtct 780
ctacatccgg gtccccgtgg gcacgctggt gaaggaggga ggcagagttg tggccgacct 840
gtcttgcgtg ggagatgagt acattgccgc gctgggaggg gcaggaggga aaggcaaccg 900
cttcttctctg gccacaaca accgtgcccc tgtgacctgt acccctggac agccaggaca 960
gcagcgagtt ctccacctgg agctcaagac ggtggcccac gccggaatgg tgggattccc 1020
caacgcgggg aagtcctcac tgctccgggc catttcaaac gccagaccgg ccgtggcttc 1080
ctaccggttc accacctga agccccacgt cgggatcgtc cactacgaag gccacctaca 1140
aatagcagtg gccgacatcc ccggcatcat acgaggcgcc caccagaaca ggggtctggg 1200
gtccgccttc ctgaggcaca tcgagcgctg ccgctttctc ttgttcgtgg tggatctttc 1260
tcagcctgag ccgtggactc aagttgacga tttaaaatat gaactggaga tgtatgaaaa 1320
gggcctgtct gcgaggcccc acgcaatcgt cgcaaacaag attgacctcc ctgaagcccc 1380
agccaatctg tcccagctcc gggatcactt gggacaggag gtcacgtgctc tgcggcgctt 1440
gaccggcgag aacctggagc agctgctgtt gcacctgaag gtgctgtatg acgcctacgc 1500
ggaggccgag ctggggccagg gccgccagcc gctcaggtgg tagccacgcc agagcggggg 1560
cgctctggg cctctgtctg agcaaacctg ggtgtgaatt cgggtggtttt gaatgcataa 1620
agtgccttgt ggacacgggg gagttgtggt gcttctgggt ctctgggccc cgctgctggt 1680
cctgagatgc cctcatgttg ggaagcattc cgtgcccccc accccgectg ccctccgtat 1740
ttcctgcacc tgtcagcctg cgctgactga t

```

&lt;210&gt; 55

&lt;211&gt; 2724

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2504472CB1

&lt;400&gt; 55

```

gctgaccagt tggcgacatg gtggcaccgg tgctggagac ttctcacgtg ttttgctgcc 60
caaaccgggt gcggggagtc ctgaactgga gctctgggcc cagaggactt ctggcctttg 120
gcacgtctctg ctccgtggtg ctctatgacc ccctgaaaag ggttggtgtt accaacttga 180
atggtcacac cgcccgagtc aattgcatac agtggatttg taaacaggat ggctcccctt 240
ctactgaatt agtttctgga ggatctgata atcaagtgat tcaactggga atagaggata 300
atcagctttt aaaagcagtg catcttcaag gccatgaagg acctgtttat gcggtgcatg 360
ctgtttacca gaggaggaca tcagatcctg cattatgtac actgatcggt tctgcagctg 420
cagattctgc tgttcgactc tgggtctaaa aggggtccaga agtaatgtgc cttcagactt 480
taaacttttg aaatggattt gctttggctc tctgcttate ttttttgcca aatactgatg 540
taccaatatt agcatgtggc aatgatgatt gcagaattca catatttgct caacaaaatg 600
atcagtttca gaaagtgtt tctctctgtg gacatgagga ttggattaga ggagtggaa 660
gggcagcctt tggtagagat cttttcctag caagctgttc acaagattgc ctgataagaa 720
tatggaagct gtatataaag tcaacatctt tagaaactca ggatgacgat aacataagac 780
tgaaagaaaa tacttttacc atagaaaatg aaagtgttaa aatagcattt gctgttactc 840
tgagacagct gctagccggg catgaaaact gggtaaatgc agttcactgg caacctgtgt 900
tttacaaaaga tgggtgtcta cagcagccag tgagattatt atctgcttcc atggataaaa 960
ccatgattct ctgggctcca gatgaagagt caggagtttg gctagaacag gttcgagtag 1020
gtgaagtagg tgggaatact ttgggatttt atgattgcca gttcaatgaa gatggctcca 1080
tgatcattgc tcatgcttcc caccgagcgt tgcacctttg gaaacagaat acagttaacc 1140

```

```

caagagagtg gactccagag attgtcattt caggacactt tgatgggtgc caagacctag 1200
tctgggatcc agaaggagaa tttattatca ctgttgggtac tgatcagaca actagacttt 1260
ttgtccatg gaagagaaaa gaccaatcac aggtgacttg gcatgaaatt gcaaggcctc 1320
agatacatgg gtatgacctg aaatgttttg caatgattaa tcggtttcag tttgtatctg 1380
gagcagatga aaaagtctct cgggtttttt ctgcacctcg gaatttttg gaaaattttt 1440
gtgccattac aggacaatca ctgaatcatg tgctctgtaa tcaagatagt gatcttccag 1500
aaggagccac tgtccctgca ttgggattat caaataaagc tgtctttcag ggagatatag 1560
cttctcagcc ttctgatgaa gaggagctgt taactagtac tggttttgag tatcagcagg 1620
tggcctttca gccctccata cttactgagc ctcccactga ggatcatctt ctgcagaata 1680
ctttgtggcc tgaagttaa aaactatatg ggcacgggta tgaaatattt tgtgttactt 1740
gtaacagttc aaagactctg cttgcctcag cttgtaaggc agctaagaaa gagcatgcag 1800
ctatcattct ttggaacact acatcttgga aacagggtga gaatttagtt ttccacagtt 1860
tgacagtcac gcagatggcc ttctcaccta atgagaagtt cttactagct gtttccagag 1920
atcgaaacctg gtcatgtgtg aaaaagcagg atacaatctc acctgagttc gagccagttt 1980
ttagtctttt tgcttccacc aacaaaatta cttctgtgca cagtagaatt atttgggtctt 2040
gtgattggag tcctgacagc aagtatttct tcaactgggag tcgagacaaa aagggtggtg 2100
tctggggtga gtgcgactcc actgatgact gtattgagca caacattggc ccctgctcct 2160
cagtccctgga cgtgggtggg gctgtgacag ctgtcagcgt ctgcccagtg ctccaccctt 2220
ctcaacgata cgtggttgca gtaggattgg agtgtggaag gatttgctta tatacctgga 2280
aaaagactga tcaagtcca gaaataaatg actggacca ctgtgtagaa acaagtcaaa 2340
gccaaagtca tacactgggt atcagaaaat tatgctggaa gaattgcagt ggaaaaactg 2400
aacagaagga agcagaaggt gctgagtggg tacactttgc aagctgtggg gaagatcaca 2460
ctgtgaagat acacagagtc aataaatgtg cactgtaatg gacttaataa ctacatgctt 2520
gcagtcactg gtatgtaaaa atattatcat gtaaacaggt catctttacc ttcataactg 2580
aattgagttt ctgggttttt tttttttttg agatggagtc ttgctttgtc acaacctcca 2640
cctcccaggt tcaagcgatt ctctttcttc agcctcctga gtagctggga ctagaggcac 2700
accaccatgc ccggctaatt ttg 2724

```

&lt;210&gt; 56

&lt;211&gt; 2963

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3029920CB1

&lt;400&gt; 56

```

ggccgaagag gctggcaggt ggcgccgtgg ggtgggtgct cctgggtgaga ggagtccact 60
ccgtgcgtgc gggcggaggc cggcccccga gagccgccga catgaagaaa gacgtgcgga 120
tcctgctggg gggagaacct agagttggga agacatcact gattatgtct ctgggtcagtg 180
aagaatttcc agaagagggt cctccccggg cagaagaaat caccattcca gctgatgtca 240
ccccagagag agttccaaca cacattgtag attactcaga agcagaacag agtgatgaac 300
aacttcatca agaaatatct caggctaattg tcatctgtat agtgatgcc gttaacaaca 360
agcattctat tgataaggta acaagtcgat ggattcctct cataaatgaa agaacagaca 420
aagacagcag gctgccttta atattgggtg ggaacaaatc tgatctgggt gaatatagta 480
gtatggagac catccttctt attatgaacc agtatacaga aatagaaacc tgtgtggagt 540
gttcagcgaa aaacctgaag aacatatcag agctctttta ttacgcacag aaagctgttc 600
ttcatcctac agggccctcg tactgccagc aggagaagga gatgaaacca gcttgataaa 660
aagcccttac tcgtatatat aaaatatctg atcaagataa tgatgggtact ctcaatgatg 720
ctgaaactca cttctttcag aggatttgtt tcaacactcc attagctcct caagctctgg 780
aggatgtcaa gaatgtagtc agaaaacata taagtgtatg tgtggctgac agtgggttga 840
ccctgaaagg ttttctcttt ttacacacac tttttatcca gagagggaga cacgaaacta 900
cttgactgtg gcttcgacga tttggttatg atgatgacct ggatttgaca cctgaatatt 960

```

```

tggtcccccct gctgaaaata cctcctgatt gcactactga attaaatcat catgcatatt 1020
tattttctcca aagcaccttt gacaagcatg atttggatag agactgtgct ttgtcacctg 1080
atgagcttaa agattttattt aaagttttcc cttacatacc ttgggggcca gatgtgaata 1140
acacagtttg taccaatgaa agaggttgga taacctacca gggattcctt tcccagtggg 1200
cgctcacgac ttatttagat gtacagcggg gcctggaata tttgggctat ctaggctatt 1260
caatattgac tgagcaagag tctcaagctt cagctgttac agtgacaaga gataaaaaga 1320
tagacctgca gaaaaaacia actcaaagaa atgtgttcag atgtaatgta attggagtga 1380
aaaactgtgg gaaaagtggg gttcttcagg ctcttcttgg aagaaactta atgaggcaga 1440
agaaaattcg tgaagatcat aaatcctact atgcgattaa cactgtttat gtatatggac 1500
aagagaaaata cttgttggtg catgatattc cagaatcgga atttctaact gaagctgaaa 1560
tcatttgtga tgttgatgac ctggtatatg atgtcagcaa tcccaaactc tttgaatact 1620
gtgccaggat ttttaagcaa cactttatgg acagcagaat accttgctta atcgtagctg 1680
caaagtcaga cctgcatgaa gttaaacaag aatacagtat ttcacctact gatttctgca 1740
ggaaacacaa aatgcctcca ccacaagcct tcacttgcaa tactgctgat gccccagta 1800
aggatatctt tgttaaattg acaacaatgg ccatgtatcc gcacgtgaca caagctgacc 1860
tcaagagctc cacgttttgg cttcgagcaa gttttggtgc tactgttttt gcagttttgg 1920
gctttgctat gtacaaagca ttattgaaac agcgatgata taaaaagaaa tactgtccct 1980
acaaaaaaca aatactttta tgtacattct gaatgcttta agttctgcta gaattattga 2040
gatatttata catgcagagt tactttatta atatttgtaa ttcatgcata agagtatttt 2100
aatgatagtt ataactgcag tattggctag catatggaaa gaaaacagct aacagccaaa 2160
ctaaaatggc taaattccag aggccaaaag ggaatatatt gtataatat gtacatattc 2220
aggcaagata tgggtctccca agctgagttc tagaaatgat gtttctagac atttctaagt 2280
gggtattgta gtgtcactt ggctcactct tctaggttta agttagccca gagattgtat 2340
ttactcatgg atcactttat ttatttcaca tttactcaga atgacccctt gggttctata 2400
aggacataag gtacaatttg ccattgtctc tccattttta aaaacataca agtcagtgtc 2460
agcttaccba catgacattt tttcagtcag ttgtggtagg ccagccttga agccatcgca 2520
cagctagaaa acttgtgtag ctgagtgtgc agctcacctt taagggtgaa gttaggtaaa 2580
agcaattagc agaggcgtaa tctatgtgat tatgttgctt ccttgtcagt atgttgaatt 2640
ttatagccct ttcaatgaaa taaaaaaaaa atttgtatat taccaatgtt tttagtttaa 2700
ataaagagtc accottacta ctgttgaatt tcatcccaag tgtaaatcat tctataatgg 2760
ctgtgtctgt tatagtatat tacagtaact gcatgtgtca ccaagtgttc tatatcaggc 2820
taggataacc tagaggcagt aattttttta atgataaaat aaatctaag aatataaact 2880
ctcatgataa acctattttt tccatcatca gccttttcaa gtatttaaat aaataactgc 2940
tgtgtactgt gaaaaaaaaa aaa 2963

```

&lt;210&gt; 57

&lt;211&gt; 3332

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3332415CB1

&lt;400&gt; 57

```

gcctggcaga ggctggcggg catcgtgccg gtccctgccg gtctcccggg caccgggcca 60
ccgccccacc ccctcctccc tgccatggag cccgagctgg acgctcagaa gcagcctcga 120
ccgcgaggagc gaagccgccc ggccctctggg ctcagcacgg agggagcgac ggggccttcg 180
gccgacacct ccgggtcgga gctggacggg agatgttccc ttcggagagg cagctccttc 240
acattcttaa cacctggccc caactgggac ttcactttga aaagaaaacg cagagagaaa 300
gatgatgatg ttctaagcct tagcagcctt gatctgaagg agccaagcaa taaaagagtt 360
cgacctctgg ctctgtcac gtccttgga aatttaactc ctctgtaag aaatggagct 420
gtcagacggt ttggtcaaac aatacagtc tttacccttc gtggtgacca cagatcccca 480
gcctctgccg agaagttttc tagcaggtca acagtcccaa caccggccea gagaaggagc 540

```

```

agtgcactgt ggtcagagat gctggacatc accatgaagg agtctctcac caccagggag 600
atcagacggc aggaggcaat atatgaaatg tcccagggtg aacaggattt aattgaggat 660
ctcaaaacttg caagaaaggc ctacatgac cccatgttaa agttgtccat catgtcagaa 720
gaggaactca cacatatatt tggatgactg gactcttaca tacctctgca tgaagatttg 780
ttgacaagaa taggagaagc aaccaagcct gatggaacag tggagcagat tggtcacatt 840
ctcgtgagct ggttaccgcg cttgaatgcc tacagagggt actgtagtaa ccagctggca 900
gccaaagctc ttcttgatca aaagaaacag gatccaagag tccaagactt cctccagcga 960
tgtctcgagt ctcccttcag tcgaaaacta gatcttttga gtttcctaga tatccctcga 1020
agtcgcctag tcaaataccc tttactgtta aaagaaattc ttaaaccacac tccaaaagag 1080
cacctgatg ttcagcttct ggaggatgct atattgataa tacagggagt cctctctgat 1140
atcaacttga agaaaggatga atccgagtgc cagtattaca tcgacaagct ggagtacctg 1200
gatgaaaagc agagggaccc cagaatcgaa gcgagcaaag tgctgctgtg ccatggggag 1260
ctgcggagca agagtggaca taaactttac attttcctgt ttcaagacat cttggttctg 1320
actcggcccg tcacacggaa cgaacggcac tcttaccagg tttaccggca gccaatccca 1380
gtccaagagc tagtcttaga agacctgcag gatggagatg tgagaatggg aggtctcttt 1440
cgaggagctt tcagtaactc agagaaagct aaaaatatct ttagaattcg cttccatgac 1500
ccctctccag cccagtctca cactctgcaa gccaatgacg tgttccacaa gcagcagtgg 1560
ttcaactgta ttcgagcggc cattgcccc ttccagtcgg caggcagtc acctgagctg 1620
cagggcctgc cggagctgca cgaagagtgt gaggggaacc accctctgc gaggaaactc 1680
acagcccaga ggagggcatc cacagtctcc agtggttactc aggtagaagt tgatgaaaac 1740
gcttacagat tgggctctgg catgcagatg gcagaggaca gcaagagctt aaagacacac 1800
cagacacagc ccggcatccg aagagcgagg gacaaagccc tttctggtgg caaacggaaa 1860
gagacttttg ttagagaag gctctgtgtg ttaactgatg ggagagactg tttgtttata 1920
aatgtgtaca gttttgttt ctcgtaaggg gagcatcata ggggttacttt ataccagttg 1980
taacattttc attgtttttg gttgttcttt tttcttttt taatggcagc taaagatata 2040
cagattactg ttaaattgca gtcctttttt ttttaaagat attttcttga gttatttaga 2100
acatggtaag cctggtattt tttaataaaa caaaatatat atgaaatggg ttttctctta 2160
attctggatt catcatggct ttctaatacc aattgtaata tttacaatat tcacaaaaac 2220
ttagaatttt gcaaatgctg gaattctgcc agtggttctt tgctaagcct tgcagcaaaa 2280
atthgaaatt ttaacattgg caccctaaac ctacatggaa tgatgtctg gagtatttca 2340
aactttacat tgaacataa tttccttgga aaacaaacca taagcctgag gaggttttta 2400
tcaactggaa tgctttatat tagtttgttt ttcactgtac attcctcatt ttacattcat 2460
tttaactgccc gattatttaa tttttttatt gtaaagtagt ttttagcatt tgctttttatt 2520
tttttacttt gatgcctttt caaattggca tgtctttaa gtatttttct tcctgattaa 2580
aaatgtgtgt gtatgtgtgt gtgtgtgtgt atatatatat atttttttta atcacattaa 2640
ttttaccaag tgaaaccaag ccatactgtt tttgagccaa ttaagaaaat tgccattttt 2700
aaagtgtagc atttcagggt aaagacccat gaaatggctt gatgtattct agactactga 2760
aagaaaacca cttcaaagat tttgttgaaa gttttagtgt tgtctgaaat gcaagagggg 2820
aggtgattgg tagtgagtta aaagaaaaag agagggaaaag agagttagtt tgtcttcaag 2880
taaaatgtct ggttggtgca gacatttcac aagtgtgaaa ggagatagga gaagctcaac 2940
ttgagggcgt gtagtaagtt gtagaaggct cgaggggacg tggacttatt tgccttggtt 3000
tgcaatacct gcaataaatg agtttgaaaa gaaacaatga aatgtgttaa aaatttgacc 3060
atattagata aattttggtg gatttagtca taagatggaa aaagactggt gaatctttta 3120
ttacaaaatg tttctgttaa aatgggatca tcatctttga aaggggggag gaggagtaaa 3180
agcccgatta taatggtgat caattcaagt cagtgttgac tattctgtga aatatatttg 3240
gccagtggaa atgataatca gaaaagactg taaatagatc catccaaatg atttctctgt 3300
acaaatgaat gatactatta aaaaaaaaaa aa 3332

```

&lt;210&gt; 58

&lt;211&gt; 2617

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;223&gt; Incyte ID No: 4031536CB1

&lt;400&gt; 58

```

tttagtaatg tgcctgtatt acatgtagag agtattcgtc aaccaagagg agttttaaaa 60
tgtcaaaacc gggaaaacct actctaaacc atggcttggt tcctgttgat cttaaaagtg 120
caaaagagcc tctaccacat caaactgtga tgaggatatt tagcattagc atcattgccc 180
aaggcctccc tttttgtcga agacggatga aaagaaagtt ggaccatggg tctgaggtcc 240
gctctttttc tttgggaaag aaaccatgca aagtctcaga atatacaagt accactgggc 300
ttgtaccatg ttcagcaaca ccaacaactt ttggggacct cagagcagcc aatggccaag 360
ggcaacaacg acgccgaatt acatctgtcc agccacctac aggcctccag gaatggctaa 420
aaatgtttca gagctggagt ggaccagaga aattgcttgc ttagatgaa ctcatgata 480
gttgtgaacc aacacaagta aaacatatga tgcaagtgat agaaccacag tttcaacgag 540
acttcatttc attgctccct aaagagttgg cactctatgt gctttcattc ctggaaccca 600
aagacctgct acaagcagct cagacatgct gctactggag aattttgggt gaagacaacc 660
ttctctggag agagaaatgc aaagaagagg ggattgatga accattgcac atcaagagaa 720
gaaaagtaat aaaaccagggt ttcatacaca gtccatggaa aagtgcatac atcagacagc 780
acagaattga tactaactgg aggcgaggag aactcaaadc tcctaagggt ctgaaaggac 840
atgatgatca tgtgatcaca tgcttacagt tttgtggtaa ccgaatagtt agtggttctg 900
atgacaacac tttaaaagtt tggtcagcag tcacaggcaa atgtctgaga acattagtgg 960
gacatacagg tggagtatgg tcatcacaaa tgagagacaa catcatcatt agtggatcta 1020
cagatcggac actcaaagtg tggaaatgcag agactggaga atgtatacac accttatatg 1080
ggcatacttc cactgtgctg tgtatgcac ttcatgaaaa aagagttggt agcggttctc 1140
gagatgccac tcttaggggt tgggatattg agacaggcca gtgtttacat gttttgatgg 1200
gtcatgttgc agcagtcctg tgtgttcaat atgatggcag gagggttgtt agtggagcat 1260
atgattttat ggtaaagggt tgggatccag agactgaaac ctgtctacac acgttgacag 1320
ggcatactaa tagagtctat tcattacagt ttgatggtat ccatgtggtg agtggatctc 1380
ttgatacacc aatccgtggt tgggatgtgg agacagggaa ttgcattcac acgttaacag 1440
ggcaccagtc gttacaagt ggaatggaac tcaaagacaa tattcttgct tctgggaatg 1500
cagattctac agttaaaatc tgggatatca aaacaggaca gtgtttacaa acattgcaag 1560
gtcccaacaa gcatcagagt gctgtgacct gtttacagtt caacaagaac tttgtaatta 1620
ccagctcaga tgatggaact gtaaaactat gggacttgaa aacgggtgaa tttattcgaa 1680
acctagtcac attggagagt ggggggagtg ggggagttgt gtggcggatc agagcctcaa 1740
acacaaagct ggtgtgtgca gttgggagtc ggaatgggac tgaagaaacc aagctgctgg 1800
tgctggactt tgatgtggac atgaagtga gagcagaaaa gatgaatttg tccaattgtg 1860
tagacgatat actccctgcc ctccccctg caaaaagaaa aaaagaaaag aaaaagaaaa 1920
aaatcccttg ttctcagtgg tgcaggatgt tggcttgggg caacagattg aaaagacct 1980
cagactaaga aggaaaagaa gaagagatga caaaccataa ctgacaagag aggcgtctgc 2040
tgtctcatca cataaaaggc ttcacttttg actgagggca gctttgcaaa atgagacttt 2100
ctaaatcaaa ccagggtgca ttatttcttt attttcttct ccagtgggtc ttgggcagtg 2160
ttaatgctga aacatcatta cagattctgc tagcctgttc ttttaccact gacagctaga 2220
cacctagaaa ggaactgcaa taatatcaaa acaagtactg gttgactttc taattagaga 2280
gcatctgcaa caaaaagtca tttttctgga gtggaaaaagc ttaaaaaaat tactgtgaat 2340
tgtttttgta cagttatcat gaaaagcttt tttttttttt tttgccaacc attgccaatg 2400
tcaatcaatc acagtattag cctctgttaa tctatttact gttgcttcca tatacattct 2460
tcaatgcata tgttgctcaa aggtggcaag ttgtcctggg ttctgtgagt cctgagatgg 2520
atttaattct tgatgctggg gctagaagta ggtcttcaaa tatgggattg ttgtcccaac 2580
cctgtactgt actcccagtg gccaaactta tttatgc 2617

```





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, 16/18, A61K 38/17, G01N 33/68</b>		<b>A3</b>	(11) International Publication Number: <b>WO 00/31263</b>
			(43) International Publication Date: <b>2 June 2000 (02.06.00)</b>
(21) International Application Number: <b>PCT/US99/28013</b> (22) International Filing Date: <b>23 November 1999 (23.11.99)</b> (30) Priority Data: 60/109,592      23 November 1998 (23.11.98)      US 60/118,610      4 February 1999 (04.02.99)      US 60/127,990      6 April 1999 (06.04.99)      US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US      60/109,592 (CIP) Filed on      23 November 1998 (23.11.98) US      60/118,610 (CIP) Filed on      4 February 1999 (04.02.99) US      60/127,990 (CIP) Filed on      6 April 1999 (06.04.99) (71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View,</b>		<b>CA 94040 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US).</b> (74) Agents: <b>BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</b> (81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b> <b>Published</b> <i>With international search report.</i> (88) Date of publication of the international search report: <b>14 September 2000 (14.09.00)</b>	
(54) Title: <b>GTPASE ASSOCIATED PROTEINS</b>			
(57) Abstract			
<p>The invention provides human GTPase associated proteins (GTPAP) and polynucleotides which identify and encode GTPAP. The invention also provides expression vectors, host cells, antibodies, agonist, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GTPAP.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/28013

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K16/18 A61K38/17 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOOSLEHNER K ET AL: "STRUCTURE AND EXPRESSION OF A GENE ENCODING A PUTATIVE GTP-BINDING PROTEIN IDENTIFIED BY PROVIRUS INTEGRATION IN A TRANSGENIC MOUSE STRAIN" MOLECULAR AND CELLULAR BIOLOGY 1991, vol. 11, no. 2, 1991, pages 886-893, XP000891270 ISSN: 0270-7306 abstract; figure 1 ---	1-12
A	WO 98 37196 A (LUDWIG INST CANCER RES) 27 August 1998 (1998-08-27) abstract; claims 1-52; examples 1-8 ---	1-20
A	WO 94 16069 A (SCHERING CORP ; NAKAFUKU MASATO (JP); KAZIRO YOSHITO (JP)) 21 July 1994 (1994-07-21) abstract; claims 1-39 ---	1-6,9-15
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

24 March 2000

Date of mailing of the international search report

05. 07. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/28013

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 91 15582 A (CETUS CORP) 17 October 1991 (1991-10-17) abstract; claims 1-46; example 10 ---	1-16,19, 20
A	WO 90 00607 A (CETUS CORP) 25 January 1990 (1990-01-25) abstract; claims 1-55; figures 3,4 -----	1-14

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/28013

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 19,20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 17 18 20  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
claims 1-20 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17 18 20

Claims 17,18,20 refer to an antagonist and agonist and the use of antagonist of polypeptide of claim 1 without giving a true technical characterization. Moreover, no such compound is defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (art.5 and 6 PCT). No search can be carried out for such speculative claims the wording of which, is in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1-20 (partially)

A protein with amino acid with seq.id. 1 and corresponding nucleotide sequence with seq.id. 30 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 2. Claims: 1-20 (partially)

A protein with amino acid with seq.id.2 and corresponding nucleotide sequence with seq.id. 31 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 3. Claims: 1-20 (partially)

A protein with amino acid with seq.id.3 and corresponding nucleotide sequence with seq.id. 32 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 4. Claims: 1-20 (partially)

A protein with amino acid with seq.id.4 and corresponding nucleotide sequence with seq.id. 33 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 5. Claims: 1-20 (partially)

A protein with amino acid with seq.id.5 and corresponding nucleotide sequence with seq.id. 34 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 6. Claims: 1-20 (partially)

A protein with amino acid with seq.id.6 and corresponding nucleotide sequence with seq.id. 35 , method for detecting a polynucleotide, expression vector ,host cell , method for

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

## 7. Claims: 1-20 (partially)

A protein with amino acid with seq.id.7 and corresponding  
nucleotide sequence with seq.id. 36 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

## 8. Claims: 1-20 (partially)

A protein with amino acid with seq.id.8 and corresponding  
nucleotide sequence with seq.id. 37 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

## 9. Claims: 1-20 (partially)

A protein with amino acid with seq.id.9 and corresponding  
nucleotide sequence with seq.id. 38 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

## 10. Claims: 1-20 (partially)

A protein with amino acid with seq.id.10 and corresponding  
nucleotide sequence with seq.id. 39 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

## 11. Claims: 1-20 (partially)

A protein with amino acid with seq.id.11 and corresponding  
nucleotide sequence with seq.id. 40, method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 12. Claims: 1-20 (partially)

A protein with amino acid with seq.id.12 and corresponding nucleotide sequence with seq.id. 41 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 13. Claims: 1-20 (partially)

A protein with amino acid with seq.id.13 and corresponding nucleotide sequence with seq.id. 42 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 14. Claims: 1-20 (partially)

A protein with amino acid with seq.id.14 and corresponding nucleotide sequence with seq.id. 43 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 15. Claims: 1-20 (partially)

A protein with amino acid with seq.id.15 and corresponding nucleotide sequence with seq.id. 44 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 16. Claims: 1-20 (partially)

A protein with amino acid with seq.id.16 and corresponding nucleotide sequence with seq.id. 45 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 17. Claims: 1-20 (partially)

A protein with amino acid with seq.id.17 and corresponding nucleotide sequence with seq.id. 46 , method for detecting a polynucleotide, expression vector ,host cell , method for

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

**18. Claims: 1-20 (partially)**

A protein with amino acid with seq.id.18 and corresponding  
nucleotide sequence with seq.id. 47 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

**19. Claims: 1-20 (partially)**

A protein with amino acid with seq.id.19 and corresponding  
nucleotide sequence with seq.id. 48 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

**20. Claims: 1-20 (partially)**

A protein with amino acid with seq.id.20 and corresponding  
nucleotide sequence with seq.id. 49 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

**21. Claims: 1-20 (partially)**

A protein with amino acid with seq.id.21 and corresponding  
nucleotide sequence with seq.id. 50 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

**22. Claims: 1-20 (partially)**

A protein with amino acid with seq.id.22 and corresponding  
nucleotide sequence with seq.id. 51 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 23. Claims: 1-20 (partially)

A protein with amino acid with seq.id.23 and corresponding nucleotide sequence with seq.id. 52 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 24. Claims: 1-20 (partially)

A protein with amino acid with seq.id.24 and corresponding nucleotide sequence with seq.id. 53 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 25. Claims: 1-20 (partially)

A protein with amino acid with seq.id.25 and corresponding nucleotide sequence with seq.id. 54 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 26. Claims: 1-20 (partially)

A protein with amino acid with seq.id.26 and corresponding nucleotide sequence with seq.id. 55 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 27. Claims: 1-20 (partially)

A protein with amino acid with seq.id.27 and corresponding nucleotide sequence with seq.id. 56 , method for detecting a polynucleotide, expression vector ,host cell , method for producing a polypeptide , pharmaceutical composition , antibody , agonist and antagonist , method for preventing a disorder

## 28. Claims: 1-20 (partially)

A protein with amino acid with seq.id.28 and corresponding nucleotide sequence with seq.id. 57 , method for detecting a polynucleotide, expression vector ,host cell , method for

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

29. Claims: 1-20 (partially)

A protein with amino acid with seq.id.29 and corresponding  
nucleotide sequence with seq.id. 58 , method for detecting a  
polynucleotide, expression vector ,host cell , method for  
producing a polypeptide , pharmaceutical composition ,  
antibody , agonist and antagonist , method for preventing a  
disorder

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: 1st Application No

PCT/US 99/28013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9837196 A	27-08-1998	AU 6661298 A EP 0981613 A	09-09-1998 01-03-2000
WO 9416069 A	21-07-1994	AU 6083894 A CA 2153486 A EP 0679185 A JP 8507204 T	15-08-1994 21-07-1994 02-11-1995 06-08-1996
WO 9115582 A	17-10-1991	AU 7554691 A EP 0537155 A	30-10-1991 21-04-1993
WO 9000607 A	25-01-1990	US 5104975 A AT 156518 T AU 627764 B AU 4034989 A DE 68928242 D DE 68928242 T EP 0466688 A EP 0649908 A US RE35171 E US 5234839 A US 5760203 A US 5763573 A US 5830684 A	14-04-1992 15-08-1997 03-09-1992 05-02-1990 11-09-1997 18-12-1997 22-01-1992 26-04-1995 05-03-1996 10-08-1993 02-06-1998 09-06-1998 03-11-1998

